The investigation, development and application of non-targeted metabolic methods applying dried blood spot collection by Palmer, Elliott
THE INVESTIGATION, DEVELOPMENT AND APPLICATION OF
NON-TARGETED METABOLOMIC METHODS APPLYING DRIED BLOOD
SPOT COLLECTION
by
ELLIOTT ANDREW PALMER
A thesis submitted to the University of Birmingham for the degree of
DOCTOR OF PHILOSOPHY
School of Biosciences
College of Life and Environmental Sciences
University of Birmingham
September 2019
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 

iii
Abstract
The use of dried blood spots (DBS) as an alternative sampling method to venous blood
draws is a well established technique within clinical and pharmaceutical research set-
tings, with routine assays applied to quantify a small number of analytes applying
targeted analytical assays. However the use of DBS within non-targeted metabolomics
research is limited. Concerns about DBS have limited its use for non-targeted work and
therefore its applicability in large scale studies where DBS is a very attractive alterna-
tive. With lower costs associated with collecting, storing and transporting samples,
DBS offer a great alternative to whole biofluid samples.
This thesis aims at assessing the applicability of DBS collection in non-targeted
metabolomics scenarios. Initially, the stability of DBS was studied over the course
of 12 months, at various temperatures and guidelines surrounding the best practices
of storing DBS identified with suitable stability at room temperature in the short term
however for longer term storage of samples should be at -20◦C or -80◦C.
Secondly a surface analysis method was developed with the aim of increasing the
throughput of DBS data collection. The method developed applied a simple 5 second
extraction from the surface of a DBS with parameters optimised to be able to extract
multiple thousands of features and similar analytical performance to a comparable
direct infusion mass spectrometry method.
Additionally, a new method for normalisation of whole blood volume spotted on
iv
to the DBS card was developed for non-targeted analysis with the goal of reducing
non-biological variation within the sample. Results demonstrated applying the Brad-
ford assay to the measurement of total protein content with a DBS reduced the non-
biological variation present within the sample.
Finally, a surrogate of DBS in dried serum and plasma spots were applied in a
medium scale biological study in developing countries, proving that whether or not
you are using the whole biofluid or whether it is dried, a comparable biological con-
clusion is reached with similar lipid classes significantly changing in relation to hyper-
vitaminosis A in both plasma or serum and their associated dried biofluid spots.
The research presented within this thesis has demonstrated the applicability of DBS
for non-targeted metabolomics in mammalian research. With new methods to nor-
malise data, to reduce technical variation and analyse DBS using a surface analysis
technique. Further assessment in real world biological research applications are re-
quired to expand the application of DBS.
v
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Chapter 1
Introduction
1.1 Metabolomics
Metabolomics as a recognised field has been around since 1998 [1], but the theory
behind metabolomics has been around since the 1950s [2]. Metabolomics can be de-
scribed as the study of the metabolome which is the total representation of metabolites
present within a specific biological sample. Metabolomics compared to other ‘omic’
fields can be considered a dynamic measurement of all of the metabolic processes oc-
curring within the biological system being interrogated [3, 4]. Due to metabolomics
being thought of as ‘downstream’ from the other ‘omics’ processes such as genomics,
transcriptomics and proteomics [5], often changes occurring at these levels, present
themselves as changes within the biochemical pathways that make up the metabolome.
The range of compounds measured in the metabolome are generally less than 1500
Da [6]. This range covers a large number of classes of biologically relevant compounds
from sugars to phospholipids which can be used to investigate the physiological state
of the subject from which the biological sample originated. Many of the compounds
analysed within metabolomics have key biological roles and most are involved in the
different biochemical pathways within the biological subject which take part within
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FIGURE 1.1: Representation of the ’omics’ cascade with all areas contribut-
ing to the overall phenotype of the biological subject. Figure reproduced
from [10].
many different functions in order for it to survive. Within humans for example the
up-regulation and down-regulation of many metabolites can have profound effects
on the physiological health of the subject due to the many metabolic pathways that
metabolites may be a component of [7–9]. Therefore, identification of any anomalous
levels which fall outside of typical metabolite ranges can be key in predicting phys-
iological health or disease status. Consequently, it is important that the interactions
and functions between the many thousands of metabolites are understood and how
the different metabolic pathways which rely on these metabolites function and relate
to physiological health.
In addition to the key biological functions that metabolites have on physiological
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health, the metabolic phenotype is another highly dynamic product that has a large
effect on the metabolome. The metabolic phenotype can be defined as the interaction
of different environmental and lifestyle factors as well as genotype influences on the
metabolome [11]. Due to the regularity in which these interactions occur, the metabolic
phenotype can change very quickly. Thus it can be a good predictor of health and
disease [12, 13].
The role in which metabolites have on the general health in biological organisms
is wide ranging, from the regulation of insulin to control blood glucose levels [14], to
the break down of acetylcholine by acetylcholinesterase [15] to allow muscles to re-
lax. Due to the large number and complex nature of the compounds which makeup
the metabolome, there has been a huge effort within the research community in pro-
viding databases of known and predicted compounds that are expected. These in-
cluded databases such as The Human Metabolome Database [16], LIPID MAPS [17]
and KEGG[18]. Currently HMDB reports above 114,008 compounds (September 2019),
both measured and expected, but the volume of which are actually real metabolites is
heavily debated. However, whilst these databases are useful resources in the identifi-
cation and annotation of the metabolome, none of these databases provide a defini-
tive and complete view of the metabolome. Whilst the use of these databases has
allowed putative annotations of many compounds within non-targeted studies, the
actual identification of metabolites requires further analysis than just matching to an
m/z value. Fragmentation and measurement against chemical standards further help
and increases the confidence that the compound being measured is the one expected
and not just an isomer or isobar.
As mentioned towards the beginning, although metabolomics and it’s theory has
been around since the 1950s, the technical ability to measure the large number of
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FIGURE 1.2: Environmental and physiological factors which influence the
metabolism and subsequently alter the phenotype of an individual. Figure
reproduced from [19]
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metabolites present in a non-targeted manner has only recently been developed within
the last 20 years. Initially, nuclear magnetic resonance spectroscopy was used to inves-
tigate perturbations within the metabolome before the advent of GC-MS and high reso-
lution mass spectrometry systems which vastly increased the total number of metabo-
lites able to be detected within a single sample. Combined with the advancement in
separation sciences (both in liquid chromatography and gas chromatography), there
are a large number of metabolites which can now be measured and subsequently
identified through mass spectrometric measurement of various biofluids (serum and
plasma [20–22], urine [23–25], cerebrospinal fluid[26–28], tears[29, 30], tissue [31–33]
and many more). Furthermore, the use of different LC column chemistries within
chromatography allow a wider range of compounds to be separated and subsequently
detected, thus leading to better and more confident identification. Major examples
include the complementary use of reversed-phase and hydrophilic liquid interaction
column chemistries to ensure as many metabolites as possible [34], from the polar to
the non-polar can be separated from each other and be detected as a individual feature
rather than an annotation of one of a possible many.
Alongside the term metabolomics also comes the term ‘metabonomics’ [35]. Whilst
the two are often used interchangeably, there is often a defined difference between the
two. While metabolomics looks at the analytical approach as to how systems work and
aims to quantify the presence of metabolites within a biological sample, metabonomics
looks at the response of a system to external changes and identifies what changes occur
within the metabolome and is defined as ’the quantitative measurement of the dynamic
multiparametric metabolic response of living systems to pathophysiological stimuli or
genetic modification’ [4].
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1.1.1 Types of Metabolomic Study
Within metabolomics there are different areas of experimental design which apply
fundamentally different approaches to the measurement of metabolites within the
metabolome. These different areas can broadly be defined as targeted [36, 37], semi-
targeted [38] and non-targeted [39–41]. Firstly, targeted studies are aimed towards
quantifying the absolute concentrations of a select few metabolites that are of interest.
This may be compounds involved in a specific metabolic pathway or biomarkers of a
particular disease being investigated. Conversely, non-targeted strategies aim at de-
tecting as many metabolites as possible with minimal loss of biological compounds.
With regard to data analysis, due to the large number of metabolites being present
in non-targeted studies instead of absolute quantification, relative responses between
metabolic features is the main parameter used in extracting significant changes occur-
ring within the metabolome, with preliminary data analysis often applying multivari-
ate statistical techniques such as principal component analysis (PCA) to identify and
select features of potential interest. Finally, a third area of metabolomics study design
is semi-targeted. Whereas with targeted studies the number of compounds detected
is typically a maximum of 20 which are fully quantified, and in non-targeted studies
low thousands are detected but with quantification limited to relative peak intensities.
In semi-targeted, the aim is to quantify a few hundred metabolites which may make
up a series of metabolic pathways of interest. However quantification within semi-
targeted studies is usually limited to 1-point calibrations or performing a calibration
against a compound of the same class of compound such as a particular lipid species.
Within recent years there have been commercial suppliers offering semi-targeted kits
with the materials required to perform these studies. One of the leading companies
in this field is Biocrates who offer kits that claim to quantify hundreds of metabolites
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applying their p180 [42] and p400 HR [43] kits.
With targeted studies, the requirement to analyse a select number of metabolites
usually involves more extensive sample preparation such as solid phase extraction [44,
45] to remove unwanted compounds whilst increasing the sensitivity and specificity of
any analysis performed. Instrumentation used to perform targeted studies is also dif-
ferent with triple quadrupole based mass spectrometers dominating studies applying
targeted metabolomics [46]. Non-targeted studies on the other hand aim to have sam-
ple preparation procedures which involve as fewer steps as possible to prevent any
and as little loss of metabolites [47, 48] from the sample as possible, with prepara-
tion limited to the removal of protein content from the sample typically [49]. Non-
targeted studies also tend to use instruments [50, 51] with high mass resolving power
to ensure metabolites of similar mass are able to be distinguished, many of which are
present in complex samples such as biofluids. Targeted and non-targeted studies can
also be categorised as either hypothesis testing or hypothesis generating respectively
[52]. Targeted metabolomics is generally the last step in the validation of a hypothesis
which has been generated by a non-targeted study. A panel of potential biomarkers
is then selected for further investigation to ensure that the hypothesis generated in a
non-targeted scenario, is still valid in a targeted scenario. Subsequently, absolute con-
centrations of metabolites can be then be measured between different biological classes
such as a treatment and control group.
1.1.2 Metabolomics studies involving blood and urine
For metabolomics studies involving whole blood, it is required that soon after collec-
tion it is processed into either serum or plasma to ensure the long term integrity of the
sample [53, 54]. This is due to the inability to freeze whole blood which would lead
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to cell lysis [55, 56]. Therefore many studies involving the collection of whole blood
through venipuncture, are often performed using serum or plasma.
Serum and plasma are prepared through the low speed centrifugation of whole
blood. In the case of serum preparation, whole blood is collected into tubes without
an anticoagulant present and the blood is allowed to clot. After clotting the sample
can then be centrifuged and the supernatant remaining is serum [22]. With plasma
preparation, whole blood is collected into collection tubes containing an anticoagulant
such as lithium heparin or sodium EDTA [57]. The sample is then centrifuged with
the plasma being left as the supernatant layer. Although the two processed biofluids
are metabolically similar they do differ in part due to the lack of clotting factors that
have been removed in the serum compared to plasma [22, 58]. Additionally, because
of the presence of anticoagulant, adverse effects on MS sensitivity can appear when
analysing plasma due to ionisation suppression [59]. However having the flexibility to
collect and prepare blood in either scenario is a benefit to metabolomics and can afford
a wide range of experimental design approaches.
Another major biofluid that has been widely studied in non-targeted metabolomics
is urine [25, 60]. Urine undergoes a variety of changes depending on the physiological
condition of the subject (pH [61], ionic strength [62, 63] and osmolality [64]), thus often
complicating experimental analysis when compared to serum or plasma. To negate
this effect normalisation methods are used to ensure that the physiological changes
that occur readily within urine samples such as the dilution due to hydration or con-
centration of various compounds that are excreted via the kidneys due to toxicity have
no effect on the resulting data that is collected [64, 65].
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1.1.3 Extraction methods for non-targeted studies
There are a variety of methods used for the extraction of metabolites from the biolog-
ical matrix into LC and MS compatible solvents. The two main methods used within
the literature today apply liquid-liquid extraction (LLE) and solid phase extraction
(SPE) [66] (including solid phase micro-extraction (SPME) [67]. LLE involves the addi-
tion of organic solvents into to a sample and thorough mixing to partition metabolites
from their native environment within the biofluid into the organic solvent. Depending
on the choice of extraction solvent, major influences can occur on the classes of com-
pounds which are extracted from the biofluid, with different solvent mixtures being
more suited towards the extraction of specific compounds over others. Thus depend-
ing on the assay that is to be performed can cause major decisions to be made within
experimental design to ensure the correct classes of molecules can be extracted.
One of the most common methods of metabolite extraction methods is applying
a monophasic solvent mixture typically based off a polar organic solvent such as
methanol, isopropanol or acetonitrile mixed with water [32]. Extraction applying a
monophasic solvent system is simpler and requires less steps, than biphasic and solid
phase extraction methods, however optimal extraction of the many classes of com-
pounds present within the sample is not possible with a monophasic system. There-
fore biphasic solvent extraction systems are available and are frequently used within
non-targeted metabolomics research. Solvent systems developed by Bligh & Dyer [68]
and Matyash [69, 70] are common throughout non-targeted metabolomics in the opti-
mal extraction of multiple classes of compounds from a single sample. Bligh & Dyer’s
biphasic system is based on a combination of chloroform/methanol/water, with lipid
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classes preferentially extracting into the chloroform phase, with polar metabolites ex-
tracted into the methanol/water phase. Matyash’s biphasic system employs methyl-
tert-butyl ether as the non-polar phase and can be viewed as a more preferred alter-
native due to the carcinogenic nature of chloroform. Additionally, with Matyash’s
method, the protein pellet formed forms at the bottom of the extraction vial instead
of in between the two phases as with the Bligh & Dyer method. This allows it to be
a more suitable extraction method for automated systems which lack the fine motor
skills of manual handling to avoid the protein pellet [70].
When applying SPE, specific chemistries of stationary phase are loaded with sam-
ple upon which differing strengths of mobile phase are then washed through. This
removes components which are unwanted leaving behind metabolites of interest on
the stationary phase which can then subsequently be eluted for analysis. This proce-
dure can also be performed the other way around where components of interest are
eluted first off the stationary phase. SPE is often more suited towards targeted analysis
due to the removal of much more of the metabolome leading to a more specific group
of compounds ready to be analysed [71]. Due to the presence of proteins within serum
and plasma, it is required that these are removed from the sample prior to analysis.
This is achieved alongside metabolite extraction through the addition of organic sol-
vents such as methanol and acetonitrile [72]. With the addition of organic solvents,
proteins are crashed out of solution leaving a purely metabolite based extract present
within the organic solvent.
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FIGURE 1.3: Example of a Whatman 903 Collection card
1.2 Dried Blood and Urine Spots
Due to the challenges in the analysis of whole blood and the processing requirements
to be able to store and transport samples confidently, there has been a large increase
in interest in using filter paper based collection cards not just for metabolomics but in
other research areas. Through the use of collection cards, samples can be collected di-
rectly onto filter paper based mediums before allowing to dry and then storage. This is
in direct comparison to the processing requirements for either plasma or serum where
samples are required to be collected by trained personnel and then subsequent physical
processing through centrifugation to prepare samples that can be stored appropriately
with minimal changes to the biofluid.
The use of dried blood spots as an alternative to whole blood collection dates back
to the 1960s where Guthrie and Susi [73] spotted blood from the heel of neonates
onto filter paper. Subsequent assays were then performed to test for phenylketonuria
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(PKU). PKU is a genetic condition that can lead to impeded learning ability, be-
havioural problems and epilepsy due to the inability to metabolise phenylalanine
[74]. Thus early detection of the disease is key to prevent any long term effects for
the neonate. Since this novel assay was developed, there has been a large increase
in the number of assays performed using DBS. Most of this increase in use of DBS
can be explained through the large number of inborn errors of metabolism which are
now screened for in developed countries around the world. With inborn errors of
metabolism it is key that any of these conditions are caught early on, and with the use
of DBS, discomfort to the neonate is kept to a minimum whilst still being able to col-
lect enough blood upon which is then sent for analysis to detect any inborn error of
metabolism which occurs in 1 in every 2500 births [75]. Therefore targeted analysis of
DBS is commonplace within clinical settings.
1.2.1 Advantages
Compared to typical blood sampling procedures, where trained clinical staff are re-
quired to ensure the safe collection of blood, DBS can be collected by the patient them-
selves [76, 77] if required using only a spot of capillary blood, usually collected from
the tip of a finger or in the case of neonatal patients, the heel. Blood is collected through
a small puncture in the skin created using a lancet device.
Due to the low complexity required to collect samples, training materials can be
prepared in advance before either sending to patients who have agreed to collect their
own samples, or to researchers who are not trained in phlebotomy but are still inter-
ested in the use of DBS for their own research. Therefore samples can be collected
away from the lab in environments where specialist laboratories are not availabel for
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FIGURE 1.4: Image describing how a DBS is created through the pressure
of a spot of blood at the end of a finger to a collection card. Image repro-
duced from [78].
the processing of whole blood directly. Another key advantage that is of huge ben-
efit to patients is the volume required to prepare a single DBS compared to that of a
serum or plasma sample. With DBS, sample volumes range from 10-20 µL [79] and
thus discomfort is kept to a minimum whilst also maintaining sample integrity. This
is compared to whole blood draws through venipuncture where volumes can range
from 0.1 mL up to 10 mL [80]. Additionally, due to the low volumes required, sam-
ples can be collected in challenging environments [81–83] where collecting a venous
sample would either require any potential dynamic research to be halted such as col-
lecting samples whilst an athlete was exercising, or from a patient who has a severe
phobia of needles. Due to the low volumes of blood, costs of collection, transport and
storage of samples is drastically reduced when compared to whole biofluids [83, 84].
If the stability of analytes has been determined to be stable whilst present as a DBS,
then collection cards can be sent via typical commercial mail routes [85, 86] rather than
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employing specialist couriers to transfer plasma and serum samples using cold storage
techniques such as dry ice or ice packs. Therefore, opportunities arise where samples
can be collected in remote locations before being sent back to the analysis laboratory,
again, widening the range of research that can be conducted. Also, for researchers that
have already prepared plasma or serum, yet are either volume limited to reluctant to
send large volumes of whole biofluid, the volumes required to prepare replicates of
these samples as dried biofluids and then shipped to collaborators is much cheaper.
1.2.2 Identified Drawbacks
Although DBS analysis has been around now for over half a century, using DBS for
high throughput, non-targeted metabolomics has only become technically possible in
the last 10 years. With the advent of advanced high resolution, high sensitivity mass
spectrometric techniques, the routine analysis of DBS is now possible. However, val-
idating DBS for use in non-targeted metabolomic research has also become a wide
research areas in itself.
Due to the nature of DBS, there can be a wide variety of ways in which samples can
be collected. This could be down to the nature of the filter paper used, to the amount
of training given to the person collecting the samples, as well as physical properties of
DBS which could have effects on any analysis completed. One of the major concerns
with DBS is the effect of haematocrit [87–90] and chromatographic effects arising from
the deposition of whole blood onto filter paper collection cards [91]. Haematocrit levels
can be defined as the amount of red blood cells (RBC) within a sample of blood and is
expressed as a percentage of the total volume [92]:
Haematocrit =
Volume of Red Blood Cells
Total Volume of Blood
∗ 100 (1.1)
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Typically haematocrit levels vary on a variety of external factors such as sex, diet
and race, however accepted levels for men are in the range of 40-53% and for women
are 36-48% [93]. Higher haematocrit levels lead to a more viscous blood sample which
when deposited onto a collection card will lead to a smaller DBS in radius [94]. This is
in comparison to low haematocrit samples which when deposited will spread further
even if the same volume of blood has been deposited onto the collection card.
In many studies, standard procedures indicate that when a DBS is to be extracted
for analysis, a small sample of the DBS, typically taken using a hole punch is removed
from the larger spot. Thus, if separate samples are prepared with differing haematocrit
levels, when a fixed size is removed from the original DBS, two different volumes of
blood will be represented, consequently leading to potential for quantitative bias in
any analysis performed.
In addition to haematocrit issues surrounding DBS, chromatographic effects can
also arise in DBS analysis. Due to the multicomponent nature of whole blood com-
pared to serum or plasma, there is a potential that whenever a DBS is prepared, the
separation of these various components within the filter paper matrix can occur [95,
96]. This therefore can lead to variation in response of analytes, depending on where a
subsection of the DBS was removed.
An obvious solution to the above issues of haematocrit and chromatography effects
is the removal and extraction of any metabolites from the whole spot instead of a sub-
section of the sample. However due to the way in which DBS are collected (typically
through applying the collection card directly to the finger or heel), ensuring the same
volume of blood is collected onto the collection cards is incredibly difficult and instead
there ends up being a wide variation in the volume of whole blood that ends up on the
collection card. Combine this with the issue of haematocrit, it is therefore not possible
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to deduce an accurate estimate for the amount of blood deposited onto the collection
card purely from measuring the radius of the DBS itself.
1.2.3 DUS compared to DBS
In addition to DBS, collection cards can also be used for a variety of other biofluids such
as plasma and serum, but also for urine [97–99], saliva [100–102] and cerebrospinal
fluid [103, 104]. From these it is most likely that any further development of non-
targeted metabolomics research using collection cards, would have more applicability
for using dried urine spots that any other. This is due to its already widespread use
within the metabolomics community as a way to look at biological breakdown prod-
ucts of many pathways within the human body as well as an endpoint for many bi-
products of food [105] and drug metabolism [106]. It is also easy to obtain in larger
volumes compared to blood (>50 mL) and due to the method in which it is collected,
would allow it to be prepared in a dried format more easily than most other biofluids.
With little in the way of protein or lipids present within urine, it is also a favourable
biofluid to analyse, with fewer steps required to ensure the comprehensive analysis of
the many small molecules present.
1.2.4 Collection devices for dried biofluid collection
There are many different collection devices that can be used to prepare DBS & DUS
alongside various other dried biofluid spots. Most are based on filter paper which
is a cellulose based material [107, 108], which allows the biofluid to disperse within
the matrix of the material. These collection cards are also prepared in different vari-
ations depending on the application upon which is required. Some collection cards
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are treated with specific materials such as FTA R© cards which have been shown to de-
activate certain pathogenic viruses such as Avian Influenza Virus after just 1 hour of
being deposited [109]. Most filter cards used however in DBS collection are untreated
such as the Whatman 903 and Perkin Elmer 226 brand of cards which are commercially
available from many suppliers.
In addition to the untreated cards being most common, the Whatman 903 and
Perkin Elmer 226 cards are the only devices approved by the FDA in the USA for
medical use [91, 107]. Consequently they are highly monitored for performance and
variation in batch quality.
Alongside the filter paper based collection cards however, is a developing indus-
try of alternatives which aim at ensuring the downsides associated with spot based
collection such as haematocrit and chromatography effects are negated.
First is a company called Neoteryx which produce a ‘stick’ like device with an ab-
sorbent material on the end [110]. The device can be purchased in different forms
which allow either 10 µL or 20 µL of blood to be collected within the absorbent ma-
terial. The company claims that the reproducibility of volumes that are collected fall
within an acceptable range for non-targeted metabolomic studies.
In addition to the above there is also a company called Spot On Sciences which
produce an all in one device called Hemaspot [113] which acts to collect three drops of
blood which then disperse onto a fan shaped material where the whole blood dries in
a cartridge. Once the blood has dried it can then be shipped to the laboratory where
each ‘segment’ of the fan can be removed before extraction and analysis. However
unlike the Neoteryx kit which aims to remove any volume related issues in collection,
with Spot On Sciences kit, there is still the issue of unknown volumes of blood being
deposited onto the material itself. So whilst it is a convenient kit to use, issues are still
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(A) (B)
FIGURE 1.5: Examples of (A) Neoteryx Mitra and (B) Spot On Science
Hemaspot Devices. Images reproduced from [111, 112]
present which may prevent its use within non-targeted metabolomics studies.
Whilst manufactured kits are possible alternatives for dried biofluid collection, the
cost of using these kits still remains greater than that of filter paper based collection
cards therefore specific applications would have to be required which takes advantage
of one of the unique selling points to be justified within studies.
1.2.5 Extraction of Dried Blood Spots
As with the extraction of whole biofluids such as plasma or serum, dried biofluids can
be extracted in same manner with the addition of organic solvents. Many organic sol-
vents have been utilised for extracting DBS such as acetonitrile [114], methanol [115]
and ethyl acetate [116]. Because whole blood cannot be directly infused into a mass
spectrometer, whole blood in its liquid form is typically prepared as plasma or serum
before extraction. This is not required for DBS analysis and therefore removes an ad-
ditional preparation step. Due to this, any extraction of DBS, also contains the intra-
cellular components that are present within the cells in blood and additional metabolic
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FIGURE 1.6: Total number of publications as indexed by Scopus on 5th
September 2019 applying the search terms "Metabolomics" AND "NMR"
or "Metabolomics" AND "Mass Spectrometry"
information may be gathered. Organic solvents however are still required to remove
protein content and clotting factors, which can then be removed through centrifuga-
tion. The resultant supernatant can then be removed and transferred to separate tubes
for drying down under vacuum or nitrogen gas.
1.3 Analytical Techniques
The total number of analytical techniques available for metabolomics researchers has
vastly increased in recent decades. However the two main areas of focus in which de-
velopments have occurred are within nuclear magnetic resonance (NMR) spectroscopy
[117] and mass spectrometry (MS) [10] instrumentation. Whilst NMR was the most
prevalent towards the start of metabolomics research, since the turn of the twenty-first
century [4], MS has become the dominant technique in use.
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The primary reason for MS becoming the most prevalent technique can be at-
tributed to a variety of reasons. The skill level required to operate instrumentation
and interpret MS data has a lower level barrier to entry so the training of researchers
in the operation of MS instrumentation can be easier and quicker than training some-
one to operate NMR spectroscopy instruments and interpret data. Furthermore, with
the recent advances in high resolution mass analysers and the ease in coupling liquid
chromatography devices prior to MS detection, the total number of compounds which
can be detected is vastly higher than what can be hoped for NMR spectroscopy experi-
ments. However where NMR spectroscopy excels is its ability to elucidate structures of
compounds within the sample [50] in addition to the excellent technical reproducibility
and ability to integrate data collected in different batches across multiple months and
years. Structural confirmation and therefore metabolite identification is still an area in
which MS is inferior to NMR spectroscopy. MS often relies on accurate mass annota-
tion of compounds and/or MS/MS fragmentation to elucidate structures [118]. Both
of these methods are susceptible to false annotations which may direct the researcher
interpreting the data down the wrong pathways or hypotheses [19].
Because this thesis solely uses MS instrumentation, the theory behind NMR analy-
ses will not be discussed and instead the next section will solely focus on the detection
and applicability of MS instrumentation in non-targeted metabolomics.
1.3.1 Mass Spectrometry
As briefly mentioned in the previous section, the use of MS in metabolomics research
is now much larger than NMR. The versatility of MS has allowed a wide range of
applications to be developed, mainly in part due to the large number of ion sources
and separation modes that can be placed before the MS detector.
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Today a wide variety of mass spectrometric methods are available for the
metabolomics analysis of different biofluids. These include hyphenated techniques
comprising of a separation technology followed by MS detection such as:
• Ultra-high performance liquid chromatography – mass spectrometry (UHPLC-
MS). - Note: UPLC is often used within the literature however is not used within
this thesis because UPLC is a trademark of Waters Corporation. Therefore UH-
PLC refers to LC systems by other manufacturers.
• Nano-liquid chromatography – mass spectrometry (nLC-MS)
• Gas chromatography – mass spectrometry (GC-MS)
In addition to separation based techniques, direct analysis techniques are also very
commonly employed for non-targeted research [119–121]. Whilst lacking separation
removes a vital component in separating complex mixtures such as biofluids, the in-
crease in throughput can allow large scale studies to be performed in a much shorter
space of time. This presents itself well if the technique is used purely as a discovery
based tool with further analysis performed later on a much more select group of poten-
tial markers that have been identified. However with no separation, correct annotation
of metabolites becomes much more difficult without the addition of MS/MS data col-
lection, which can still prove problematic with complex spectra where the isolation of
narrow m/z ranges for fragmentation may be difficult.
1.3.2 Chromatography
The use of chromatographic techniques allows the separation of a complex mixture
based on the interaction of the different compounds within a sample with a stationary
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phase before finally eluting from the column before detection. Compounds present
can either be separated based on their interaction with a stationary phase either in a
gaseous or liquid form. Whilst GC-MS is more suited towards volatile compounds
or compounds which can be derivatised to ensure volatility [50], LC-MS has come to
the forefront of hyphenated metabolomics techniques due to its ability to handle a
wide range of molecular classes through separation on an equally wide range of sta-
tionary phases that are commercially available from many manufacturers [122]. In
recent years, both reversed-phase [123, 124] stationary phases and hydrophilic inter-
action [125–127] phases have been the primary columns used in LC-MS metabolomics
. Further technical advances within the LC area have also led to the development of
columns with narrower internal diameters [128, 129] and smaller particle sizes [130,
131], increasing the sensitivity and resolution of any separation performed [132]. In
addition to smaller internal diameters and particle sizes, the advancement of instru-
mentation which can handle the increased back pressures have also allowed for faster
LC run times whilst maintaining separation performance [133].
1.3.2.1 Column Parameters and Effect on LC Performance
As previously mentioned, there are a few key parameters that can affect the perfor-
mance of any LC separation. These are:
• Particle size
• Length of column
• Internal diameter
• Stationary phase
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• Mobile phase selection
• Column temperature
Many columns used in metabolomics research are now based on particle sizes of
2 µm, with a length of between 5 and 15 cm using an internal diameter of 2.1 mm.
Especially for high throughput and large scale studies, these parameters can have a
major influence on the time taken to separate the complex mixtures and the overall
run time for the study.
The main parameter that describes the efficiency of any separation in LC and GC
is the total number of theoretical plates. The Van Deemter Equation as described by
Equation 1.2 is used to calculate the efficiency of a column where HETP is the height
equivalent to the theoretical plates, A is the Eddy diffusion parameter, B is the random
molecular diffusion term and C is the mass transfer term.
A larger number of theoretical plates for a column will lead to an increased chro-
matographic resolution and lower full width half maximum (FWHM) for any particu-
lar peak, indicating better separation of a complex mixture. Whilst decreasing particle
size increases the total number of theoretical plates, as described by the Eddy diffusion
term in the Van Deemter equation, decreasing particle size also leads to an increase in
back pressure as described by the Kozeny-Carman Equation (Equation 1.3).
HETP = A +
B
u
+ Cu (1.2)
In the Kozerny-Carman Equation ∆P relates to the change in back pressure, η is the
viscocity, F is the flow rate, L is the length of the column, K0 is the specific permeability,
r is the radius and dp is the particle size.
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∆P =
ηFL
K0πr2d2p
(1.3)
From Equation 1.3 any decrease in particle size, has an inverse square effect on
back pressure. Therefore instrumentation has to be able to handle the increased back
pressures that come with columns of smaller particle sizes. Additionally, by decreasing
the particle size, an increase in resolution is possible which can be explained by the
efficiency term of the Purnell equation.
Rs =
√
N
4
(
α− 1
α
)(
k
1 + k
)
(1.4)
With α denoting separation factor of two peaks and k defining the retention factor,
N is the efficiency term and can be calculated by the following equation:
N ≈ L
2dp
(1.5)
Upon which L is column length and dp denotes particle size
Therefore any decrease in particle size, has an inverse effect on the efficiency term
which when increased, increases the resolution of any peak separation. Therefore
higher column separation performance is possible through the decrease of particle size,
providing the instrumentation and method developed can cope with the increased
back pressures.
From Equation 1.5 we can also see that an increase in column length will lead to
an increase in the efficiency term of the Purnell equation which defines resolution.
Therefore, by using longer columns, resolution can be increased however this comes
at the cost of decreased throughput and higher costs if analyses time is increased for
fewer samples.
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Finally, the effect of reducing the column diameter also increases the resulting back
pressure as explained by Equation 1.3 again.
Therefore any choice of column to be used for any separation has to be a careful
choice of optimising the performance of the separation whilst maintaining compatibil-
ity with any LC system that is to be used and which can handle either the optimum
flow rates and pressure required to use a column efficiently.
1.3.2.2 Different Stationary Phases used in Metabolomics
Within metabolomics, there are a few main types of stationary phases that are common
and presently used in many applications. Firstly is the use of RPLC columns which in-
volve the use of a non-polar stationary phase and the use of a polar mobile phase such
as a methanol:water mixture. Thus RPLC excels in separation of semi-polar and non-
polar compounds. RPLC stationary phases are often made of particles consisting of
C18 carbon chains bonded to silica beads, consequently, non-polar compounds interact
with these chains leading to better separation and polar molecules pass through along
with the mobile phase and are poorly retained. Other carbon chain lengths have also
been used for analysis of larger molecules such as proteins, or the use of C30 columns
for the separation of lipid classes.
Whilst reversed-phase chromatography has poor retention for highly polar com-
pounds, normal phase chromatography can retain these compounds on a polar (com-
monly silica) stationary phase and using a non-polar mobile phase such as hexane.
However due to the organic nature of the mobile phase, this technique becomes in-
compatible when coupling with MS systems and the ionisation source required such
as electrospray ionisation. This incompatibility and requirement to separate polar com-
pounds which dominate a huge part of the metabolome, has led to the development
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FIGURE 1.7: Retention mechanism of a sulfoalkylbetaine zwitterionic
based HILIC stationary phase. Compounds first partition into the wa-
ter rich layer before further electrostatic interactions with the stationary
phase. Figure reproduced from [126].
of hydrophilic interaction liquid chromatography columns (HILIC). The mechanism
by which HILIC works is based upon two steps. Firstly a water rich layer is formed
between the mobile phase and the stationary phase upon which polar metabolites par-
tition into. Secondly whilst in the water rich layer, further retention on the column
is then based on the electrostatic interaction that occurs between the analytes and the
stationary phases at specific pH.
Polar and thus more hydrophilic compounds partition into this water phase and
interact with the stationary phase and are retained longer than any non-polar com-
pounds. Typically solvents applied for HILIC separation are based on a binary mix-
ture of acetonitrile and water, which are both compatible with MS systems in direct
comparison to normal phase chromatography.
Therefore there are a wide range of separation techniques available for almost any
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type of compound that may be of interest to the researcher. However, where discovery
based studies are not focused on a specific area of the metabolome then a combination
of both RP and HILIC columns can be used to ensure as many metabolites as possible
is gathered and any biochemical pathway perturbations can be detected.
1.3.2.3 Nano Liquid Chromatography
As with the move from HPLC to UHPLC columns, where the internal diameter and
particle sizes have decreased to improve resolution and flow rates can be increased
to achieve the same performance in quicker run times, there has also been further
miniaturisation of internal diameters to sub-milimeter diameters to further increase
the performance of separation. Where column diameters are less than 1 mm, the term
micro liquid chromatography is often applied and internal diameters of less than 300
microns, nano liquid chromatography used. Making matters complicated however is
that the boundaries for these terms are blurred, and terminology used is often different
depending on the author of any corresponding research.
However as mentioned earlier, any decrease in particle size has an inverse square
effect on the total back pressure. To be able to deal with the increase in column back-
pressures, a reduction in flow rate is often applied, however this leads to increased
run times and costs per sample. To date, several companies have developed commer-
cial systems to perform nano-LC separations, including all the major MS instrument
manufacturers. The reduction in internal diameters leads to stronger chromatographic
bands eluting from the column from the same volume of sample, this increase in sensi-
tivity allows smaller volumes of samples to be used and due to the reduced flow rate to
ensure optimum performance, as well as a massive decrease in the amount of solvent
used.
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Many studies using nano-LC have been applied to proteomics [134–136], with very
few studies relating to the analysis of small molecules [137, 138]. The advantages of-
fered by applying nano-LC therefore offer a promising potential in the future of non-
targeted metabolomic applications. However due to the complex nature of sample
preparation to ensure high column performance and the inability to run large scale
studies in ‘reasonable’ run times, this leads to a requirement in the improvement in
performance of the instrumentation required to cope with the flow rates and back pres-
sures required to reduce run times to allow large scale studies.
1.3.3 Ionisation Methods
After sample separation, compounds are required to be ionised before detection by
mass spectrometry. Furthermore, by imparting a charge on an analyte, it can then be
manipulated based on electrical, magnetic and RF potentials for movement throughout
the mass spectrometer before mass analysis and detection.
To be able to be detected, a molecule must be present in the gaseous phase. Unlike
for GC where analytes are already in the gaseous phase either through their natural
volatility or through derivatisation, analytes in LC must first be converted into the gas
phase. Additionally, all mass spectrometry systems rely on the measurement of an
analytes mass-to-charge ratio (m/z, thus analytes need to be charged prior to detection.
To achieve this there are two main techniques used which can either be classed
as ionisation under high vacuum or ambient pressures. Each technique has a variety
of characteristics which can be utilised either for the identification of analytes or the
flexibility to modify and operate at atmospheric conditions.
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1.3.3.1 High Vacuum Ionisation for Gases
The two major techniques which ionise under high vacuum are electron ionisation
(EI) and chemical ionisation (CI). Both methods produce significantly different types
of ions with EI being classed as a high energy technique which produces many frag-
ments, whilst CI is much ‘softer’ ionisation technique leading to more intact and solely
protonated molecules.
1.3.3.1.1 Electron ionisation
Initially developed in 1929 by Bleakney [139], electron ionisation as a technique
is mainly used for GC-MS analysis and involves the bombardment of analytes with
electrons. Due to this, many fragments are produced [140] leading to easier structural
elucidation. Most EI source operate at 70 eV which produces electrons with a corre-
sponding wavelength similar to that of a covalent bond. When the molecule interacts
with specific wavelengths, complex interactions occur which promote the loss of an
electron [140]. The molecule remaining then undergoes fragmentation or rearrange-
ment to lose the energy imparted. GC-MS EI fragmentation libraries have vast wealth
of knowledge and make the annotation of analytes more straightforward than other
methods, and when all EI sources operate at the same energy of 70 eV, direct compar-
isons between fragmentation libraries are possible [141]. Electrons for the fragmenta-
tion are typically produced from a heated filament and then accelerated towards the
gaseous analytes. EI is a useful ionisation tool due to the similar wavelength specific
energies of electrons and bond lengths of analytes leading to the formation of fragment
ions.
1.3.3.1.2 Chemical Ionisation
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Chemical ionisation can be viewed as a complementary technique to EI due to the
much lower energy of ionisation that is achieved through the collision of analytes with
primary ions already present in the source [140]. First developed in 1966 by Muson et
al [142], CI, using reagent ions such as NH+3 which have already been ionised by EI are
collided with analyte ions entering the source. The protonated CI gas then provides
the charge to the analyte molecule through a series of gas phase reactions. This charge
transfer is at much lower energy than EI, leading to less chance of fragmentation.
1.3.3.2 Atmospheric Pressure Ionisation
Due to the high vacuum nature of EI and CI, coupling systems such as UHPLC instru-
mentation can become problematic. Therefore since the early 1990s there have been a
huge research focus on the development and application of on-line coupling of tech-
niques which operate at atmospheric pressures such as UHPLC to the high vacuum
status of detectors within a mass spectrometer.
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FIGURE 1.8: Representation of the formation of a Taylor Cone at the end
of the ESI needle and subsequent formation of ions from larger droplets.
Figure redrawn from [144].
1.3.3.2.1 Electrospray Ionisation
In 1989 Fenn et al [143] published research which demonstrated that multiply
charged ions could be obtained from proteins applying an electrospray ionisation (ESI)
technique. Because the ionisation of analytes can be described as ‘soft’ and is much
more comparable to CI than EI, ESI provides the ability to convert analytes present
in a liquid to a gaseous form whilst maintaining the chemical structure of the analyte
itself.
ESI works through the application of a high electric field to the analyte mixture
passing through a capillary under high temperature. When the mixture arrives at the
end of the capillary, due to the large electric field applied to the mixture and the poten-
tial difference between the capillary and counter electrode, a charge accumulation on
droplets occurs at the end of the capillary. Along with the continuous flow of mixture
through the capillary, this droplet (commonly referred to as a Taylor cone) breaks off.
The droplets are then pulled towards the MS orifice due to the negative pressure differ-
ential between the atmospheric pressure and high vacuum operation of the instrument
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Whilst moving towards the MS orifice, temperatures within the source are often ele-
vated much higher than the boiling point of solvents used in the mobile phase. Thus
any solvent still present within the droplet evaporates off, and as the volume of droplet
decreases the amount of charge per unit volume is increasing. Once droplets have
reached a specific size and the charge present per droplet reaches the Rayleigh limit,
further and smaller droplets of analytes are ejected eventually leading to a repeating
cycle of ejection of smaller and smaller droplets until individual ions are infused di-
rectly into the MS.
Typically, efficiency of the ionisation process can be improved through the reduc-
tion in size of initial droplets [145]. Therefore the time taken to reach individual an-
alytes in the gaseous phase is reduced. Predictably, the use of what is termed nano-
electrospray ionisation (nESI) is often coupled with nano-LC due to the low flow rates
involved. This partnership makes nESI and nLC one of the most sensitive MS tech-
niques commercially available from suppliers.
1.3.3.2.2 Atmospheric Pressure Chemical Ionisation
Much like with CI, atmospheric pressure chemical ionisation (APCI) can be viewed
as an analogous technique to the use of CI in GC-MS. However as with ESI, APCI can
work at atmospheric pressures without the requirement of high vacuum leading to the
ability to couple to separation techniques such as LC.
Developed in 1975 by Carroll et al. [146], APCI works through the nebulisation of
the analyte mixture alongside a nebulisation gas, typically N2. The nebulised gas then
passes through an environment of increased temperature where mobile phase solvents
are allowed to evaporate leaving purely the analytes of interest. After this the analytes
passes through an area of reagent molecules produced from a corona discharge which
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when at a specific voltage and current produces reagent ions. These reagent ions then
react with the analyte molecules, passing their charge based on their proton affinities.
After reaction with the reagent ions, the protonated or deprotonated ions in the case of
negative ion mode analysis, pass into the MS for analysis.
Both ESI and APCI have broad applicability for use in non-targeted metabolomics
workflows, with each technique being more favourable to the ionisation of specific
compounds over the other [50]. Therefore the use of a particular technology is often at
the researcher’s discretion and what instrumentation ultimately is available for their
use.
1.3.4 Direct Infusion Mass Spectrometry
Direct infusion mass spectrometry (DIMS) is another technique commonly used in the
metabolomic community. The advantages of removing the chromatographic separa-
tion step prior to MS analysis allows the high throughput of samples with run times
of less than 5 minutes per sample commonly seen within the literature [147, 148]. This
reduction in analysis time allows the high throughput of samples with many hundreds
able to be analysed each day. For global profiling studies where large numbers of sam-
ples are available, then DIMS analysis can direct further research appropriately whilst
reducing cost and time taken to perform the research.
Removal of chromatography also introduces a dependant axis that is highly repro-
ducible and based solely upon the mass to charge ratio of ions instead of retention
time that is used in LC-MS studies. The retention time of LC studies can be highly
variable and is dependant on many properties, many of them physical factors of the
column separation itself. Whilst the retention time parameter in LC studies can be re-
producible, it can vary widely on depending on conditions. One of the major factors
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which alter the reproducibility of retention time is the different mobile phase condi-
tions that are often present between studies spread over multiple batches of mobile
phase and different procedures in the preparation of mobile phases between laborato-
ries. With LC, age, solvent composition, dead volume and pump motions all can have
effects on the retention time of the resulting separation. This can lead to issues in large
scale or multi-batch experiments where the retention time for the same compound can
vary leading to annotation or grouping issues for the creation of data matrices.
Two major disadvantages however surround the usage of DIMS. Due to the lack of
separation, ion suppression caused by matrix effects can significantly lower the sensi-
tivity of any analyses performed. With all components of the sample being delivered
to the ionisation source at the same time, only the compounds which have the high-
est ionisation efficiency are going to dominate any resultant spectrum. Additionally
with instruments which rely on combining ‘packets’ of ion together before detection
(e.g., Orbitrap based systems), this ‘packet’ of ions once again will be dominated by
the most abundant ions and any ions which either struggle to ionise or are low in
abundance will not appear in the data.
To reduce the effect of ionisation suppression, reduction of flow rates and the use of
nanoESI sources have vastly improved the performance of DIMS techniques in recent
years [149]. As mentioned in Section 1.3.2.3, the reduction in flow rate and use of nESI
reduces the ionisation suppression that is a major hurdle in non-targeted metabolomic
direct analysis techniques. When the flow rate of the infusion into the MS is sufficiently
reduced, the ionisation efficiency is increased due to the smaller droplets being formed
in the nESI process, thus more analytes are being ionised at any one time.
Currently the commercial leader in DIMS nESI technology is Advion with the
Triversa NanoMate system [149]. As a nESI source it is versatile allowing both coupling
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FIGURE 1.9: Image of an Advion Triversa NanoMate source coupled to an
Orbitrap Elite mass spectrometer
to LC systems and a wide variety of instrument manufacturer’s whilst also allowing
DIMS experiments using an automated robotic platform.
1.3.4.1 Liquid Extraction Surface Analysis
As part of the Advion instrument, a surface analysis technique is also available. Mar-
keted under the Liquid Extraction Surface Analysis (LESA) brand, LESA has the ability
to perform direct surface sampling as part of the DIMS workflow [150, 151]. In recent
years LESA has also been coupled to LC to provide additional separation.
The operation behind the LESA technique was first developed in 2005 by Kertesz et
al [151] and involves several automated steps to complete a surface extraction. Firstly,
the Nanomate robot picks up a conductive pipette tip and aspirates extraction solvent
from a pre-selected reservoir. This pipette tip is then moved to a user selected x and
y coordinate above the surface of the sample before dispensing of a specific volume of
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solvent directly onto the surface of the sample. This dispensation of solvent forms a
liquid micro-junction (LMJ) between the sample and the conductive pipette tip which
is then allowed to remain on the sample for a selected amount of time (usually a few
seconds however this can be user selected based on the application). Following the
dwell of solvent on the surface of the sample, the Nanomate instrument respirates the
solvent forming the LMJ into the conductive pipette tip and then moves to the nESI
chip present in front of the orifice of the MS. An application of voltage is then made to
the conductive pipette tip to start the ESI process and a back-pressure applied to the
solvent within the tip to start the flow of extracted analytes through the nESI nozzle
and into the MS.
The use of LESA within non-targeted metabolomics is limited and most studies in-
volving small molecules are targeted or based on mediums other than collection cards
such as glass slides [152, 153]. Additionally, the main application focus of LESA has
been heavily towards proteomics with a wide range of research applying LESA to DBS
[154–158].
1.3.5 Mass Analysers
The ability to have mass analyser resolutions of greater than 50,000 and beyond at
FWHM for m/z 200 has been one of the major driving forces behind the expansion of
metabolomics, particularly non-targeted research. Compared to LC where resolution
defines the ability to separate two peaks eluting at similar times, MS resolution refers
to the mass measurement made and its precision to the actual theoretical mass of the
ion measured. When resolution is low, such as for single quadrupole mass analysers,
typically only nominal mass measurement can be made, limiting its use for the analysis
of complex mixtures such as in non-targeted metabolomics.
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However at high resolutions as with FT-ICR and Orbitrap based instruments, ac-
curate measurement of molecules which are separated by sub-ppm mass differences is
possible, this leads to increased confidence in any subsequent annotations as well as
improved sensitivity and number of metabolic features ultimately detected.
After either the separation of metabolites via LC or the direct infusion followed by
ionisation, metabolites can then be analysed via a variety of different methods to ob-
tain a mass to charge (m/z) ratio. This m/z ratio is not the actual mass of the metabolite
but instead the ionised form which bears a charge due to either it’s protonation/depro-
tonation, or it’s combination with a variety of adducts that commonly combine with
analytes alongside the charge due to the complex gas phase chemistry that occurs at the
temperatures and voltages present in the ionisation process. Additionally, due to the
presence of electrical fields, in-source fragmentation can occur based on the desolva-
tion and activation energies that are present throughout the ESI process or additionally
in the ion optics present within the instrument. This once more can produce complex
fragments which are then subsequently analysed by the MS producing complex spec-
tra.
1.3.5.1 Quadrupole
As mentioned in the previous section, quadrupole mass analysers are typically the low-
est resolution of those found in modern instrumentation. Quadrupole mass analysers
separate molecules based on their interaction with oscillating electric fields applied to
four rods in a circular geometry, where the electric fields are made up of both radio
frequency (r.f.) and direct current (d.c.). When an ion enters the quadrupole, through
careful selection and oscillation of both the r.f. and d.c. fields, an ion will pass through
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towards the detector. Whether or not an ion reaches the detector is based upon a se-
ries of equations of motion, which can be described by the Mathieu stability diagram
which describes the regions of stability for ions of different masses.
Due to lack of precision in mass measurement, applying single quadrupole mass
analysers to metabolomics, particularly non-targeted is deemed as a poor tool for the
measurement of the complex mixtures that biofluids are considered to be.
In addition to being used as a mass analyser, quadrupoles can also be used as a
mass filter device when operated in r.f. only modes. This mode focuses the trajectory
of ions as they pass through the instrument and can be enhanced through the addition
of further parallel sets of rods to create hexapole and octapoles.
1.3.5.2 Ion Trap
Like quadrupole mass analysers, ion trap technologies apply an r.f. and d.c. elec-
tric field to manipulate and ‘trap’ ions within a confined region. Ion traps have been
around since the 1950s and has since produced two types of analyser, firstly was the
3D ion trap which is commonly referred to as the Paul trap [159] and secondly is the
2D ion trap [160].
The 3D ion trap was developed by Paul and Steinwedel and consisted of a circular
electrode with two caps on either end. Ions enter through one end of the caps as one
before being subject to an electric field. As this electric field is altered, ions will leave
the trap based on their molecular mass before being detected.
A 2D ion trap is much more similar to a quadrupole in geometry and is often re-
ferred to as a linear ion trap. Ions will enter a 2D ion trap and will travel towards
one end of the linear configuration of 4 rods, before being repelled back towards an-
other end cap. As with 3D ion traps, ions are then ejected from the trap based on their
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interaction with a changing electric field.
Due to configuration and method of analysis, both traps experience a phenomenon
called ‘space charge’ effects. ‘Space charge’ effects occur when a high concentration of
charged ions are confined within a region. The ions towards the edge of the ‘packet’
present within the ion trap then act as a shield to the electric field present, thus chang-
ing the voltages at which specific ions are then ejected from the trap [161]. This ulti-
mately has an effect on the total accuracy of the mass measurement made. One of the
major benefits of 2D ion traps is the higher capacity of ions that can be present before
‘space charge’ effects start to have an effect on mass accuracy and therefore are much
more sensitive and have a greater dynamic range.
1.3.5.3 Fourier Transform Ion Cyclotron Resonance
Fourier transform ion cyclotron resonance (FT-ICR) mass analysers achieve by far, the
highest mass resolving power of any analyser on the market [162]. However the cost
of installing and maintaining these instruments often make then prohibitive to many
research groups. The main cost behind the installation and maintenance of FT-ICR
instrumentation is the superconducting magnets that are required to operate in the
region of around 3 to 9.4 Tesla.
FT-ICR works through the trapping of ions in a circular, magnetic trap. Ions are
then excited by a fixed magnetic field. For a uniform magnetic field, ions of differing
masses will be bent into unique circular paths base on their charged molecular mass
which will be perpendicular to the magnetic field. Subsequent measurement of the ion
cyclotron frequency is then able to be measured.
After the measurement of the ion cyclotron frequency, a Fourier transform can be
applied to convert the intensity measured as a function of frequency, to a measurement
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of intensity as a function of time which can then be converted into a mass spectrum.
1.3.5.4 Orbitrap
The Orbitrap mass analyser is the most recently commercially developed mass anal-
yser available on the market. First developed in 2000 by Makarov [163, 164], Orbitrap
analysers have been one of the most influential factors in the development and growth
of non-targeted metabolomics research. Due to the ability to reach sub parts per million
mass accuracy and resolutions of greater than 500,000 [165], Orbitrap mass analysers
are now common pieces of instrumentation in most metabolomics research groups.
Because the Orbitrap analyser can be manufactured within a ‘bench top’ size instru-
ment and the lack of requirement for a superconducting magnet, the requirements for
installation within a laboratory are not as burdensome as a FT-ICR, whilst still being
able to achieve incredibly high mass resolving power.
Orbitrap analysers work through the injection of packets of ions in-between two
electrodes (an inner spindle electrode and an outer electrode) which form to make a
spindle shaped device. An electrostatic field is then applied between the two electrodes
and kinetic motion is imparted to the ions present within the Orbitrap analyser.
Ions then travel in an oscillating path up and down the length of the inner electrode.
The frequency of these oscillations can be described by Equation 1.6.
ω =
√
z
m
× k (1.6)
Where ω is the frequency of harmonic oscillations along the central electrode and k
is the instrumental constant. Ions of different masses then take their own trajectories
along the inner electrode oscillating at different frequencies depending on their mass.
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FIGURE 1.10: Schematic diagram of an Orbitrap mass analyser. Repro-
duced from [166]
Lighter ions will travel further and oscillate at an increased frequency compared to
heavier ions.
Following excitation and oscillation, the current produced by the oscillating ions is
then measured and converted via a Fourier transform from the frequency domain to
the time domain to produce a mass spectrum.
Another key element of Orbitrap based MS is the ’C-trap’. Ions entering the C-trap
collide with nitrogen gas to dissipate any energy before injection into the Orbitrap for
mass analysis. The use of a C-trap allows ions to be focused and then introduced into
the Orbitrap analyser as a single packet of ions instead of a continuous flow. Addition-
ally, depending on the configuration of the Orbitrap MS system used, ions can then
undergo further fragmentation by being passed into a higher-energy collisional dis-
sociation (HCD) cell, passed back into the C-trap again and then the fragmented ions
injected into the Orbitrap analyser.
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(A)
(B)
FIGURE 1.11: Schematic diagrams of (A) Q-Exactive Plus and (B) Orbitrap
Elite mass spectrometers. Figures reproduced from [166]
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One of the major advantages that Orbitrap analysers provide is the wide range of
configurations which can be manufactured and the ability to couple with other mass
analysers such as ion traps to perform simultaneous detection and fragmentation of
ions. This flexibility in configurations has allowed Orbitrap based systems to be in-
stalled in proteomic based research labs in addition to metabolomics.
Throughout this thesis, all work was conducted on Orbitrap based systems to take
advantage of the high mass resolving power whilst maintaining flexibility in the MS
experiments and method development that was to be performed.
1.4 Informatics and Data Processing
Performing non-targeted experiments often leads to the measurement of >100,000 indi-
vidual variables. Therefore the computational need for resources to be able to interpret
large amounts of non-targeted metabolomics data is key in ensuring viable conclusions
are made.
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FIGURE 1.12: Typical non-targeted metabolomics experimental workflow
Figure 1.12 describes a typical non-targeted metabolomics workflow. Before data
can be statistically analysed however, a data matrix containing the response of each
variable (metabolite feature) per sample has to be produced from the raw data that has
been collected by the instrument.
1.4.1 Data-processing
To convert raw data into a data matrix there are several open source and closed source
programs available to use. Typically the closed source packages are developed directly
by the instrument manufacturer and only handle the specific format of data that is
output from that specific instrument. Examples of this included Thermo Scientific’s
Compound Discoverer which only handles Thermo .raw data format. Therefore, the
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computational tools and methodologies are generally regarded as commercial secrets
and are not publicly available.
On the other side is open source software which generally handles a much wider
range of data formats. Currently the most popular open source pre-processing tools are
XCMS [167], MZmine [168], with many other smaller tools available such as OpenMS
[169], MS-Dial [170] and MAVEN [171].
1.4.1.1 Pre-Processing of UHPLC-MS data
Typically the major function of these open source tools is to convert raw data into a
human readable peak matrix upon which statistical analysis can be conducted. This is
achieved through the peak picking and grouping of features within samples applying
algorithms specialised in the detection of true peaks against background noise. The
data matrix output of these programs contains m/z-RT pairs corresponding to a singu-
lar metabolite feature (or in the case of DIMS data only m/z) followed by intensities of
each metabolite feature in each sample processed.
This data matrix can then undergo statistical analysis to attempt to pull out features
of interest such as those which are changing significantly between biologically different
classes.
1.4.1.2 Normalisation and Transformation of Data for Statistical Analysis
Prior to the univariate and multivariate analysis of non-targeted metabolomics data,
it is often suitable to apply various different mathematical procedures to ensure the
validity of any statistical technique undertaken. Examples of this include the normali-
sation of data. Due to non-biological variance that often enters the workflow through
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sample preparation and instrument analysis, correction of this variate is often neces-
sary to ensure variance within the dataset is stable [172]. Additionally, for multivariate
analysis it is preferential that missing value imputation is performed to ensure multi-
variate statistical methods are valid due to their improved performance with no miss-
ing values within the dataset [173]. Finally, data is often transformed and scaled to
remove any present heteroscedasticity and to adjust for any significant fold changes
between metabolites [174].
1.4.1.3 Pre-Processing of DIMS data
Due to the high degree of ionisation suppression that occurs with DIMS data, typical
full-scan analysis modes often have low sensitivity and dynamic range. With hybrid
Orbitrap based instruments such as the Orbitrap Elite and Velos Pro, the configura-
tion and hybridisation of an ion-trap and Orbitrap mass analyser, affords the ability to
minimise the effect of any ionisation suppression. This is through the utilisation of a
method called SIM-stitching.
Developed by Southam et al. [175] SIM-stitching, as the name suggests, stitches
multiple SIM-windows together computationally, instead of the analysis of one large
mass range. Through the filtering of ions in the ion-trap, only a select mass range
enters the Orbitrap for mass analysis. By removing any dominant features that may
be present within a specific mass range, both the dynamic range and sensitivity of the
instrument can be improved leading to higher quality data. After the collection of data,
the multiple SIM ‘windows’ are then computationally stitched together to produce a
single, comprehensive spectrum and subsequent data matrix.
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1.4.2 Statistical Analysis
1.4.2.1 Mulitvariate
The large number of variables present within non-targeted metabolomics data leads to
the requirement of all observations to be viewed at simultaneously and with relation
to one another. Therefore multivariate statistical techniques are commonplace within
any non-targeted analysis. One of the most common is the use of principal component
analysis (PCA). Due to the large number of variables, there can be viewed to be as
many dimensions to the data as there are variables. PCA reduces the dimensionality
of the data producing a plot where all variables are condensed into a single repre-
sentation of the sample it belongs too. A PCA scores plot will have two axes which
represent the direction of the data which explains the most variance and a loadings
plot which explains how each variable relates to each principal component. [176, 177]
Initial conclusions can be made from PCA scores plot due to biologically similar sam-
ple grouping closer together than those which are biologically different. Overlaid on
top of sample metadata and class information, conclusions can be made as to whether
or not there are initial, obvious biological changes happening between two classes of
samples.
Whereas PCA can be described as an unsupervised method of multivariate analysis
due to the lack of class information present in calculating variance, supervised meth-
ods of multivariate analysis are also useful in determining important features which
are different between classes. In supervised analysis, class information is present
when calculating the model. One example of a method where the class information
is present, is partial least squares discriminant analysis (PLS-DA), with the objective to
maximise the variance between groups based on the class information present within
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each sample [178].
1.4.2.2 Univariate
Applying statistical analyses to each individual feature independent of every other
feature present within the dataset can be classed as univariate analyses. Common uni-
variate analyses performed are the t-test and analysis of variance (ANOVA) statistical
tests, however these tests are parametric and can only be implemented when certain as-
sumptions about the data are met. In the case of metabolomics data, these assumptions
are often broken so non-parametric methods are often applied such as Mann-Whitney
U-Test and Kruskall-Wallis tests. [179]
Applying both multivariate and univariate statistical tests allow robust interpreta-
tion of the data to be made and any discriminant features that are determined as signif-
icant in a multivariate model, can further be tested for statistical significance through
univariate tests.
1.4.3 Metabolite Annotation
Following the pre-processing of data to obtain a single data matrix, describing the
response of each metabolite feature with each sample, the annotation and identification
of data is key in the correct and valid interpretation of data.
Depending on the level of information present within the data and experimental
design, correct annotation and identification can be difficult [180, 181]. For example,
with DIMS data, there is only mass information present, so it is not possible to sepa-
rate isobaric compounds that would potentially elute from an LC column at different
times to represent two separate compounds and would instead be reported as a sin-
gle annotation. Additionally complicating procedures is the presence of adducts and
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fragments [19], with individual metabolites able to be represented as multiple metabo-
lite features. Therefore attempts should be made to filter out these extraneous features
through the grouping of potential mono-isotopic masses and fragments through re-
tention time similarity and response correlation. Additional correlation calculations
can be made to check for intensity correlations between two ions. This is because if
the two features are not correlated then they may not be two features of the same
compound but instead two features of different compounds and should therefore be
retained within the data matrix.
Confident annotation of metabolites though can be made through the use of
MS/MS and RT data and comparison against chemical standards and with an increas-
ing number of parameters that can be matched against then high confidence in anno-
tations can be made. For example, matching against m/z can only provide a list of po-
tential metabolites related to a molecular formula. Through the acquisition of MS/MS
data, additional structural information about the metabolite can be gathered and with
further RT data, the physiochemical properties of the compound and its interaction
with a specific stationary phase can be gathered on an independent orthogonal param-
eter. Finally, through the acquisition of an authentic chemical standard and comparison
against the data described above, high confidence in a specific metabolite annotation
can then be made.
Due to the complexity and wide range of annotations that are reported within
the literature, the Metabolomics Standards Initiative has defined guidelines and lev-
els which metabolite features can be reported as [182] to help both the researcher and
the readers in determining the level of confidence in the data that has been presented.
These are the following:
• Level 1 – Identified Compounds
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• Level 2 – Putatitvely annotated compounds
• Level 3 – Putatitvely characterised compound classes
• Level 4 – Unknown compounds
Thus annotations that have been made based purely on m/z along can be defined as
having met Level 3, whereas annotations that have been made based on m/z, RT and
potentially a spectral match with a public MS/MS library can be Level 2.
1.5 Conclusion
Overall, the impact that high resolution mass spectrometry has had for metabolomics
cannot be understated. The ability to detect hundreds to thousands of compounds in
a single sample extract has allowed a huge variety of non-targeted applications to be
performed that would not have been possible without the recent developments both
in separation science and mass analyser technologies.
Applying HRMS to the analysis of DBS opens up the ability to collect samples away
from clinical environments to then be sent back to laboratories for processing and anal-
ysis. This widens applicable research, but could also allow patients to collect their own
samples, allowing greater opportunity for recruitment to large scale population based
studies at reduced cost.
However, because of the lack of applications surrounding DBS and non-targeted
metabolomics, there are optimisations and recommendations to be made, methods to
be developed and applications of which can be used to validate DBS use within non-
targeted metabolomics.
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1.5.1 Research Objectives
This thesis aims to demonstrate the applicability of DBS in non-targeted metabolomics
research as well as define the limitations that may be present when applying DBS col-
lection. Therefore the subsequent four research chapters aim to investigate four sepa-
rate areas of metabolomics research where the knowledge gaps present currently limit
DBS from being applied. These are as follows:
Chapter 2 aims at defining the stability of DBS & DUS over an extended period
of time at different temperatures across the whole metabolome applying multiple
UHPLC-MS assays. Current research investigating the stability of the metabolome
when applying DBS collection is currently limited, with many studies focused on spe-
cific areas of the metabolome, or only investigating stability over a short period of time.
Additionally, there is very little in the way of published research surrounding the use
of DUS within the application of non-targeted metabolomics research.
Therefore this chapter aims to quantify the proportion of the metabolome which
could be expected to be stable when performing a long term study which would re-
quire knowledge about the behaviour of the metabolome over an extended period of
time.
Chapter 3 aims at developing a novel method of normalising for blood volumes
that are present when collecting blood spots without any accurate measurement of
volume at the time of sample collection. The requirement to normalise spots to col-
lected blood volume is important for the accurate relative quantification of metabolites
present within any DBS. Errors in measurement of these metabolites could introduce
greater technical variance between individual DBS, thus masking any genuine biolog-
ical variance between DBS.
Current methods used for the normalisation of blood volume in DBS either employ
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expensive technical equipment which may not be present in every laboratory, or de-
stroy the DBS during the measurement of any factor used for normalisation. The assay
applied, whilst not novel to the field of quantitative biology, has not been applied for
the normalisation of DBS before the publication of this thesis. The method, applying
the Bradford assay, is quick to perform and can be performed on left over sample af-
ter the initial extraction of metabolites from the sample, therefore gaining information
from a sample that is destined for waste.
Consequently, this chapter aims at defining the performance of employing such a
method and its ability to normalise samples both prior to the acquisition of data and
subsequently after data has been acquired.
Chapter 4 explores the development of a LESA-MS method to directly analyse a
DBS without prior need for sample extraction. Whilst LESA-MS has been applied
for the analysis of DBS before, it has only been used for the proteomic analysis of
DBS. Through the development of a fast and reliable LESA-MS method, the ability to
screen samples regularly could become commonplace in scenarios where looking for
anomalous levels of metabolites is required such as in areas involving inborn errors
of metabolism. In this chapter, different parameters which can be altered on the LESA
platform used to observe their effect on the data collected with recommendations given
based on their individual performance, with a final method recommendation made for
those that wish to apply LESA-MS to their samples.
Finally, Chapter 5 involves the study of two separate cohorts in developing world
countries where the excess of Vitamin A in young children’s diet is potentially causing
harmful side effects. To investigate the effect that excess Vitamin A has on a subjects
metabolome, the use of both dried serum spots and dried plasma spots are compared
against the current gold standard of metabolomics samples such as serum and plasma.
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Through comparing metabolomes which have been exposed to excess Vitamin A levels
in two independent populations and comparing the dried filter paper results to the
whole biofluid results, similarities and differences between the two samples types can
be reported and thus identifying whether there is potential for the application of dried
substrates in non-targeted metabolomic workflows.
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Chapter 2
Stability of Dried Blood and Urine
Spots
Note: Many parts of this chapter have been submitted for publication as part of a peer-reviewed
article in Analytical Chemistry. Palmer, E. A; Cooper, H. J.; Dunn, W. B.; Investigation of the
12-month stability and detectable metabolomes of dried blood and urine spots applying untar-
geted UHPLC-MS metabolomic assays; Analytical Chemistry. Article has been re-submitted
following reviewer comments.
2.1 Introduction
The use of dried blood spots (DBS) in non-targeted metabolomics research has advan-
tages over the typical whole blood sample collection and associated sample prepara-
tion and processing [183]. Samples can be collected quickly without the need for qual-
ified phlebotomists and the volumes collected are much smaller than those through
venipuncture draws.
Potential scenarios for collection of DBS away from clinical settings are therefore
possible whether that be in patient homes or in foreign countries where the presence
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of laboratory facilities to collect and process whole blood samples may not be present.
Additionally, the transportation of DBS samples is considered to be at much lower cost
due to the decreased volume of samples and can therefore be sent in an envelope rather
than require the use of specialist couriers and packaging to ensure sample integrity
[184]. Furthermore, where cost is considered, applying DBS to large scale population
based studies represents significant cost savings, in both the collection and storage
of many thousands of potential samples required. Therefore DBS collection can be
viewed as a future alternative to whole biofluid collection.
However, whilst the application of DBS collection cards within clinical settings
has been commonplace for many years with neonates and detecting inborn errors of
metabolism, their use for non-targeted metabolomics research is limited however with
issues surrounding normalisation, chromatography effects and stability.
The disadvantages associated with varying hematocrit level (correlated to red
blood cell count) and chromatographic effects of spotting biofluids onto collection
cards (with different rates of diffusion of different metabolites) can cause quantitative
issues. Importantly, hematocrit has been normalized through various factors such as
potassium content [94], using near infrared (NIR) spectroscopy [185] and hemoglobin
measurement using non-contact diffuse reflectance spectroscopy [186].
Chromatography effects [187] can be adjusted for through accurate volume collec-
tion[188, 189] (for example, Neoteryx kits) and extraction of the whole biofluid dried
spot, though different blood volumes are introduced on to the cards during sampling
and standardization of this volume is not possible.
Currently literature surrounding the application of non-targeted metabolomics for
the analysis of DBS is limited with papers published limited to investigating the is-
sues preventing the widespread adoption of metabolic phenotyping of DBS. Whilst
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the hematocrit variation between individuals and chromatography effect of spotting
samples has been widely discussed[190–192], the stability of the metabolites present
in a biofluid once dried on filter paper card has not been investigated in detail with
most studies focused on a single or a small set of metabolites applying targeted as-
says [193–195] than a global view of metabolites applying non-targeted metabolomics
assays [196–198]. Therefore, current literature that has published which demonstrates
the use of metabolic phenotyping when applied to DBS is limited and is mainly fo-
cussed on areas where DBS are already used such as inborn errors of metabolism [199],
rather than new and novel areas where DBS have yet to be applied. As such, current
literature is limited to either targeted metabolomic [200], semi-targeted [198] (low hun-
dreds of metabolites) or shorter term[196] (<1 month) approaches to defining stability.
The study described here presents a 12-month study of metabolite stability in DBS
and DUS samples stored at different temperatures (-20◦C, +4◦C and room temperature
(defined from now as +21◦C)) compared to plasma and urine samples stored under
the same conditions. Two complementary non-targeted ultra high performance liquid
chromatography-mass spectrometry (UHPLC-MS) assays were applied to maximize
metabolite detectable coverage. The influence of storage temperature on stability at 5
different time points (days 1, 14, 28 and months 6 and 12) were investigated.
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2.2 Methods and Materials
2.2.1 Materials
All extraction (HPLC grade Methanol and Water) and UHPLC solvents (Optima grade
Water, Isopropanol and Acetonitrile) were purchased from Fisher Scientific (Loughbor-
ough, UK). Formic acid (≥98.0% purity) was purchased from VWR International (Lut-
terworth, UK) and ammonium formate (≥98.0% purity) was purchased from Sigma
Aldrich (Poole, UK).
2.2.2 Sample Preparation
A single rat whole blood sample (collected in to Lithium Heparin plasma tubes) and a
single rat urine sample (pooled from multiple Wistar Hannover rats) were purchased
from Seralab (West Sussex, UK). Both pooled samples were delivered on ice and pro-
cessed within 36-48 hours of sample collection. Upon delivery, 20 µL of whole blood
or urine was pipetted onto Whatman 903 Protein Saver cards (Fisher Scientific, Lough-
borough, UK) and allowed to dry at room temperature for 3 hours before storage in foil
“Ziploc” bags alongside silica-based desiccant (Fisher Scientific, Loughborough, UK).
Plasma and urine samples were prepared from the same pool of whole blood and
urine, respectively, by centrifugation (2500g, 4◦C, 15 minutes) followed by aliquoting
of 20 µL into 2.0mL Eppendorf SafeLock tubes (Scientific Laboratory Supplies Ltd,
Hessle, UK).
All samples were stored in triplicates at three different temperatures (temperature
controlled at +4◦C and -20◦C and at room temperature (variable temperature, approx-
imately +21◦C). All samples were kept away from light at all times throughout storage
to prevent any UV degradation of metabolites.
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FIGURE 2.1: Flow diagram demonstrating the different conditions which
samples were kept in and for how long, including the general experimen-
tal design and workflow leading up to the analysis of data.
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Figure 2.1 demonstrates the conditions and length of time that samples were stored
in. Additional consideration had to be made when deciding whether or not to anal-
yse samples directly after extraction and perform multiple analyses across the year
compared to one large batch at the end. However the expected technical variation be-
tween instrument condition was expected to be higher than the biological variation,
thus potentially introducing difficulties when integrating multiple MS data sets col-
lected across an extended time span. Therefore, the degradation that could potentially
occur to metabolites, even when stored at -80◦C was considered to be preferable that
the expected alternative of large technical variation between experimental batches.
2.2.3 Sample Extraction
At set time points (days 1, 14 and 28 and months 6 and 12), samples stored at -20◦C
were removed from storage and allowed to defrost on ice for 30 minutes. Samples
stored at 4◦C and 21◦C were removed from storage and placed on ice for 30 minutes.
For both DBS and DUS samples, whole spots were removed from the collection card
using a sterile scalpel and cut into multiple pieces to aid the extraction process.
DBS samples were extracted in 100 µL of methanol/water (4:1 (v/v)), DUS were
extracted in 180 µL of methanol/water (8:1 (v/v)), 20 µL plasma was extracted in 80
µL methanol (assuming 20 µL water volume in plasma) and 20 µL urine was extracted
in 160 µL methanol (assuming 20 µL water volume in urine). All DBS and DUS samples
were then extracted under gentle agitation using a vortex mixer for 20 minutes before
centrifugation (21,000g, 4◦C, 15 minutes).
All plasma and urine samples were extracted under agitation for 30 seconds before
centrifugation (21,000g, 4◦C, 15 minutes). The supernatant for each sample was then
separated into two equal volume aliquots before being dried down under vacuum
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for 2 hours at 35◦C (Savant SPD111V SpeedVac Concentrator connected to a RVT5105
Refridgerated Vapout Trap, Thermo Scientific, UK). After drying, samples were stored
at -80◦C until analysis by UHPLC-MS after the 12-month storage period.
2.2.4 Ultra High Performance Liquid Chromatography - Mass Spec-
trometry (UHPLC-MS) Analysis
When ready for analysis, samples were reconstituted in suitable starting solvents (DBS
- 80 µL, DUS – 89.6 µL, Plasma - 112 µL, Urine – 142.4 µL) before vortexing and centrifu-
gation (21,000g, 4◦C, 15 minutes) and transferring into low recovery LC vials (Chro-
matography Direct Ltd., Runcorn, UK). A pooled QC sample was then prepared to
monitor instrument variability during analytical batches. QC samples were produced
from reconstituted samples by aliquoting 10 µL from each sample and pooling together
into a 2mL Eppendorf SafeLock tubes (Scientific Laboratory Supplies Ltd, Hessle, UK)
and vortexing thoroughly for 5 minutes.
Blank samples were additionally created through the extraction of blank filter paper
discs using the extraction methods outlined above. 40 µL of each reconstituted sample
was then subsequently aliquoted into low recovery LC vials.
Samples were analysed separately in positive and negative ion modes using a Van-
quish UHPLC coupled to an electrospray Q Exactive Plus mass spectrometer (Thermo
Scientific, San Jose, CA, US). Data were acquired at a mass resolution of 70,000 (FWHM
at m/z 200), with the AGC target set at 3e6.
Three separate assays were applied (assay 1, assay 2 and assay 3). Assays 1 and 2
were applied to study DBS and plasma samples and assays 1 and 3 were applied to
study DUS and urine samples. Samples to be analysed by assay 1 or 2 were reconsti-
tuted in 95% acetonitrile/water (v/v) and 60% acetonitrile/water (v/v) respectively,
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and samples to be analysed by assay 3 were reconstituted in 100% water. All assays
were 14 minutes in length.
Assay 1 was a hydrophilic interaction chromatography (HILIC) method which used
a Thermo Accucore 150 Amide column (2.1 x 100mm, 2.6 µm) with a flow rate of 500
µL/min and with two mobile phases, mobile phase A (10mM ammonium formate in
95% acetonitrile/water (v/v) + 0.1% formic acid) and mobile phase B (10mM ammo-
nium formate in 50% Acetonitrile/water (v/v) + 0.1% formic acid). A 14 minute gradi-
ent elution was applied as follows: 0 min, 1% B; 1 min, 1% B; 3 min, 15% B; 6 min, 50%
B; 9 min, 95% B; 10 min, 95% B; 10.5min, 1% B. A 4 µL injection volume was applied.
Assay 2 was a lipidomics method which used a Thermo Hypersil GOLD column
(2.1 x 100mm, 1.9 µm), with a flow rate of 400 µL/min flow rate and with two mobile
phases, mobile phase A (10mM ammonium formate in 60% acetonitrile/water (v/v)
+ 0.1% formic acid) and mobile phase B (10mm ammonium formate in 90% propan-2-
ol/acetonitrile (v/v) + 0.1% formic acid). A 14 minute gradient elution was applied as
follows: 0 min, 20% B; 0.5 min, 20%B; 8.5 min, 100% B; 9.5 min, 100% B; 11.5 min, 20%
B. A 4 µL injection volume was applied.
Assay 3 was an aqueous C18 reversed-phase method which used a Thermo Hypersil
GOLD aQ column (2.1 x 100mm, 1.9 µm) with a flow rate of 300 µL/min and with two
mobile phases, mobile phase A (0.1% formic acid in water) and mobile phase B (0.1%
formic acid in acetonitrile). A 14 minute gradient elution was applied as follows: 0
min, 1% B; 0.5 min, 1% B; 2 min, 50% B; 9 min, 99% B; 10 min, 99% B; 10.5 min, 1% B.
A 4 µL injection volume was applied.
Assay 1 applied a m/z range of 150-2000 Da, Assay 2 applied a m/z range of 70-1050
Da and Assay 3 applied a m/z range of 100-1500 Da. In total 8 batches of samples were
analysed with each batch representing one biofluid comparison using one assay in a
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single polarity mode. DBS and plasma samples were analysed together in the same
batch. DUS and urine samples were analysed in the same batch. All batches were
randomized across groups as such that 3 replicates of the same biofluid, time point and
temperature were measured sequentially within a run to ensure instrument drift did
not affect any subsequent precision calculations. Each batch was preceded by 5 leading
QC samples followed by an extraction blank sample and an additional 5 QC samples.
Batches were then terminated by 2 QC samples followed by a second extraction blank
sample. QC samples were analysed after every 6th injection.
2.2.5 Data Processing
Data were analysed applying Compound Discoverer 3.0 with processing parameters
shown in Appendix A. (Thermo Fisher Scientific, San Jose, USA). QC filtering of data
was performed and compounds with a relative standard deviation >20% for all QC
samples (from QC sample nine) were removed from the dataset prior to data analysis.
Compounds were retained when showing a RSD of less than 20% in QC samples. Data
matrices were exported as .csv files. Noise (peak response <10,000) were reported as
Not a Number (NaN). Metabolite features that were detected in <2 of 3 triplicates of
the identical sample type, storage temperature and storage time were replaced with a
missing value (NaN) for all three replicates.
Univariate statistical analysis (two-way repeated measures ANOVA and t-test)
were applied after normalization by sum and glog transformation and were performed
using MetaboAnalyst (version 4) [200].
Prior to multivariate analysis, data were normalised by sum and underwent glog
transformation and pareto scaling [201]. Missing values were imputed using the k-
nearest neighbour method for multivariate analysis. Multivariate statistical analysis
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was performed using Metaboanalyst [202]. To assess the blank contribution from the
filter cards we also processed the raw data with XCMS [203]. The parameters applied
are included in Appendix B.
2.2.6 Metabolite Identification
Metabolite identification was performed by applying the mzCloud & Chemspider
Search modules in Compound Discoverer applied MS1 matching to molecular for-
mula and MS2 spectral matching to compounds present in the mzCloud mass spec-
tral database. Additionally, in-house mass spectral annotation software applying MS1
data only were applied to provide further annotations. Accurate mass annotations
were made against HMDB, KEGG and LIPIDMAPS databases using a 5ppm mass er-
ror window. The workflows produced annotations consistent with reporting level 2 of
the Metabolomics Standards Initiative recommendations [182] for annotated metabo-
lites.
2.3 Results and Discussion
UHPLC-MS data were collected and processed to generate four data matrices con-
structed of metabolites (rows) vs. samples (columns). Metabolites were reported after
grouping of all metabolite features in to a single metabolite (or compound as defined
in Compound Discoverer). All metabolites demonstrated a relative standard deviation
(RSD) of less than 20% and a detection rate >70% for all QC samples following data
filtering in Compound Discoverer 3.0.
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Principal Components Analysis scores plots for all four combined biofluid-dried
biofluid datasets showed compact clustering of replicate injections of QC samples com-
pared to the same single biological sample stored at different temperatures and periods
of time and therefore demonstrates suitable data quality to proceed with further anal-
ysis of the data (Appendix C).
2.3.1 Metabolite information content of DBS and DUS samples
DBS filter paper cards are expected to contain non-biological chemicals released dur-
ing sample extraction. The software applied (Compound Discoverer) performed re-
moval of blank-related peaks from the dataset. To investigate whether chemicals were
present and extracted from the DBS cards, data were processed with XCMS to define
the number of blank-related peaks. These data showed that across all assays applied,
14.7-19.4% of all detected signals were extracted chemicals from the filter paper used
in DBS cards. These results highlight the importance of analyzing an extracted blank
DBS card to remove detected peaks which are not of biological origin.
Base peak chromatograms for each assay and pair of samples are shown in Ap-
pendix D and demonstrate that the biofluid and associated dried sample are visually
comparable. Further investigations showed that the majority of metabolites detected
in the biofluid (plasma or urine) were also detected in the dried sample (Table 2.1).
One limitation of dried blood and urine spot sample collection is that lower biofluid
volumes are typically collected compared to plasma, serum and urine samples and
therefore analytical sensitivity can be decreased. Comparisons were made to data ac-
quired from the analysis of plasma applying the same analytical methods but using 60
µL rather than 20 µL biofluid volumes and the results are shown in Table 2.1; 60 µL
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TABLE 2.1: Comparison of metabolites detected in dried blood spots,
plasma, dried urine spots and urine following extraction of either 20 µL or
60 µL sample volumes. Two assays were applied in positive and negative
ion modes to analyse each sample type to maximize metabolite coverage.
Reported detected metabolites is before filtering of data related to stability.
Sample Type Assay Polarity Sample Volume Collected (µL) Number of Metabolites Detected
Dried Blood Spot
HILIC Positive 20 537Negative 20 417
Lipidomics Positive 20 2162Negative 20 1110
Plasma
HILIC Positive 20 364Negative 20 337
Lipidomics Positive 20 1554Negative 20 981
Dried Urine Spot
HILIC Positive 20 2449Negative 20 1029
C18 Reversed-phase
Positive 20 4558
Negative 20 3019
Urine
HILIC Positive 20 2327Negative 20 1022
C18 Reversed-phase
Positive 20 4900
Negative 20 3043
Plasma
HILIC Positive 60 1000Negative 60 628
Lipidomics Positive 60 1889Negative 60 1221
Urine
HILIC Positive 60 2638Negative 60 2327
C18 Reversed-phase
Positive 60 3684
Negative 60 4785
volumes are the standard volume applied in the author’s laboratory. For plasma, in-
creased numbers of metabolites are detected when applying the larger sample volume.
Increased analytical sensitivity may provide greater metabolite coverage (for example,
the use of 1.0mm ID instead of 2.1mm ID analytical columns [182]).
Comparison of data collected for urine showed a mixed set of conclusions; nega-
tive ion mode assays showed higher numbers of detected metabolites when the higher
sample volume was applied but this was not observed for positive ion mode data in
either assay.
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TABLE 2.2: The number of metabolites identified as unstable in dried blood spots and plasma derived
from rats following storage for 14, 28, 180 and 365 days at three different storage temperatures (-20◦C,
+4◦C and +21◦C))
Sample Type Assay Polarity Time Comparison (Days) Storage Temperature (-20◦C) Storage Temperature (+4◦C) Storage Temperature (+21◦C)
DBS
HILIC
Positive
1 vs. 14 0 (0.0%) 0 (0.0%) 2 (<0.1%)
1 vs. 28 5 (0.1%) 64 (6.0%) 260 (24.4%)
1 vs. 180 0 (0.0%) 237 (22.3%) 394 (37.0%)
1 vs. 365 67 (6.3%) 249 (23.4%) 503 (47.3%)
Plasma
1 vs. 14 112 (10.5%) 16 (1.5%) 385 (36.2%)
1 vs. 28 25 (2.3%) 155 (14.6%) 475 (44.6%)
1 vs. 180 553 (52.0%) 588 (55.3%) 698 (65.6%)
1 vs. 365 690 (64.8%) 688 (64.7%) 806 (75.8%)
DBS
Negative
1 vs. 14 0 (0.0%) 0 (0.0%) 0 (0.0%)
1 vs. 28 0 (0.0%) 0 (0.0%) 4 (0.5%)
1 vs. 180 12 (1.6%) 6 (0.8%) 215 (29.4%)
1 vs. 365 5 (0.7%) 79 (10.8%) 506 (69.4%)
Plasma
1 vs. 14 0 (0.0%) 37 (5.1%) 168 (23.0%)
1 vs. 28 4 (0.5%) 0 (0.0%) 227 (31.1%)
1 vs. 180 170 (23.3%) 177 (24.3%) 233 (32.0%)
1 vs. 365 391 (53.6%) 176 (24.1%) 520 (71.3%)
DBS
Lipidomics
Positive
1 vs. 14 0 (0.0%) 75 (1.9%) 0 (0.0%)
1 vs. 28 0 (0.0%) 2 (0.1%) 24 (0.3%)
1 vs. 180 0 (0.0%) 216 (5.5%) 549 (13.9%)
1 vs. 365 - - -
Plasma
1 vs. 14 0 (0.0%) 9 (0.2%) 2979 (75.6%)
1 vs. 28 0 (0.0%) 147 (3.7%) 2948 (74.8%)
1 vs. 180 483 (12.3%) 2443 (62.0%) 3264 (82.9%)
1 vs. 365 1196 (30.4%) 2586 (65.7%) 3276 (83.2%)
DBS
Negative
1 vs. 14 0 (0.0%) 2 (0.2%) 0 (0.0%)
1 vs. 28 0 (0.0%) 5 (0.4%) 12 (0.9%)
1 vs. 180 2 (0.2%) 30 (2.4%) 86 (6.8%)
- - - -
Plasma
1 vs. 14 0 (0.0%) 22 (1.7%) 61 (4.8%)
1 vs. 28 0 (0.0%) 69 (5.4%) 962 (75.6%)
1 vs. 180 329 (25.8%) 735 (57.7%) 1027 (80.7%)
1 vs. 365 508 (39.9%) 667 (52.4%) 1079 (84.8%)
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TABLE 2.3: The number of metabolites identified as unstable in dried urine spots and urine derived from
rats following stor-age for 14, 28, 180 and 365 days at three different storage temperatures (-20◦C, +4◦C
and +21◦C)
Sample Type Assay Polarity Time Comparison (Days) Storage Temperature (-20ĄC) Storage Temperature (+4ĄC) Storage Temperature (+21ĄC)
DUS
HILIC
Positive
1 vs. 14 0 (0.0%) 0 (0.0%) 5 (0.2%)
1 vs. 28 0 (0.0%) 5 (0.2%) 312 (9.7%)
1 vs. 180 0 (0.0%) 127 (4.0%) 1807 (56.4%)
1 vs. 365 2 (0.1%) 486 (15.2%) 1272 (39.7%)
Urine
1 vs. 14 0 (0.0%) 8 (0.2%) 1162 (36.3%)
1 vs. 28 0 (0.0%) 65 (2.0%) 1544 (48.2%)
1 vs. 180 97 (3.0%) 796 (24.8%) 1737 (54.2%)
1 vs. 365 193 (6.0%) 1037 (32.4%) 2096 (65.4%)
DUS
Negative
1 vs. 14 0 (0.0%) 0 (0.0%) 0 (0.0%)
1 vs. 28 0 (0.0%) 0 (0.0%) 67 (6.0%)
1 vs. 180 0 (0.0%) 0 (0.0%) 232 (20.9%)
1 vs. 365 5 (0.5%) 286 (25.7%) 419 (37.7%)
Urine
1 vs. 14 0 (0.0%) 1 (0.1%) 920 (82.8%)
1 vs. 28 0 (0.0%) 0 (0.0%) 550 (49.5%)
1 vs. 180 10 (0.9%) 227 (20.4%) 877 (78.9%)
1 vs. 365 86 (7.7%) 370 (33.3%) 889 (80.0%)
DUS
Reversed-phase
Positive
1 vs. 14 3 (<0.1%) 0 (0.0%) 0 (0.0%)
1 vs. 28 0 (0.0%) 0 (0.0%) 48 (0.8%)
1 vs. 180 0 (0.0%) 0 (0.0%) 2335 (37.8%)
1 vs. 365 0 (0.0%) 609 (9.9%) 1488 (24.1%)
Urine
1 vs. 14 0 (0.0%) 15 (0.2%) 1500 (24.3%)
1 vs. 28 1 (<0.1%) 1 (<0.1%) 3643 (59.0%)
1 vs. 180 1 (<0.1%) 1250 (20.2%) 3680 (59.6%)
1 vs. 365 0 (0.0%) 1402 (22.7%) 4080 (66.1%)
DUS
Negative
1 vs. 14 1 (0.0%) 2 (0.0%) 2 (0.0%)
1 vs. 28 0 (0.0%) 0 (0.0%) 16 (0.4%)
1 vs. 180 1 (0.0%) 58 (1.6%) 801 (21.7%)
1 vs. 365 4 (0.1%) 381 (10.3%) 981 (26.5%)
Urine
1 vs. 14 0 (0.0%) 0 (0.0%) 2143 (58.0%)
1 vs. 28 0 (0.0%) 24 (0.6%) 2973 (80.5%)
1 vs. 180 10 (0.3%) 722 (19.5%) 2794 (78.6%)
1 vs. 365 6 (0.2%) 860 (23.3%) 2856 (77.3%)
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For urine, no significant number of additional metabolites were detected in the
biofluid compared to the dried sample and vice versa (Table 2.1). However, and as
expected, additional metabolites were detected in the DBS samples with the additional
metabolites suggested to originate from the red and white blood cells present in whole
blood and which are removed using centrifugation in the preparation of plasma (Table
2.1). 23.7 and 47.5% of additional metabolites were detected in the HILIC negative
and positive ion modes, respectively. 13.1 and 39.1% of additional metabolites were
detected in the lipidomics negative and positive ion modes, respectively.
The annotated metabolites detected in DBS and not in plasma are comprised of
five major enriched classes of acyl carnitines (21 metabolites), aromatic metabolites
(18 metabolites), fatty acids/esters/oxidized fatty acids (34 metabolites), glycerophos-
pholipids (42 metabolites) and lysoglycerophosphoserines (12 metabolites). The fatty
acids and (lyso)glycerophospholipids suggest detection of lipid components of cell
membranes and potentially lipoproteins. Acyl carnitines shuttle long chain fatty acids
across the inner mitochondrial membrane and so can be expected to be cell-derived.
The exclusion of glycolytic intermediates suggest that either (i) the whole blood vol-
ume used does not allow detection of many metabolites expected to be present only
within the cell, (ii) that cells in DBS samples are not lysed during storage or extraction
and therefore metabolites are not released from the cell for analysis or (iii) the metabo-
lites are not present at any concentration or are present but at a concentration below
the assay’s limit of detection.
70 Chapter 2. Stability of Dried Blood and Urine Spots
FIGURE 2.2: Plot demonstrating the number of statistically significant an-
notated features at each time point and temperature. Plot represents the
HILIC positive results for the DBS and plasma comparison. All other plots
can be found in Appendix E
2.3.2 Stability of dried blood and dried urine spots stored at different
temperatures
We performed t-test analyses to compare day 1 data to each other time point separately
for each storage temperature and UHPLC-MS assay. The results are shown in Table 2.2
for DBS/plasma and Table 2.3 for DUS/urine. A critical p-value of 0.1 (following cor-
rection for multiple testing using Benjamin Hochberg method) and a relative change of
greater than 20% was applied to define a metabolite which was identified as being un-
stable or whose relative concentration changed for another reason. Visual comparison
of the data described in Tables 2.2 and 2.3 are included in Appendix E with an example
shown in Figure 2.3.
A lowest storage temperature of -20◦C was chosen to study as previous studies
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have assessed storage at -80◦C and demonstrated this as an appropriate storage tem-
perature [198, 204]. The results showed that DBS samples were stable at -20◦C over
the first six months (less than 1.6% of detected metabolites showed a change in rela-
tive concentration). Some additional instability is observed between months 6 and 12
(in total less than 6.3% of detected metabolites showed a change in relative concen-
tration). We therefore conclude that collection and immediate storage of dried blood
spots at -20◦C provides a stable and representative sample for metabolomics studies
for a minimum of 12 months and for the majority (but not all) metabolites. DBS sam-
ples showed a greater level of instability if stored at 4◦C or room temperature for 6
or 12 months, with 2.4-23.4% of metabolites showing a relative concentration change
depending on the UHPLC-MS assay. These results validate other short-term studies of
up to 1 month applying non-targeted and targeted assays and long-term studies of up
to 2 years applying a targeted assay for detection of amino acids and acyl carnitines.
These studies demonstrated short-term stability at room temperature but increased
instability with storage at room temperature over time and recommendations for stor-
age at -20◦C [195, 198, 204, 205]. Importantly, storage at -20◦C and -80◦C across 1
month has shown similar levels of stability and so samples do not necessarily have
to be stored at -80◦C [205]. In the study reported here, more metabolites were unsta-
ble in the HILIC assay data compared to the lipidomic dataset suggesting changes in
polar metabolites. We therefore recommend that DBS samples can be collected and
transported at room temperature for up to 28 days but recommend storage at -20◦C or
-80◦C for longer term storage. DBS samples were more stable than plasma samples at
all storage temperature and time comparisons investigated in this study. Metabolites
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FIGURE 2.3: PCA plot demonstrating the separation and clustering of
plasma and dried blood spot samples respectively. Plot represents the
HILIC positive results for the DBS and plasma comparison. All other plots
can be found in Appendix E
which showed instability within the first 28 days after dried blood spot collection in-
cluded sphingosine, vitamins A and E and tryptophan/phenylalanine-related metabo-
lites with lower relative concentrations at 28 days compared to 1 day storage at room
temperature. (This data and following conclusions related to this data can be found in
Appendix F.) Increased proteolysis was observed also with many peptides detected at
higher concentrations at day 28 compared to day 1 storage at room temperature.
Longer term instability at 6 and 12 months was observed in multiple metabo-
lite classes including primarily glycerophospholipids, lysoglycerophospholipids and
acyl carnitines which all showed large decreases in their concentrations at day
365 compared to day 1 storage at room temperature. Decreased concentrations of
(lyso)glycerophospholipids and acyl carnitines does not appear to be caused by their
enzymatic degradation and release of fatty acids because increased concentrations of
2.3. Results and Discussion 73
fatty acids were not observed. The decreased concentrations may be caused by non-
enzymatic degradation which releases other chemicals and products which are not
fatty acids or may be caused by continued drying and absorption on to the filter paper
over 12 months with the use of methanol as an extraction solvent not providing the
release of glycerophospholipids from the filter paper. Further studies are required to
confirm this though a similar number of glycerophospholipids were detected in this
study which showed no relative change in concentration which suggests that poor ex-
traction efficiency is not the cause.
Increased proteolysis was observed also with many peptides detected at higher
concentrations at day 28 compared to day 1 storage at room temperature. We expected
to see significant increases in lipid oxidation but only a small percentage of oxidized
lipids were detected applying our UHPLC-MS assays and only a small number of those
detected showed changes in relative concentration. Oxidised lipids may be present but
at concentrations lower than were detectable applying the volumes and assays applied
in this study. The storage of samples in a sealed dark bag with a desiccant may also
help to protect lipids from oxidation but further studies would be required to test this
hypothesis.
A similar conclusion can be derived for stability of DUS samples as was discussed
for DBS samples above. Less than 0.5% of detected metabolites were unstable if stored
at -20◦C for up to 365 days compared to urine which demonstrated up to 80% of
metabolites to be unstable. Storage of DUS at 4◦C for up to 180 days showed less
than 4% of metabolites to be unstable and if extended to 365 days showed less than
23.4% of metabolites to be unstable. If stored at room temperature then up to 10% of
metabolites are unstable after 28 days and up to 40% of metabolites are unstable up to
365 days. We therefore recommend that DUS samples can be collected and transported
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at room temperature for up to 28 days but recommend storage at -20◦C or -80◦C for
longer term storage.
DUS samples were more stable than urine samples at all storage temperatures and
time comparisons investigated in this study. Dopamine showed a 500-fold decrease
in relative concentration after 12 months compared to day 1 DUS samples. Vitamin
C (ascorbate metabolites showed lower relative concentrations at 365 days compared
to day 1 also. Of interest was that a large number of metabolites were stable when
present in plasma and urine at +21◦C for 12 months. Both of the biofluids studied
were acellular and therefore no cellular metabolism can be expected to be occurring
as both biofluids do not contain enzymes at a high concentration and therefore lack of
metabolism will help maintain the stability in metabolite concentrations across the 12
months. Instability of metabolites can be proposed to occur through thermal degrada-
tion.
This study has provided a broad panel of detected metabolites but shows limita-
tions. Firstly, we applied whole blood and urine samples which had been stored on
ice for 36-48 hours before being processed and spotted on to DBS cards. This storage
period could allow for degradation of highly labile metabolites (e.g. glutathione and
ATP) and bias the results though the cellular metabolic flux would be much lower than
observed at a body temperature of 37◦C. Secondly, we applied one pooled sample for
each biofluid and did not assess across multiple rats and other mammalian species.
Thirdly, the precision measurement used to define whether a metabolite was unstable
was +/-20% which is very conservative because biological variability between differ-
ent subjects in serum and urine is typically much higher (see [206, 207] for examples).
Finally, we used a single extraction solution for both UHPLC-MS assays applied to
each sample type and therefore detection of all lipids was not possible (for example,
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only a small number of triacylglycerides and cardiolipins were detected).
2.4 Conclusion
The study presented has shown that DBS samples and DUS samples can provide broad
metabolome coverage and therefore offer an alternative to collection of whole blood,
plasma, serum and urine away from a clinic and where specialized staff and laborato-
ries are not available. Broad metabolome coverage was observed with 20 µL of biofluid
which was subsequently dried compared to a typically used volume of 60 µL which
is applied in the author’s and others laboratories. However, when applying standard
UHPLC-MS assays, fewer metabolites were detected when compared to the analysis
of standard volumes of biofluid, thus development of an assay providing increased
analytical sensitivity would be appropriate (for example, using 1.0mm ID or narrower
UHPLC columns or through sample enrichment).
Collection, transport and short term storage of dried blood and urine spot samples
at room temperature is appropriate and provides only a small number of metabolites
where relative concentration changes were observed. However, instability increased
across time for the two higher storage temperatures and long term storage at room tem-
perature is not recommended, instead storage at -20◦C or -80◦C being recommended.
The study has provided a general recommendation for temperatures for collection,
transport and short-term and long-term storage. However careful design of experi-
ments and thought should be undertaken to ensure that using cellulose based collec-
tion cards are suitable for the experiment to be considered. This is due to the still
high proportion of metabolites that have unacceptably high RSD’s, when just a reduc-
tion in storage temperature for the whole biofluid can outweigh the benefit of using
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DBS and DUS. This could especially be the case for small scale local studies where
the logistical effort of collecting DBS/DUS samples will not necessary be financially
or scientifically beneficial. However, benefits are clear for larger scale studies where
samples are required to be sent through local postal mail services and the logistical
challenge of recruiting subjects to travel to clinics for whole blood sample collection
can be challenging. The use of filter paper collection cards within this scenario could
provide a large cost saving, and the benefits of being able to recruit larger cohort sizes
can potentially increase the statistical power of studies which can be a major issue in
metabolomic studies.
Although a large number of blank features were present within the datasets, due
to the way in which DBS and DUS are collected, direct comparison against blank filter
paper from the same card can also be made, thus removing any potential interfering
features that will inevitably be extracted directly from the collection card. This is not
necessarily possible with biofluid samples where samples may be sent between col-
laborators where samples have been processed using multiple tubes and unused tubes
are not normally available to determine their contribution to the metabolic profile ac-
quired.
Whilst DBS samples have a much greater use within clinical research, DUS also
have been demonstrated to provide an alternative means of sample collection, with
appropriate stability demonstrated at room temperatures, once again providing suit-
able processes are in place for samples to be placed into long term storage at reduced
temperatures at a later date. Once again, with smaller volumes required and the ease of
transportation and storage, the use of DUS afford the same advantages as DBS whilst
also removing the minimal invasive collection procedure that DBS require. Addition-
ally, due to the large volumes of urine that are collected in a single sample, many more
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replicates can be made, whilst also allowing accurate volume samples to be prepared,
thus removing volume related variance issues that are present in with the collection of
DBS samples.
Further work that could be conducted would be looking at the effect that differ-
ent collection devices (such as Neoteryx’s Mitra and Spot On Science’s HemaSpot col-
lection devices) also has on the stability of samples. Furthermore, additional semi-
targeted research could be conducted applying Biocrates p180 and p400 kits to iden-
tify stability of a smaller, more select number of metabolites compared to the number
measured in a non-targeted study.
Studies also looking at the short term stability of metabolites throughout the dry-
ing process would also be of interest, with potential implications on the storage of DBS
and DUS whilst samples are being prepared. With typical procedures relying on the
drying of samples at ambient temperatures for multiple hours, there will no doubt
be biological changes occurring much faster than the time scale that this research ob-
serves. Therefore it would be of interest to identify these changes to further understand
the limitations of DBS collection.
Overall DBS and DUS will remain popular choices for the collection of biofluid
samples in targeted studies for the foreseeable future, and with the development of
techniques aimed at reducing the quantitative effects of storing blood and urine as
dried specimens, they will become of greater use in non-targeted settings and in the
development of personal health monitoring scenarios.
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Chapter 3
Applying the use of a total protein
content assay to normalise for variation
in dried blood spot volume
3.1 Introduction
Non-targeted metabolomics data contains both non-biological and biological sources
of variation. Ensuring that these sources of variation have minimal effects on the data
is important in the valid interpretation of any analysis performed. Typically, normal-
isation to correct for this variance can occur prior to the analysis of samples, through
alteration of reconstitution volumes, or computationally afterwards applying calcula-
tions to every measurement made.
Sources of biological variation can arise from many factors which can be difficult
to account for, even in the most controlled experimental settings. The most common
sources of biological variation within mammalian systems include the age and sex of
the subject in which the sample has been taken from. Due to the different biochem-
ical processes that occur between different sexes and subjects of different ages, these
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ultimately effect the levels of metabolites which are subsequently analysed in any non-
targeted study. Additionally, the fed and fasted states of subjects can have large influ-
ences on specific metabolites. Therefore careful design of experiments are required in
ensuring that large sources of biological variation that are unrelated to potential class
information are not introduced.
Non-biological variation occurs after the sample has been collected. This can be
introduced through poor liquid handling techniques or instrument setup procedures
which subsequently effect any measurement made. Careful sample handling and
preparation is therefore required in addition to proper standard operating procedures
in setting up and calibrating instruments. Any failure in the above can drastically
effect results obtained from incorrectly calibrated instruments to large drops in sensi-
tivity based on poor sample preparation procedures.
A common technique in correcting for biological variation is normalising
data based on the measurement of a physiological paramter. Normalisation of
metabolomics data based on a physiological measurement within the sample itself has
been commonplace within many non-targeted and targeted metabolomics applications
for many years [208, 209]. One of the most common biofluids that is corrected for is
urine. Due to the large variation in volume of urine that is collected day to day, it is
necessary to normalise data to ensure integrity. This variation can be due to many fac-
tors including simply the hydration status of the subject donating the sample to the
kidney function and its ability to excrete urine [210]. Therefore there has been exten-
sive research performed in the area of methods to normalise urine after the donation
of the sample but before acquisition itself.
More straight forward is the normalisation of biofluid samples which can be seen
as having low biological variability within the donor subject itself such as serum or
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plasma. Due to the low variation in samples collected simply based on basic physiolog-
ical health such as weight or hydration status, these types of samples are not normally
normalised prior to data acquisition, and instead normalisation typically occurs post
acquisition of data [211–214]. This is to correct for any inherent biases in the analyti-
cal collection of the data instead of the biologically variation within the sample. This
could either be arising from instrument drift or from biases occurring throughout sam-
ple preparation. As with normalising urine prior to the collection of data, normalising
post acquisition has been the focus of many researchers and can be computationally
achieved through multiple techniques such as through probabilistic quotient normali-
sation [211] or normalisation by sum [Xia2011xx], mean [martuccixx] or median [214]
of metabolite responses across a sample as a normalisation factor [201].
In addition to serum/plasma and urine based metabolomics experiments, studies
involving tissues also require the use of normalisation to ensure that the mass differ-
ences that will arise due to the collection of different samples, has no overall effect on
the outcome of the experiment. Typically, samples are normalised via their weight and
then reconstituted in varying amounts of solvent depending on the overall weight of
the sample itself [215].
Both methods of normalisation, whether it is normalising prior to data acquisition,
or computationally, after the data has been collected, are key aspects of the experimen-
tal design to ensure that any external non biological variability within the samples is
controlled and any genuine biological variation between sample classes is not masked
and can be interpreted correctly to ensure either a valid hypothesis being generated or
validated.
Compared to the techniques presented above, if a normalisation procedure were to
be applied to DBS, it would easily be thought of as most convenient to use a method
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which corrects for the total volume of blood that has been spotted onto the card, as per
procedures undertaken when normalising for tissues. However, if DBS are collected
directly onto a collection card with no prior measurement of blood volume as is very
typical in clinical and research settings, then this is not possible, and the volume of
blood actually deposited onto the card is unknown. An additional complication with
DBS, is the heamatocrit level of each individual patient. Due to varying haematocrit
levels, the volume of blood within a DBS is not proportional to its size on the collection
card. Ultimately this means that spots of higher haematocrit demonstrate a smaller
radius of DBS compared to those with lower haematocrit levels. Additionally, this also
means if fixed size hole punches are taken from spots, then different volumes of blood
are being extracted from sample to sample.
There are volume specific collection devices within the field of collecting whole
blood [216–220], however in terms of the popularity of filter paper based collection
cards both in regard to the minimal cost in being able to allow patients to collect their
own samples, to the many hundreds of thousands of samples that have already been
collected and stored in biobanks around the world, these devices are not going to solve
the issue of volume variation for studies which wish to look at these samples directly.
Methods have been published which demonstrate the ability to measure several
characteristics of DBS of which can then be normalised against [191, 221, 222], however
many of these methods either require spare samples due to the destructive nature of
the test or expensive instruments in order to characterise various aspects.
This chapter aims at demonstrating a cheap, easy, quick and non-destructive
method for the determination of total protein content within a DBS in order to nor-
malise against varying blood volumes that will be present from sample to sample. To
measure the total protein content of a sample, a Bradford assay was used which fulfils
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all the criteria for a suitable test.
In order to test the validity and effectiveness of any normalisation that has been
performed, various performance metrics will be used to identify any improvement
in the quality of the data. This includes monitoring the range of RSD’s seen across
all detected metabolites, the total number of features which demonstrate an RSD of
less than 30%, the sum of all intensities for all features as well as the total number of
significant features between different volumes.
Through the monitoring of these features a recommendation can be made regarding
the usefulness and effectiveness of performing a Bradford Assay on DBS as a means to
normalise for differing total blood volumes on each spot.
3.2 Materials and Methods
3.2.1 Materials
HPLC Grade methanol, water, acetonitrile and isopropanol were purchased from VWR
Chemicals. Rat whole blood (Pooled gender, Wistar Hannover strain) was purchased
from BioIVT. Whole blood was collected in lithium heparin collection tubes to prevent
coagulation before preparation of DBS. Time between collection of whole blood and
preparation of DBS was less than 48 hours. Whatman 903 filter paper collection cards,
dessicant and foil ziploc bags were purchased from Fisher Scientific (Loughborough,
UK). 2M hydrochloric acid, bovine serum albumin and Coomassie Brilliant Blue G
(CBB-G) were purhcased from Merck (Poole, UK). Deionised water (d.H2O) was pre-
pared in laboratory using an Elix Essential 10 UV water purification system (Merck,
UK). .
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3.2.2 Sample Preparation
DBS samples were prepared by pipetting accurate volumes of rat whole blood onto
Whatman 903 Filter Paper based collection Cards. Cards were then allowed to dry for
three hours at ambient temperature before storage at -80◦C until analysis. In total five
different volumes of blood were deposited onto DBS collection cards (10 µL, 15 µL, 20
µL, 25 µL, 30 µL).
3.2.3 Metabolite Extraction
Samples were removed from storage and allowed to defrost on ice for 30 minutes prior
to extraction. Samples were then incised from the collection card using a sterile scalpel
and cut into smaller sizes to aid in extraction by increasing surface area of the spot.
Samples were then extracted in 500 µL of methanol under gentle agitation using a vor-
tex mixer for 20 minutes before centrifugation (21000 g, 4 ◦C, 20 minutes). Supernatant
from each sample was then transferred into two separate aliquots (150 µL each) before
being dried down under vacuum for 40 minutes at 35 ◦C. After drying samples were
stored at -80 ◦C until analysis by UHPLC-MS.
3.2.4 Extraction of DBS protein
After aliquots had been taken for the metabolomics analysis, the remainder of the sam-
ple (including the DBS as prepared in Section 3.2.3) was dried down under vacuum
for 30 minutes at 35 ◦C to remove any excess organic solvent. Subsequently, 1 mL of
deionised water was then added to the DBS sample and mixed under high agitation
using a vortex mixer followed by centrifugation (21000 g, 4 ◦C, 5 minutes). A 125 µL
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aliquot was then taken and diluted with 875 µL of deionised water and mixed thor-
oughly. Another 125 µL was then taken in duplicate and added to a 96 well plate
ready for total protein content determination.
3.2.5 Preparation of Bradford Assay standard curve
The protocol used follows a modified version of [223]. Stock solution of 1 mg/ml of
BSA was prepared and subsequently diluted into the following concentrations with
deionised water, 100 µg/ml, 70 µg/ml, 60 µg/ml, 50 µg/ml, 40 µg/ml, 35 µg/ml, 25
µg/ml, 16 µg/ml, 10 µg/ml, 8 µg/ml, 6 µg/ml, 4 µg/ml, 2 µg/ml, 1 µg/ml. 125 µL
of each concentration was then prepared in triplicate into a 96 well plate alongside
samples.
3.2.6 Preparation of CBB-G reagent and total protein content analy-
sis
A CBB-G stock solution was prepared by dissolving 60 mg of CBB-G in 100 mL of 2M
HCl and stirring for 40 minutes before being filtered using a 0.2 µm syring filter to en-
sure a particulate free solution. A CBB-G working solution is then prepared by mixing
together d.H2O, CBB-G stock and 2M HCl (3:1:1, v/v/v). After preparation, 125 µL of
CBB-G working solution is then added to each sample in the 96 well plate. The 96 well
plate was then incubated for 10 minutes at room temperature before analysis using a
TECAN Infinite F200 Pro microplate reader running TECAN iControl (v1.10) software
applying an absorbance wavelength of 595 nm.
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3.2.7 Reconstitution of Samples for Metabolomics Analysis
3.2.7.1 Post-Data Acquisition Normalisation
Samples to be normalised post data acquisition were all resuspended in 56 µL of appro-
priate solvent depending on the LC assay performed. For samples analysed applying
a lipidomics assay this was a mixture of 75% IPA and 25% water. For samples analysed
applying a HILIC assay this was a mixture of 95% acetonitrile and 5% water.
3.2.7.2 Pre-Data Acquisition Normalisation
Samples which were normalised pre-data acquisition, were resuspended according to
the total protein content measured in Section 3.2.6. Volumes samples are resuspended
in are shown in Table 3.1.
3.2.8 UHPLC-MS Analysis
Samples were analysed in both positive and negative ion modes applying both a HILIC
and lipidomics method using a Thermo Vanquish UHPLC coupled to a Thermo Q-
Exactive Plus MS (Thermo Scientific, San Jose, CA).
A pooled QC sample was prepared from the extracts of all samples (including sam-
ples which were normalised both pre and post data acquisition) and then prepared in
the same way as all samples before being injected every 8th sample with 10 leading
QC’s to condition the column. Both LC methods were 14 minutes in length and data
was collected at mass resolution 70,000 resolution (FWHM at m/z 200). The HILIC
method used an Accucore 150 Amide column (100 mm x 2.1 mm i.d., 1.9µm pore size).
Solvent A was acetonitrile/water/formic acid (95/4.9/0.1, v/v/v) with 10 mM am-
monium formate. Solvent B was acetonitrile/water/formic acid (50/49.9/0.1, v/v/v)
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TABLE 3.1: Reconstitution volumes (µL) for each sample based on the
method of normalisation.
Volume Replicate Pre Data Acquistion (µL) Post Data Acquisition (µL)
10
A 56 56
B 62 56
C 59 56
D 60 56
15
A 109 56
B 117 56
C 106 56
D 102 56
20
A 136 56
B 148 56
C 122 56
D 120 56
25
A 157 56
B 157 56
C 156 56
D 168 56
30
A 183 56
B 162 56
C 175 56
D 193 56
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FIGURE 3.1: Experimental workflow demonstrating the two separate nor-
malisation methods and when normalisation was applied.
with 10 mM ammonium formate. A 14 minute gradient elution was applied as follows
using a 500 µL/min flow rate: 0 min, 1% B; 1 min, 1% B; 3 min, 15% B; 6 min, 50% B;
9 min, 95% B; 10 min, 95% B; 10.5min, 1% B. The lipidomics method used a Hypersil
Gold C18 (2.1 x 100mm, 1.9 µm), with a flow rate of 400 µL/min flow rate and with two
mobile phases, mobile phase A (10mM ammonium formate in 60% acetonitrile/wa-
ter (v/v) + 0.1% formic acid) and mobile phase B (10mm ammonium formate in 90%
IPA/acetonitrile (v/v) + 0.1% formic acid). A 14 minute gradient elution was applied
as follows applying a 400 µL/min flow rate: 0 min, 20% B; 0.5 min, 20%B; 8.5 min,
100% B; 9.5 min, 100% B; 11.5 min, 20% B.
3.2.9 Data Pre-Processing
Raw data was first converted to .mzML format using ProteoWizard (version 3.0.1921)
before peak picking and retention time alignment using XCMS (version 3.8.0). Param-
eters for processing are described in Appendix B. The resultant peak matrix was then
filtered to remove low quality peaks applying the following filters: each feature had
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to be present in at least 60% of all QC samples; features had to show an RSD of less
than 30% across all QC samples (except the first 8 which were used for column equi-
libration); finally the mean QC response for each feature had to be 10 times greater
than the average blank response. All other features were removed. All data was pro-
cessed as one data matrix in R (version 3.6.0) applying both in-house scripts and the
MetaboAnalystR package.
3.2.10 Normalisation of samples post-data acquisition
After peak picking and data filtering, a normalisation factor was calculated for each
sample based on the total protein content measured for that sample against the sample
with the lowest total protein content.
Normalisation Factor =
Total Protein Content of Sample
Total Protein Content of Sample with Lowest Total Protein Content
(3.1)
Each feature of a specific sample was then divided by the normalisation factor calcu-
lated for that sample as determined by Equation 3.1.
Normalised Feature Intensity =
Feature Intensity
Normalisation Factor
(3.2)
The exact value of each samples normalisation factor can be found in Table 3.2.
Whilst the normalising factor appears to be linear initially, after 25 µL the normali-
sation factor appears to decrease again. This could potentially be down to the extrac-
tion solvent becoming saturated with protein, however further investigation would
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TABLE 3.2: Normalisation factor for each sample which is normalised post
data acquisition.
Volume Replicate Normalisation Factor
10
A 1.13
B 1.06
C 1
D 1.03
15
A 1.43
B 1.47
C 1.77
D 1.47
20
A 2.30
B 2.22
C 2.43
D 2.28
25
A 3.58
B 3.43
C 3.21
D 3.22
30
A 3.18
B 3.01
C 2.82
D 3.02
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FIGURE 3.2: Scatter plot demonstrating the linear response between to-
tal volume of blood spotted onto collection card against absorbance mea-
sured at 590nm.
need to be completed to determine the cause of this effect. Initial thoughts were mis-
labelling, however subsequent processing and analysis of the data demonstrated that
this was not the cause.
3.3 Results and Discussion
3.3.1 Linear response between protein content and volume of blood
Firstly to ensure linearity between the total protein content and the volume of blood
within a DBS, controlled volume spots were collected and subsequent Bradford as-
says performed. Total absorbance was then plotted against volume of blood on each
collection card. In total each volume was replicated 6 times.
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TABLE 3.3: Number of features before and after filtering for each method
of normalisation
Assay Total Number of Features
Separation Mode Polarity Before Filtering After FilteringPost Data Acquisition & TIC Normalisation Pre Data Acquisition
HILIC Positive 20953 2779 2759
Negative 14587 1083 1049
Lipidomics Positive 45171 3626 3884
Negative 26808 3597 3746
The results from this test are shown in Figure 3.2 and a clear linear trend between
whole blood volume and protein concentration can clearly be seen, with an R2 of
0.975. Most of the variation seen between the individual volumes can most likely be
explained down to errors in the preparation and extraction of the DBS themselves.
3.3.2 Quality of UHPLC-MS data
The total number of features remaining after filtering are described by Table 3.3. To en-
sure that the features which are normalised were of high quality and ensure confidence
in the data, only peaks which were present in at least 3 of 4 replicates and also present
in every single class (different volumes of whole blood present on each collection card)
were kept for each different normalisation type. All figures shown in this chapter rep-
resent only one assay (Lipidomics - Positive Ion Mode). Result for all remaining assays
can be found in Appendix G.
3.3.3 Comparison of data normalisation techniques
To compare the performance of both normalisation techniques (pre and post data ac-
quisition), several performance characteristics can be compared between normalised
data and data that had not had any normalisation procedures applied. This can then
be used to compare and measure the improvement in the quality of the data itself.
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3.3.3.1 Relative Standard Deviation (RSD)
Firstly we can look at the relative standard deviation of each feature and compare
both pre and post data normalisation to data which has not been normalised. RSD is
often used within non-targeted metabolomics data analysis as a quality filter within
the QC samples. Typically any features that show an RSD of greater than 30% across
all QC samples are removed as these features therefore show a response that means
the feature is unreliable and therefore any biological variation within actual samples
will be masked by analytical variation of that feature. As a point to note, due to each
sample originating from a single biological source, there will be no biological variation
between samples. Variation between samples will have only be due to non-biological
sources such as sample preparation variation or instrument bias.
To calculate the RSD’s of each feature and ensure a reliable representation of the
dataset, only features which were present in at least 75% of all replicates within all
groups were kept. This was to prevent any features that may not have been detected
due to falling below the limit of detection of the detector having an effect on the calcu-
lation.
Figure 3.3 shows the effect that the different normalisation procedures have on the
RSD of all features across the volumes of blood that have been spotted on the collection
cards.
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FIGURE 3.3: RSD of all high quality features in the lipidomics, positive ion
mode assay before and after normalisation either pre or post data acqui-
sition or normalising applying total ion current alone. Verticle line indici-
ates a 30% RSD cut off.
TABLE 3.4: Percentage of total features that show a RSD of less than 30%
in each assay.
Assay Normalisation Type
Column Polarity No Normalisation TIC Normalisation Post-Data Acquisition Pre-Data Acquisition
HILIC
Positive 42.1 70.8 61.1 89.0
Negative 27.5 53.4 57.5 85.4
Lipidomics
Positive 20.0 70.2 51.1 81.8
Negative 15.0 68.1 63.7 78.4
It can clearly be seen that there is a vast improvement in the number of features that
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show an RSD of less than 30% for both normalisation methods, however the improve-
ment when reconstituting pre data acquisition is better than computationally normal-
ising post data acquisition. Another observation made is the similarity in RSD distri-
bution between both datasets which have been normalised before and after data ac-
quisition. Although the distribution for the post data acquisition set is shifted towards
higher percentage RSD’s by about 5%, it demonstrates that the majority of features
have improved RSD’s when compared to applying no normalisation procudures.
The total percentage of features that show an RSD of less than 30% depending on
the normalisation method applied are shown in Table 3.4.
A comparison between the performance of normalising to total protein content
alone was made to normalising against the total ion current (TIC) which is a commonly
used normalisation method used within non-targeted studies. Normalising against the
TIC works through each feature within a sample is divided by the sum of all intensities
present within the same sample to produce a normalised value. The performance of
the TIC normalisation can be seen in Figure 3.3 and Table 3.4. As with normalising
to total protein content, both before and after data acquisition, an improvement in the
RSD’s are demonstrated in Figure 3.3, however with a wider distribution. Table 3.4
also demonstrates that the improvement to the number of features which demonstrate
an RSD of less than 30% is better than normalising post data acquisition, but not as
good as normalising prior to the collection of data through volume. This is the case for
all assays apart from HILIC negative where TIC normalisation doesn’t perform as well
as both methods of normalising to total protein content.
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FIGURE 3.4: Sum of all intensities from features that are present in at least
75% of all replicates within every group.
3.3.3.2 Sum of all features
Another procedure in determining whether or not normalisation has improved the
quality of the data is to calculate the sum of all intensities within the data matrix. This
can identify if there is a general trend within the data and can give an indication of a
general increase in concentration of the sample. Once again, the sum of all intensities
was only calculated on features that were present in at least 75% of all replicates that
were present within each and every group.
Figure 3.4 shows non-normalised data with a clear increase in the sum of intensities
of all features. This it to be expected due to the increase in concentration of all features
that are present within a fixed reconstitution volume down to the volume of blood that
is present on the collection card. To represent an improvement in quality of the data,
the differences between each volume should be as minimal as possible to ensure that
any variation that is seen is biological in nature rather than analytical.
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(B) Pre-data acquisition
FIGURE 3.5: Sum of all intensities from features that are present in at least
75% of all replicates within every group. (A) Post-data acquisition nor-
malisation. (B) Pre-data acquisition normalisation.
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FIGURE 3.6: Sum of all intensities from TIC normalised features that are
present in at least 75% of all replicates within every group.
After normalisation, both pre and post normalisation techniques show a decrease
in the gradient of the total sum of intensities as shown in Figure 3.5. However whilst
normalising post-data acquisition appears to bring the higher volume groups into line
with each other, there is a significant decrease in the sum of all intensities after the 10
and 15 µL spots. This drop off could potentially be explained by the reconstitution
volume that is used. Due to reconstituting in the same volume, where larger volumes
of blood have been placed on the cards it could be the case that not all of the sam-
ple which has been dried down is going into solution and therefore the reconstitution
solvent is saturated with sample.
Normalising pre-data acquisition shows good performance when normalising both
the highest and lowest volume groups together. Although there does seem to be wide
variation within each group, this variation is still better than not normalising at all,
and in conjunction with the results seen in the improved RSD’s for features, then this
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TABLE 3.5: Number of significant features as defined by a one way
ANOVA with a p value (FDR corrected) ≤ 0.05 for each assay and nor-
malisation method.
Assay No Normalisation TIC Normailisation Post-Acquisition Normalisation Pre-Acquisition NormalisationSeperatation Mode Polarity
HILIC Positive 2565 (92.3%) 2285 (82.2%) 2336 (84.1%) 1315 (47.7%)
Negative 924 (85.3%) 857 (79.1%) 854 (78.9%) 563 (53.7%)
Lipidomics Positive 3285 (90.6%) 3061 (84.4%) 2661 (73.4%) 2075 (53.4%)
Negative 3370 (93.6%) 3108 (86.4%) 3097 (86.0%) 2221 (59.3%)
is still much preferred and the quality of the data is vastly improved.
Due to the addition of an extra step of measurement of total protein content and
thus subsequent changes in reconstitution volume when preparing samples for nor-
malisation prior to the acquisition of data, variance within samples is larger. This is
demonstrated in Figure 3.5 where the errors bars are larger in the pre data acquisition
dataset compared to post.
3.3.3.3 Individual Features
To demonstrate the effect that normalising both pre and post data acquisition has on
individual features, as well as comparing to a purely computational metric such as TIC
normalisation, an ANOVA was performed and the number of features determined to
be statistically significant before normalisation then compared to the number which
are not significant after normalisation. These results are described in Table 3.5 and a
few select peaks are plotted in Figures 3.7a & 3.7b.
There is a clear trend where features which are statistically significant prior to nor-
malisation are then no longer significant afterwards. This demonstrates a clear im-
provement in the quality of the data for individual features and could allow for poten-
tial biological variances to be seen.
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FIGURE 3.7: Intensities for (A) (-)-Carvone and (B) Stearoylcarnitine be-
fore and after normalisation applying total protein content normalisation.
Volumes in µL.
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FIGURE 3.8: Intensity of (-)-Carvone and Stearoylcarnitine after TIC nor-
malisation
Whilst there does appear to be a dilution trend as demonstrated by Figure 3.7b,
this does not appear to occur in specific classes of metabolites and occurs randomly
throughout the dataset. Whilst it would be preferable if this trend was not present, the
quality of the data has still vastly been improved through the application of normalis-
ing against total protein content.
When comparing data which has solely been corrected for by applying TIC nor-
malisation, very little reduction in the total number of significant features is observed,
with both post and pre data acquisition normalisation strategies based on total pro-
tein content, demonstrating improved performance. This is not what was observed
when comparing the improvements in RSD’s in Section 3.3.3.1. In Section 3.3.3.1, the
improvement in RSD ranges fell between normalising post and pre data acquisition.
Therefore from that conclusion alone it could have been suggested as an alternative
strategy for normalising dried blood spots of different volumes. However, from Table
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3.5, with minimal reduction in the total number of features which have been deter-
mined to be statistically significant when compared to the other normalisation strate-
gies based on total protein content, normalising against TIC cannot be recommended.
Whilst there are still a significant number of metabolites which show statistically
significant differences after pre-data acquisition normalisation, this can be explained
through the use of a single source of whole blood to prepare the spots of different vol-
umes. Therefore there is no biological variability present within the spots and all vari-
ance seen is technical in nature. In a typical study where DBS will have been collected
from multiple sources, biologically variability will be much greater than technical vari-
ability. Thus the technical variability within this study has been magnified due to the
lack of biological variability and the number of statistically significant differences.
3.4 Conclusion
Throughout this chapter I have described a method of normalising DBS which is non-
destructive to the original sample destined for metabolomics analysis. This technique
represents a cheap (approximately 40 pence per sample), easy and reliable method
for protein determination within the DBS and can therefore offer widespread utilisa-
tion for anyone performing experiments with DBS. The assay itself is quick to perform
meaning the experiment can be performed prior to the collection of data. Additionally,
the materials required for this experiment are readily found within many laboratories
and the most expensive piece of equipment required is the spectrophotometer itself
which is already a key part of many laboratories. However, if the assay was to be
applied to large studies then proper experimental planning would be required and
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samples dried and stored for longer periods of times whilst the total protein measure-
ment is determined for large numbers of samples before reconstitution in appropriate
solvents.
Being able to normalise DBS also opens up many prospects for large scale studies
that utilise samples within biobanks around the world. Unless the DBS has been col-
lected using an accurate volume collection device, then the volume on the DBS is an
unknown. Coupled with the varying haematocrit that each individual patient has then
normalising based on spot size can also become problematic.
The technique applied here demonstrates a large improvement in the RSD for many
features in a single biological sample, thus removing as much non-biological source of
variation as is possible applying the Bradford assay. Whilst there will still be features
which demonstrate a large variation, if volume has not been recorded then this tech-
nique reduces the number of those features by a large degree, with a decrease in the
number of significant features of between 31.6% and 44.6%.
This chapter has also demonstrated that normalisation prior to data acquisition es-
tablishes a greater improvement in the quality of the data when compared to normal-
ising computationally after the collection of data with an increase of between 46.9 to
63.4% to the total number of features demonstrating an RSD of less than 30%. With
improved RSD performance and a more consistent response relating to the total num-
ber of features detected, normalisation should occur at the reconstitution step if at all
possible.
Finally, this chapter has demonstrated that whilst applying TIC normalisation alone
improves the RSD of features present to levels which are comparable to normalising
post acquisition of data, there was very little effect on the number of features which re-
mained statistically significant, thus preventing its use in a non-targeted metabolomics
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scenario where relative concentrations between classes is key in distinguishing impor-
tant biological features.
However, whilst the technique demonstrates that normalising to total protein con-
tent reduces the number of statistically significant features and improves RSD perfor-
mance, there are still improvements that could potentially be made. The variance ob-
served in the total protein content of each spot is large, therefore improvements could
potentially be made in both the method in which the Bradford assay is applied to at-
tempt to reduce these variances. Although more sensitive protein assays are avialable
for use, these were not considered for this chapter due to the Bradford assay having
more than sufficient sensitivity for the assay performed, with the sample required to
be diluted to ensure that measurements would fall within the linear dynamic range.
Potential further developments to the application of this method would be the au-
tomation of the assay. This would reduce the time taken to perform the assay whilst
reducing any human sources of variation that are naturally introduced when perform-
ing a manual extraction. Further work could also be focused on ensuring the assay
is valid for other sample types which are not whole blood. Additionally, it would be
useful to understand whether this assay could be applied to the variety of collection
devices that are available, both those which are as a card format, or those which are
specially manufactured by commercial suppliers with the specific aim of controlling
for volume based effects such as Neoteryx’s Mitra device.
In summary, the method demonstrated here, whether or not it is utilised prior to
the collection of data or afterwards, represents a method with the ability to improve
the quality of data acquired especially with spots that are widely varying in volume.
Preferentially, normalising prior to acquiring data gives best performance with regard
to decreasing RSD’s and ensuring the number of features remains constant.
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Extraction Surface Analysis methods for
Non-targeted Metabolomics studies
4.1 Introduction
The use of Liquid Extraction Surface Analysis (LESA) as a surface analysis technique
has been around since 2005 [151, 224] and has been applied to the direct analysis of
DBS in a variety of applications mainly focused around proteomics [225–228]. Whilst
LESA has been applied towards the detection of small molecules, these applications
have instead focused on other surfaces than paper based collection cards, using the
likes of thin tissue sections [229] and oral fluid, urine and fingerprints [230].
Using LESA allows the direct analysis and infusion of a sample without prior man-
ual extraction into solution. Due to this, the technique is fast and automated and a
sample can be analysed from the moment it is collected. With DBS, because there has
been no prior preparation of the blood that has been used to create the DBS, a more
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complete picture of the metabolome can be detected at any one time from the sur-
face. This is because all the constituent components that make up whole blood such as
plasma, platelets and cells (red and white) are still present within the sample as they
have not been removed because of prior sample preparation procedures.
LESA works through the deposition of solvent onto the surface of the sample and
then waiting a pre-determined amount of time before reaspirating into the same con-
ductive pipette tip. The extraction solution is then consistently infused directly into
the MS where data can be acquired. Almost every aspect of the LESA process can
be modified, making it a versatile technique with a wide range of applications that
can be developed. Developing a LESA method for metabolomics could potentially
open up applications for a rapid, high throughput procedure of analysing DBS where
the resources and knowledge required to manually extract samples for more extensive
analysis such as UHPLC-MS may not be available. This could potentially be in envi-
ronments away from a research lab or in a clinical setting where the high throughput
of samples is required.
LESA utilises a chip based on nano electrospray ionisation (nESI) system that al-
lows for an increase in sensitivity compared to typical electrospray ionisation (ESI) op-
erating in a direct infusion mode, whilst also allowing minimal volumes of solvent to
be used, therefore lending itself well to the analysis of small molecules that have been
extracted from a brief dwell on the surface of the spot. In order to be able to utilise
LESA for a non-targeted metabolomics experiment, a method needs to be optimised to
ensure enough information is extracted from the surface of the DBS to be useful.
This chapter describes the optimisation of a LESA method capable of the extrac-
tion of metabolites directly from the surface of a DBS for non-targeted metabolomics
studies. The method was then compared directly against a DI-MS method as well as
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UHPLC-MS to determine where LESA-MS of DBS has its benefits but also where other
techniques might be more applicable depending on the application.
4.2 Materials and Methods
HPLC Grade methanol, water, acetonitrile and isopropanol were purchased from VWR
Chemicals (Lutterworth, UK) along with formic acid (>98%). Rat whole blood (female,
male & pooled, Wistar Hannover strain) was purchased from BioIVT (West Sussex,
UK). Whole blood was collected in Lithium Heparin collection tubes to prevent coag-
ulation before preparation of DBS. Time between collection of whole blood and prepa-
ration of DBS was less than 48 hours. Whatman 903 filter paper collection cards, desic-
cant and foil ziploc bags were purchased from Fisher Scientific (Loughborough, UK).
Formic acid (≥98.0%) was purchased from VWR International (Lutterworth, UK)
4.2.1 Sample Preparation for LESA-MS
Samples to be analysed by LESA-MS were prepared by pipetting 20 µL of rat whole
blood for each gender separately onto Whatman 903 Filter Paper based collection
cards. Cards are then allowed to dry for three hours at ambient temperature before
storage at room temperature in foil ziploc bags alongside desiccant until analysis. All
samples were analysed within 1 week of receipt of the whole blood.
4.2.2 Sample Preparation for DI-MS & UHPLC-MS
Samples to be analysed by DI-MS and UHPLC-MS were prepared in the same manner
as in Section 4.2.1, except samples were stored at -80◦C until analysis.
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4.2.3 Extraction of DBS for UHPLC-MS and DI-MS analysis
Before extraction, samples were removed from storage and allowed to defrost on ice
for 30 minutes prior. Samples were then removed from the collection card using a
sterile scalpel and cut into smaller sizes to aid in extraction by increasing surface area
of the spot. Samples were then extracted in 480 µL of methanol and 20 µL of water
under gentle agitation for 20 minutes before centrifugation (21000 g, 4◦C, 20 minutes).
The supernatant from each sample was then dried down under vacuum for 40 minutes
at 35◦C. After drying, samples were stored at -80◦C until analysis by UHPLC-MS.
4.2.4 Reconstitution of samples for UHPLC-MS analysis
Samples were resuspended in 56 µL of acetonitrile/water/methanol (3:1:1, v/v/v),
before vortexing for 30 seconds and centrifugation (21000 g, 4◦C, 5 minutes). Samples
were then transferred to low volume LC vials for analysis.
4.2.5 Reconstitution of samples for DI-MS analysis
Samples were resuspended in 56 µL of methanol/water/formic acid
(80%/19.9%/0.1%, v/v/v) before vortexing for 30 seconds and centrifugation
(21000 g, 4◦C, 5 minutes).
4.2.6 LESA extraction and nESI parameters
Samples were analysed applying a LESA method as developed in Section 4.3. Table 4.1
describes the parameters applied with corresponding references to sections later in the
chapter where optimisations have been discussed and presented.
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TABLE 4.1: Major parameters of LESA method developed. * Relative
height above the surface of the sample, actual value used in software is
different and is adjusted based on sample height using LESA stage
Parameter Description Value Section
Solvent Volume Volume of extraction solvent aspiratedinto conductive pipette tip before extraction 6 µL 4.3.7
Dispense Volume of extraction solvent dispensedonto surface of sample 5 µL 4.3.7
Delay Amount of time to dwell on thesurface of sample 5 seconds 4.3.8
Aspirate Volume of extraction to reaspirateinto the conductive pipette tip before infusion into MS 5 µL
Dispensation Height * Height to dispense extraction solventonto the surface of the sample 0.4 mm 4.3.9
Aspiration Height * Height to aspirate extraction solventback into conductive pipette tip 0.0 mm
Voltage (Positive) Voltage to apply to the conductivepipette tip for the nESI process in positive ion mode 1.7 kV
Voltage (Negative) Voltage to apply to the conductivepipette tip for the nESI process in negative ion mode 1.4 kV
Gas pressure Pressure to apply to solvent within theconductive pipette tip to infuse it directly into MS 0.3 psi
4.2.7 DI-MS and LESA-MS data acquisition
Data was collected in both positive and negative ion mode using an Orbitrap Elite
(Thermo Scientific, San Jose, CA, US) applying an mass range of 50 - 620 Da. Data
for LESA was collected applying a ’looped’ SIM-stitch method described in Section
4.3.3. Data for DI-MS was collected in quadruplicate and subsequently applying only
a single SIM-stitch pass as demonstrated in Figure 4.5.
4.2.8 UHPLC-MS data acquisition
Data was collected in both positive and negative ion mode applying a HILIC method
using a Thermo Vanquish LC coupled to a Thermo Q-Exactive Plus MS (Thermo Scien-
tific, San Jose, CA). A pooled QC sample was prepared from the extracts of all samples
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and then prepared in the same was as all samples before being injected every 5th sam-
ple with 10 leading QC’s to condition the column. The LC method was 14 minutes
and length and data was collected at 70000 resolution (at m/z 200) using an Accucore
150 Amide column (100 mm x 2.1 mm i.d., 1.9 µm pore size. Solvent A was acetoni-
trile/water/formic acid (95/4.9/0.1, v/v/v) with 10 mM ammonium formate. Solvent
B was acetonitrile/water/formic acid (50/49.9/0.1, v/v/v) with 10 mM ammonium
formate. A 14 minute gradient elution was applied as follows using a 500 µL/min
flow rate: 0 min, 1% B; 1 min, 1% B; 3 min, 15% B; 6 min, 50% B; 9 min, 95% B; 10 min,
95% B; 10.5min, 1% B.
4.2.9 DI-MS and LESA-MS data pre-processing
Data was processed using Galaxy-M [231] using the workflow described in Figure 4.5
and the parameters described in Section 4.3.3.1. Thermo .raw files were passed into
the workflow alongside a sample list describing class structures and QC samples with
a data matrix consisting of samples and peak intensities as the final output.
4.2.10 UHPLC-MS data pre-processing
Raw data was first converted to .mzML format before peak picking and retention time
alignment using XCMS (version 3.8.0). Parameters for processing are described in Ap-
pendix B. The resultant peak matrix was then filtered to remove low quality peaks
applying the following filters: each feature had to be present in atleast 60% of all QC
samples; features had to show an RSD of less than 30% across all QC samples; finally
features had to beat the blank signal by a factor of 10 to remain in the matrix, all other
features were removed. All data was processed in R (version 3.6.0) applying both in-
house scripts and the MetaboAnalystR package.
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4.2.11 Statistical Analysis
All statistical analysis was performed in R (version 3.6.0) using both the base R-stats
package, MetaboanalystR in addition to in-house scripts.
4.2.12 Optimisation Workflow
To define the best performance characteristics a range of parameters will be monitored
and used to define an optimal method when applying LESA to the non-targeted analy-
sis of DBS. The main performance parameters used to define which instrument setting
or method optimisation is best are the following:
• Relative standard deviation of features
• Total number of features
• Number of successful infusions
• Total peak area
Through monitoring these performance characteristics, decisions can be made to move
forward with specific settings to ensure an optimal method is developed.
In addition to performance parameters, a specific order in which to complete op-
timisations is required. Thus the following order of optimisations was decided when
conducting the method development section of this chapter.
1. Selection of solvents
2. Selection of modifier content percentage
3. Data processing procedures
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4. Full scan vs SIM-Stitch
5. Repeated sampling
6. Solvent dispense volume
7. Solvent dwell time
8. Solvent depth of dispensation
4.3 Results and Discussion - Method Development
4.3.1 Selection of extraction solvents
4.3.1.1 Effect of different binary solvent systems on liquid microjunction stability
One of the key choices to be made when developing a LESA-MS method is the choice
of solvent mixture that is used for the extraction of compounds from the DBS. There-
fore the selection of solvents can have a major effect on the ability to form and maintain
a liquid microjunction (LMJ) between the conductive pipette tip and the DBS. If a LMJ
is unstable then the ability to have reproducible and reliable extractions can be com-
promised, thus affecting data quality.
To test for a suitable extraction solvent, a selection of binary solvent mixtures were
prepared at different compositions of aqueous/organic solvent ratios. Binary solvent
mixtures were chosen over single solvents due to the inability of organic solvents in-
dividually to form stable LMJ. Organic solvents selected for use were acetonitrile, iso-
propanol and methanol, all solvents which have been used extensively within non-
targeted metabolomics extractions. Binary solvent mixtures were prepared by mixing
each organic solvent with a select volume of water.
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TABLE 4.2: List of different binary solvent mixtures created. Organic sol-
vents relate to the use of either acetonitrile, isopropanol or methanol.
Mixture No. Organic Solvent (%) Water (%)
1 0 100
2 10 90
3 20 80
4 30 70
5 40 60
6 50 50
7 60 40
8 70 30
9 80 20
10 90 10
11 100 0
All of the binary mixtures prepared can be found in Table 4.2.
For each solvent mixture 2 µL was spotted onto the centre of a DBS. The time taken
for the solvent droplet to diffuse into the DBS itself and the LMJ lost was then timed.
These results for each different binary solvent composition and each different mixture
can be seen in Figure 4.1
An interesting observation is made when looking at the length of time a droplet
lasts on the surface of a DBS as shown in Figures 4.1 & 4.2. At high fractions of water
(≥90%) , a stable LMJ of 10 seconds or greater is only observed for binary solvent mix-
tures containing methanol and acetonitrile, with IPA mixtures showing a LMJ stability
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FIGURE 4.1: Time taken for 2 µL of each solvent mixture to dissolve into
the surface of a DBS.
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FIGURE 4.2: Time taken for 2 µL of each solvent mixture to dissolve into
the surface of a DBS. Same as Figure 4.1 except y-axis magnified to be-
tween 0 and 20 seconds.
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of approximately 5 seconds or less. At mixtures of greater than 10% IPA, no further sta-
ble LMJ were observed. For mixtures involving methanol, a stable LMJ of more than
5 seconds are observed for mixtures up to 50% water. Below this percentage of water,
no further LMJ were observed.
In comparison to both IPA and methanol binary solvent mixtures, acetonitrile based
mixtures demonstrated a different pattern. As mentioned in the previous paragraph,
at high percentage water content, with acetonitrile, a LMJ is able to be formed. The
stability of LMJ then gradually reduces until the percentage of organic solvent reaches
approximately 80% where the stability of the LMJ then returns. This pattern is not
observed for both methanol and IPA binary mixtures. Due to this return in stability
when the organic content of the LMJ is high (≥80%), this has the potential to be a useful
extraction solvent to apply when using LESA. A common non-targeted metabolomics
solvent composition consisting of 80% methanol and 20% water is used [232, 233],
however as can be seen by Figure 4.1 this leads to a very unstable LMJ which lasts much
less than the required 60 seconds that would be optimal for optimising many of the
other LESA parameters available. Therefore, by applying a mixture of 80% acetonitrile
and 20% water, LESA compatibility with DBS is maintained whilst also ensuring a
commonly used organic/aqueous mixture is applied.
With the surface tension of organic solvents (acetonitrile - 28.16 mN/m, methanol
22.10 mN/m, isopropanol - 23.30 mN/m [234]) being much less than water (72.05
mN/m) [234], it is expected that as the aqueous content increases, the total surface
tension of the LMJ droplet increases, thus there is better LMJ stability. This explains
the results for both methanol and IPA, but does not explain the reason for the increased
stability at high acetonitrile content. When looking at the literature for surface tension
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of binary mixtures, there is to be no increase in the surface tension of acetonitrile/wa-
ter mixtures as the organic content is increased [234], suggesting a different physical
property of the mixture that is being altered at high organic percentage.
Therefore it can be assumed that surface tension is not the main factor that leads to a
LMJ being formed and is instead controlled by another property alone or in addition to
surface tension. The answer as to what this property may be is unknown, with no clear
answer present within the literature. Potential options could be various interactions
between the intermolecular forces present within the binary solvent mixture and the
DBS allowing a stable LMJ to be formed, however further work would be required to
either confirm this or suggest alternative reasons for this observation.
Moving forward for subsequent optimisations, it was decided that an 80%/20%
mixture of acetonitrile and water was to be used.
4.3.1.2 Effect of charge modifier on acetonitrile/water LMJ stability
To ensure that any change in modifier concentration has no large impact in the stability
of the LMJ, the same experiment is repeated, except with varying concentrations of
formic acid. The mixtures tested are shown in Table 4.3.
TABLE 4.3: List of different concentrations of extraction solvent with vary-
ing contents of formic acid.
Mixture No. Acetonitrile (%) Water (%) Formic Acid (%)
1 80 20 0
2 79.95 19.95 0.1
3 79.75 19.75 0.5
4 79.5 19.5 1
5 78.5 18.5 3
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FIGURE 4.3: Time taken for 2 µL of each mixture of 80% acetonitrile/20%
water with varying amounts of formic acid to dissolve into the DBS. Box
represents the 25th and 75th quartile with the horizontal line equivalent
to the median. Whiskers indicate the highest and lowest values.
The results from this experiment are shown in Figure 4.3 and whilst there is an
effect on the ability to form a LMJ, it does not bring the instability down to below
60 seconds which is the aim for carrying on for the remainder of the optimisation.
The inclusion of a modifier such as formic acid is important to provide a source of
protons for the ionisation process. There is no difference in LMJ stability with the
addition of 0.1% of formic acid to the binary solvent mixture, or no formic acid at all.
An effect can only be seen when 0.25% of formic acid has been added to the mixture.
This effect could be caused by the decrease in organic solvent content with increased
formic acid concentration. As demonstrated by Figure 4.1, there is a region of LMJ
stability at high percentage of acetonitrile in the binary mixture. Therefore with the
addition of increased formic acid, the organic content has been reduced, thus reducing
the stability of the LMJ but not to a level which would compromise any future method
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development.
Due to there being no significant effect to the LMJ with the addition of 0.1% of
formic acid, this was the value chosen for the extraction solvent mixture.
4.3.2 Preparation of Dried Blood Spots
All samples were prepared by accurately pipetting 20µL of whole blood onto Whatman
903 filter paper based collection cards. Cards were then allowed to dry at ambient
temperature before storage in foil ziploc bags alongside dessicant. Cards were stored
at room temperature and analysed within two weeks of preparation.
Samples were unable to be stored at below freezing temperatures due to the sub-
sequent inability to form a LMJ once cards had been defrosted. This could potentially
be down to the increase in the absorption of the filter paper once the collection had
been frozen. This may have been caused by the remaining water in the DBS freezing
and expanding disrupting the clot that initially forms on the surface of the DBS which
creates a semi-impermeable barrier to prevent the LMJ from forming. When this clot is
disrupted the LMJ fails almost immediately due to the solvent being able to soak into
the filter paper based collection card beneath.
Therefore all cards which are intended to be analysed by LESA should be stored
above freezing temperature until they have been analysed at which point they could
then be stored at below freezing temperatures if further analyses is to be performed.
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4.3.3 Data Processing
To increase the dynamic range and sensitivity of DI-MS analysis, a data collection tech-
nique called SIM-Stitch can be used. SIM-stitch works through the collection of multi-
ple SIM windows within a single acquisition and then through post analysis compu-
tational processing, these multiple SIM windows can be ’stitched’ together to form a
single continuous peaklist and peak matrix.
Whilst the orginal implementation of the technique developed by Southam et al
[121, 235], is suitable for DI-MS experiments, it is unsuitable for LESA-MS analysis.
This is because the original technique employs 4 technical replicates of the same sam-
ple which is not possible with LESA-MS due to the semi-destructive nature of the ex-
traction procedure. Due to the modification of the surface it is therefore impossible to
infuse the 4 technical replicates as required by the original SIM-stitch data processing
workflow.
To be able to use the SIM-stitch technique with LESA-MS it is therefore required to
modify the original SIM-stitch workflow. These modifications include multiple SIM-
stitch loops within a single .raw file. This is compared to the original method where
only 1 SIM-stitch loop is required before moving onto the next technical replicate. The
number of SIM-stitch loops set for a single LESA-MS infusion was 3.
Due to the lack of technical replicates, it is then necessary to modify the standard
SIM-stitch data processing workflow as shown in 4.5 A. To process data which has
been collected in the method described above where multiple SIM-stitch windows
have been collected within a single .raw file, there is no need for the replicate filter
step where peaks are filtered out based upon there presence of lack of presence within
each of the technical replicates. Instead the filtering of replicate peaks that occur within
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FIGURE 4.4: A - Method setup for a DI-MS infusion. Each DI-MS infusion
is repeated multiple times. B - Method setup for a LESA-MS infusion.
Each infusion is only repeated once and ’technical’ replicates arise from
each loop of the SIM-stitch process.
each ’loop’ of the analysis occurs within the process scans step. Due to this, data pro-
cessing occurs using the steps described in Figure 4.5 B.
4.3.3.1 LESA-MS Data Processing Parameters
To process LESA-MS data the following settings were applied to each section of the
data processing workflow.
Process Scans - Used to convert data from the .raw file into a single peak list con-
taining m/z and intensities of each feature detected. For peaks to be classed as real
features, the peak has to beat the noise threshold by a factor of ten and also has to be
present in all three SIM-stitch ’loops’ within the .raw file.
Align Samples - Take each individual peak list produced from the Process Scans
step and align all detected peaks within a 2 ppm mass mz tolerance. The output of this
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FIGURE 4.5: A - Typical DI-MS processing workflow including the repli-
cate filter which is used to filter peaks present in x out of n technical repli-
cates. B - LESA-MS data processing workflow. No replicate filter step due
to the filter step being.
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step produces a data matrix of peaks and corresponding intensities within each data
file.
Blank Filter - For each feature detected, a peak has to be present in at least 75%
of all samples and have an mean intensity of greater than five times the mean blank
intensity to be retained.
Sample Filter - For each feature to be retained, it has to be present in at least 80% of
all samples within a sample class. A peak can still be retained if not present in at least
80% of samples in one class as long as it is present in at least 80% of sample in another
class.
4.3.4 3D Printing
FIGURE 4.6: 3D printed template used to ensure consistent height between
DBS
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FIGURE 4.7: Picture demonstrating the use of the 3D printed template in
use with a DBS collection card and LESA adapter.
Due to the way DBS cards are held in place in the LESA template on the Advion
Triversa Nanomate device, there can be variations in the height of each DBS due to
only having two anchor points. Therefore an additional 3D-printed template was pro-
duced to ensure a consistent height of each DBS through the addition of more anchor
points which keep each spot at the same level. Photographs of the template can be seen
in Figure 4.6
4.3.5 MS Data Acquisition
To increase sensitivity and dynamic range when performing DI-MS analysis, it is
favourable to perform a SIM-stitch style of data acquisition. However due to the na-
ture of surface sampling and only being able to sample a spot once due to the nature of
altering the surface of a spot after a single extraction, it is necessary to perform an al-
tered SIM-stitch workflow compared to the typical workflow of performing 4 identical
replicate infusions.
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FIGURE 4.8: Comparison of the total number of features detected using a
full scan and SIM-stitch acquisition mode.
To perform this a workflow was developed which involved utilising multiple SIM-
stitch acquisitions within a single DI-MS infusion. To achieve the same effect of a repli-
cate filter that is utilised in typical DI-MS data processing, peaks are filtered out instead
during the Process Scans function during data Analysis.
A comparison of the number of features detected between full scan and SIM-stitch
acquisition modes is shown in Figure 4.8. A clear increase in the number of features
detected demonstrates that a modified SIM-stitch procedure as demonstrated in Fig-
ure 4.8 improves both the number of features detected but also increases the linear dy-
namic range overall. This is to be expected and has previously been shown by Southam
et al. [121], however this is the first method which applies a spectral stitching method
to the collection of LESA data.
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FIGURE 4.9: PCA plot displaying the effect of sampling the same DBS
multiple times.
4.3.6 Repeated Sampling
Due to the inherent nature of surface sampling, it is critical to check whether or not
sampling the same spot multiple times has an effect on the data collected. To check
for this, the same spot was sampled multiple times using a 5 second dwell time. In
total, five different spots were sampled 5 times each to investigate the difference made
through multiple sampling.
Initially a PCA plot was produced from all high quality features and can be seen in
Figure 4.9.
From Figure 4.9 we can see a distinct separation between groups that have been
sampled for a set number of extractions. The greatest separation between groups is
between samples that have been analysed for the first time and then subsequently
analysed again. From this plot, it initially shows that the samples are most similar
when they have been sampled between two and four times, before further variation
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TABLE 4.4: Total number of features present after each subsequent extrac-
tion and the total number of features demonstrating an RSD of less than
30%.
Number of Times Sampled Total Features presentin at least 60% of all samples
Total Features with an
RSD of less than 30%
One 4062 3855 (94.9%)
Two 3879 3662 (94.4%)
Three 3967 3464 (87.3%)
Four 3874 3725 (96.2%)
Five 3697 3623 (98.0%)
becoming apparent once sampled for a fifth consecutive time, potentially indicating
that there may be a potential for re-sampling of the same spot.
Table 4.4 shows that there is a small loss in the total number of features that are
present in at least 60% of all samples, when moving from a sample being analysed once
against a sample that has been analysed two to four times. With a further subsequent
drop in the number of features detected if a sample is analysed five times.
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FIGURE 4.10: Total peak area of all features depending on the number of
times a spot has been sampled.
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FIGURE 4.11: Intensity of tryptophan across sampling the same spot mul-
tiple times.
Furthermore, in Figure 4.10 a decrease in the total peak area depending on the num-
ber of times a spot has been sampled, shows agreement with Table 4.4 with regard to
there being a gradual loss of data. Although the total peak area for samples which
have been sampled once or twice is shown to be similar, when combining the gradual
loss of features shown in Table 4.4 and the clear class separation in the PCA plot in
Figure 4.9 between samples that have been analysed once against samples that have
been analysed multiple times, it is clear that the surface of the spot is being modified
too much by repeated sampling and DBS should only be sampled once. Otherwise,
non-biological variation caused between samples which analysed multiple times, may
mask genuine biological variation present between the samples.
Finally, in Figure 4.11 an example of the intensity of a specific feature is shown
to demonstrate that after sampling multiple times, the intensity of features is drop-
ping to the point that any sort of relative quantitation that is required for non-targeted
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FIGURE 4.12: Violin plot of RSD’s for all features depending on the vol-
ume dispensed onto the surface of the DBS.
metabolomics is not possible.
4.3.7 Solvent Dispense Volume
To decide on the total dispense volume to use, multiple spots were sampled with vary-
ing volumes of solvent deposited onto the surface of a DBS. Solvent was then allowed
to dwell for 5 seconds before being aspirated back into the conductive pipette tip and
infused directly into the MS. In total, 6 µL was aspirated from the solvent well and
then five separate volumes were dispensed ranging from 1 µL to 5 µL.
Following the acquisition and filtering of data, the range of RSDs for all features
was plotted and can be seen in Figure 4.12.
As the volume of solvent that has been deposited onto the spot increases, the av-
erage RSDs and distribution of RSDs lowers, indicating an increase in quality of the
data. A potential cause for the increased RSDs at lower dispense volumes could be the
decrease in surface area that is sampled from and therefore any slight fluctuations in
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FIGURE 4.13: Boxplot describing the number of features detected depend-
ing on the volume dispensed onto the surface of the DBS.
the height of the card, even with the 3D printed template in use, could affect the total
surface area of the DBS that is in contact with the extraction solvent.
In addition to RSD’s the total number of features present in each group are de-
scribed by Figure 4.13.
Figure 4.13 shows no clear statistically significant difference (p=0.969, one-way
ANOVA) between the total number of features extracted from DBS and the volume
dispensed onto the surface.
Whilst an increase in the number of features present was expected, this was not
observed. An increase was expected due to the larger surface area of sample that is in
contact with the LMJ during extractions from higher volumes of solvent. The reason for
this expectation not be observed could be down to the minimal increase in the contact
area between the DBS and LMJ. Whilst this contact area was not measured directly,
visually, the increase in surface area that was extracted was not observed to be major
when moving from a 1 µL extraction to 5 µL extractions.
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Finally, as briefly mentioned in Section 4.3, stability of the nESI process is key in
obtaining reliable and reproducible data. Whilst performing the above experiment, it
was noticed that the current read back from the instrument was gradually decreasing
as time progressed through the infusion of the sample into the MS. This is shown in
Figure 4.14.
The drop in current could potentially be a problem for non-targeted studies due to
it potentially representing the concentration of sample reducing as it is infused into the
MS. Therefore due to a constantly decreasing ion signal, as each SIM-stitch ’loop’ is un-
dertaken, the concentration of any specific ion could be decreasing, thus an unreliable
intensity value will be recorded.
The cause of this decrease in ion current could be due to the extracted metabolites
being present in higher concentrations in the solvent closest to the beginning of the
conductive pipette tip. The decrease in current would then be more substantial for the
extractions where the total proportion of solvent which is dispensed onto the surface
of the spot is less, for example 1 µL (16.7% of overall solvent volume) compared to 5
µL (83.3% of overall solvent volume).
To potentially overcome this issue a mixing procedure could be applied where the
solvent is aspirated and re-aspirated but not onto a sample. However this was not
available on the system used for this development therefore the technique was not
used.
As a result, when higher proportions of the total volume are dispensed, the ex-
tracted metabolites are at a more consistent concentration throughout the total volume
of solvent and therefore the intensity of ions infused into the MS will be more consis-
tent.
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FIGURE 4.14: Current readings from instrument against time. A - 1 µL, B
- 2 µL, C - 3 µL, D - 4 µL, E - 5 µL.
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4.3.8 Solvent Dwell Time
Another key parameter to optimise for LESA is the length of dwell time on the surface
of the spot. To check the effects on extraction, multiple dwell times ranging from 1
second up to 30 seconds in varying increments. Increasing dwell time would have the
expected effect of increasing the intensity of metabolites that have been extracted from
the DBS directly. However it is the opposite that was seen for the majority of metabo-
lite related peaks seen within the sample. This could be described by the increase in
dissolution of metabolites throughout the solvent plug within the conductive pipette
tip as dwell time increases. Whereas during a 1 second extraction, the metabolites that
have been extracted from the surface of the spot are ’frontloaded’ within the solvent
plug within the conductive pipette tip. Therefore, as this is the first part of the solvent
plug that is infused into the MS, intensities are higher than those where metabolites
have been allowed to diffuse into the remainder of the solvent due to the increased
dwell time.
Figure 4.15 shows that there are a large number of features which show either a
positive or negative correlation depending on whether or not a sample is analysed for
a short or an extended duration.
Further investigation into this shows that if a feature shows a positive correlation
with sampling duration, then this is likely to fall within a specific m/z region which
can be seen in Figure 4.16 This is in comparison to features which show a negative
correlation where they are more likely to be distributed over the whole m/z region
which has been collected.
The features which demonstrate a positive correlation depending on the length of
time sampled may be due to protein related small molecules such as heme of which the
intensity has been plotted in Figure 4.18. To further investigate this, the distribution of
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FIGURE 4.15: Distribution of Pearson’s r correlation coefficients (ρ) across
all reliable features.
FIGURE 4.16: Distribution of positively and negatively correlated features
across the m/z range (50 Da - 620 Da)
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FIGURE 4.17: Distribution of features which are multiply charged across
the m/z range measured.
FIGURE 4.18: Intensity increase of heme as LESA dwell time on the surface
of a DBS is increased.
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multiply charged features present within the dataset has been plotted in Figure 4.17.
What can be seen in Figure 4.17 is that the distribution of multiply charged features
across the m/z range analysed, matches the distribution of positively correlated fea-
tures as demonstrated in Figure 4.16. Therefore it can be assumed that the positively
correlated features are protein related molecules.
Explaining the positive correlation could either be down to the high concentration
of heme within the DBS as it has not been removed with prior sample preparation
techniques or the release of heme from its protein complex as it is denatured by the
organic extraction solvent present.
4.3.8.1 Method Recommendation
Due to the decreased RSD’s as well as the minimal loss in intensity for metabolic fea-
tures, five seconds has been chosen as a suitable dwell time moving forward through-
out the optimisation.
4.3.9 Contact vs. Non-Contact LESA and Depth of Dispensation
LESA can be performed in one of two modes, Contact or Non-Contact. It has been
shown before with bacterial colonies [236] that performing LESA applying a contact
method where the conductive pipette tip is physically touching the sample, allows
additional proteins to be extracted from the sample. However by performing a contact
method of analysis, the surface area of the extraction is severely reduced and limited
to the internal diameter of the conductive pipette tip itself.
Additionally, it is also key to check whether the height that the solvent is dispensed
from the pipette tip to form the LMJ has any major effect on the extraction from the
DBS. To determine the best mode to operate in, repeat infusions (n=5) of DBS were
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FIGURE 4.19: Total number of features detected depending on the height
that the extraction solvent is dispensed onto the surface of the DBS.
made where the dispensation height of the extraction solvent above the DBS was ad-
justed from being in contact with the surface of the DBS to being 0.6 mm above, in 0.2
mm increments.
Figure 4.19 and 4.20 demonstrates that when the pipette tip is in contact with the
surface of the DBS, the reliability of the extraction is compromised with widely vari-
able number of features being extracted between replicate infusions and an RSD range
which is unsuitable for non-targeted experiments.
To further confirm that the extraction efficiency when the conductive pipette tip is
in contact with the surface of the sample is much less than when the tip is above the
surface, the total peak area has been plotted and can be viewed in Figure 4.21.
With regard to the samples that were extracted using dispensation heights that were
non in contact with the sample, the RSD’s and number of features that were extracted
were much more consistent. Applying a dispense height of 0.4 mm achieved the lowest
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FIGURE 4.20: Violin plot describing the distribution of RSD’s of all fea-
tures detected depending on the height that the extraction solvent is dis-
pensed onto the surface of the DBS.
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FIGURE 4.21: Total Peak Area observed depending on the height of the
conductive pipette tip when extracting from the surface of the spot.
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FIGURE 4.22: PCA scores plot demonstrating the large variance between
samples analysed off cards left out in ambient conditions for different
times prior to analysis.
range of RSD’s accross all features and was therefore chosen as the dispense height
used in the method.
4.3.10 Card effects
To demonstrate the need for DBS samples to be kept in similar conditions throughout
storage before analysis, multiple sets of DBS were left out in open laboratory conditions
at different times before being analysed alongside cards which were kept inside foil
bags alongside dessicant.
Cards were left out on the bench top for 18 hours and 6 hours alongside cards which
were only removed from packaging immediately before analysis.
After data acquisition and peak filtering, the following PCA scores plot was pro-
duced.
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As shown in Figure 4.22 it can be seen that leaving cards out in different conditions
has a major effect on the reproducibility of sampling spots. Therefore it is key to ensure
that samples are collected and stored at the same time, temperature and conditions to
ensure good reproducibility between samples.
The cause of this variation could potentially be down to a variety of reasons.
Through being exposed to the ambient environment for significantly longer than sam-
ples which were kept in storage in controlled environments, samples have therefore
been exposed to different conditions. DBS left in the environment with no procedures
in place to control the humidity or temperature could lead to oxidation or changes of
water content within the sample. This would not happen or would happen minimally
in a controlled environment.
4.4 Results and Discussion - Comparison between two
samples
To compare the developed LESA method against current MS approaches for
metabolomics analysis of blood samples, two samples of rat whole blood were pur-
chased from a commercial supplier (one sample collected from a male rat and another
from a female rat). Comparisons were then made using UHPLC-MS and DI-MS and
the LESA-MS method developed throughout this chapter.
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TABLE 4.5: Number of features present in each LESA-MS and DI-MS
datasets describing both the number of unique and common metabolic
features
Analytical Method Polarity Total Features Unique Features Common Features
DI-MS Positive 2694 1088 1606LESA-MS 4211 2605
DI-MS Negative 4962 3715 1247LESA-MS 4787 3540
4.4.1 Results and Disussion
4.4.1.1 Presence of common and unique features between DI-MS and LESA-MS
datasets
Following data pre-processing the total number of features present in each dataset after
peak filtering is described in Table 4.5.
Between the two nESI based methods a direct comparison can be made between
what can be assumed to be the same feature and the total number of common features
can be calculated. Direct comparisons are only made between DI-MS and LESA-MS
due to the similarity in which samples are analysed through the use of the same nESI
procedure. However a point to note is that features detected using DI-MS may also
be detected applying LESA-MS method except potentially as an adduct instead of the
molecular ion.
From Table 4.5 it is shown that the total number of features that were common
between the LESA-MS and DI-MS datasets was 1606 for positive ion mode and 1247
for negative ion mode. The difference in the total number of features detected can
potentially be explained by several factors. Through using LESA-MS the sample itself
has undergone no prior sample preparation before the direct extraction off the surface
of the spot and subsequent analysis. Therefore additional metabolites can be expected
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to be seen due to the presence of additional intercellular components of blood that are
still present within the sample.
With regard to the unique features present within the DI-MS datasets which repre-
sent 40.4% of the total number of features present in positive ion mode and 74.9% of
features in negative ion mode, these additional features can be explained through the
additional sample preparation that is performed. This undoubtedly increases the ex-
traction efficiency of metabolites from the sample whilst also removing protein related
signal.
4.4.1.2 RSD performance
Finally a direct comparison can be made looking at the range of RSD’s for every feature
within the multiple datasets and for each class.
From Figure 4.23 a clear increase in the range of RSD’s can be seen moving from
UHPLC-MS to DI-MS and then finally to LESA-MS. This increase in average RSD’s
can be down to the different analysis procedures used for each analytical method. In
UHPLC-MS, the flow rate through the ESI is much higher than that of the nESI tech-
niques running at 0.5 µL/min compared to the high hundreds of nL/min which is
used for nESI. This increase in flow rate leads to a much more stable electrospray.
4.4.1.3 Multivariate analysis
To ensure that the LESA method developed can detect the difference between the two
different samples of DBS produced, a PCA scores plot of each method and polarity was
produced. Only features which were present in both data sets were used to produce
each PCA to ensure that any information which is unique to each method has no effect
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FIGURE 4.23: Distribution of RSD’s in each dataset for each class applying
all methods.
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on the total variance explained by the PCA and also to ensure that a fair comparison
between both the LESA-MS and DI-MS methods can be made.
As can be seen by Figure 4.24, clear separation between the two sample types (male
and female) is seen meaning that the LESA-MS method developed is capable of detect-
ing the same explanatory variable that produce the separation between the two groups
as the DI-MS method.
However whilst the variance explained by PC1 is similar for both DI-MS and LESA-
MS, the comparison against UHPLC-MS data is vastly different. This increased sepa-
ration as shown in Figure 4.24 & 4.25 for UHPLC-MS data, demonstrates the benefit of
applying chromatography, even though the technique may not be as sensitive as when
applying the nESI method. Through the separation of compounds, the detection of
features that are real features and not noise improves the quality of the data through
increased confidence in the compounds detected. Additionally, features which may
have been isomeric using a direct infusion method, are chromatographically separated
and can be distinguished, giving additional information as to which features are driv-
ing the seperation between the two groups.
4.4.1.4 Univariate analysis
In addition to the multivariate analysis performed which determined that each of the
variances between the male and female samples could be distinguished by the devel-
oped LESA-MS method and has comparable performance to DI-MS. A comparison
between the number of significant features in each datset can be made. To determine
the significant features, both a Wilcoxon signed-rank test was performed in addition
to a volcano plot.
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FIGURE 4.24: PCA scores plots for all datasets. For LESA-MS and DI-MS
only features which are present within both datasets are used to produce
the scores plot. (A - DI-MS Positive, B - LESA-MS Positive, C - UHPLC-MS
Positive). Unequal class sizes are down to samples being removed due to
poor quality data at the filtering stage and failed infusions.
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FIGURE 4.25: PCA scores plots for all datasets. For LESA-MS and DI-MS
only features which are present within both datasets are used to produce
the scores plot. (A - DI-MS Negative, B - LESA-MS Negative, C - UHPLC-
MS Negative). Unequal class sizes are down to samples being removed
due to poor quality data at the filtering stage and failed infusions.
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TABLE 4.6: Total number of features determined as significant by a
Wilcoxon signed-rank test (p <0.05 (FDR corrected)) and the number of
features with a p value <0.05 and a log2 fold change value of >2. Note:
The total number of features for DI-MS and LESA-MS represent only those
that are common between the two methods.
Analysis Method Polarity Number of Features Significant Features
Wilcoxon signed-rank test p <0.05 & log2 FC >2
LESA-MS Positive 1606 650 158Negative 1247 720 227
DI-MS Positive 1606 601 164Negative 1247 745 179
UHPLC-MS Positive 5081 1876 628Negative 2956 1677 751
Table 4.6 demonstrates very similar performance between both the number of sig-
nificant features as determined by a Wilcoxon signed-rank test and those features
which have a p value of <0.05 and a Log2 fold change of greater than 2. However
Table 4.6 also shows that UHPLC-MS detects a much greater number of significant
features than both DI-MS and LESA-MS. This also explains the increased separation
present in the PCA plots in Figures 4.24 & 4.25
4.4.1.5 LESA Analysis Pros and Cons
Through the development of the LESA method and the application of it to two separate
samples it has been shown that LESA can be used to separate two separate sample
classes. However associated with the analysis performed there are downsides which
have been identified.
In Table 4.7 a SWOT analysis has been performed which discusses the strengths
and weaknesses of the developed method whist also mentioning a few opportuni-
ties afforded by the method and threats which may prevent the method from gain-
ing widespread use. Table 4.8 also compares the three methods used and looks at the
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FIGURE 4.26: General workflow applying a LESA-MS method in compar-
ison to DI-MS and UHPLC-MS demonstrating the advantage of no sample
extraction and preparation before MS analysis.
individual pros and cons of each method separately.
4.4.2 Conclusion
In this chapter I have described an optimised LESA method capable of detecting thou-
sands of metabolic features from a five second surface extraction.
The various different parameters that have been optimised have lead to various
conclusions that should be used when applying LESA-MS to the extraction of DBS.
The use of an acetonitrile based extraction solution leads to a stable LMJ where
other organic solvents have issues maintaining LMJ stability and thus compromising
the ability to perform a LESA extraction. Applying a ’looped’ SIM-Stitch MS method
to collect reproducible data from a single spot and to increase the dynamic range and
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TABLE 4.7: SWOT analysis of the developed LESA method with sum-
maries of both the strengths and weaknesses of the method in addition
to the opportunities afforded by the method and the threats that may pre-
vent the method from gaining widespread use.
Helpful (to achieving the objective) Harmful (to achieving the objective)
Internal Origin
Strengths Weaknesses
- Fast analysis times - Samples cannot be frozen
- Lack of requirement for prior
sample extraction
- Time required to allow a LMJ to
form successfully
- Initial results show the ability to
distinguish between multiple classes
- Replicate data is only collected
from a single sample and not across
multiple samples
- Limitations in the types of solvent
which can be used
External Origin
Opportunities Threats
- Could be used in clinical environments
for fast screening of samples before
further more in-depth analyses
- No sample separation due to the direct
infusion nature of analysis
- Large scale studies in reduced times
due to high throughput
- Reproducibility not as high as other
more in-depth analysis methods
TABLE 4.8: Pros and cons of the LESA-MS developed compared to DI-MS
and UHPLC-MS
Pros Cons
LESA-MS
- No prior sample extraction necessary
- Fast analysis times due to the lack
of individual replicates, with all
replicate data collected
from a single sample
- Highly sensitive due to the nESI source
- No external replication
- Samples can only be analysed
a single time
- Limitation in the solvents
that can be used
- No separation leading to reduced confidence
in metabolite annotation
DI-MS
- Fast analysis times
- Highly sensitive due
to the nESI source
- No separation
- Due to replication, total analysis
time per sample
can reach run lengths that are
matched by UHPLC-MS
- No separation leading to reduced confidence
in metabolite annotation
UHPLC-MS
- Slower individual sample analysis
times when compared to DI-MS
and LESA-MS
- Separation of samples
- Increased confidence in
metabolite annotation
- Increased run times per sample
- High costs involved
- Peak broadening can occur over batches
depending on age of columns used
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sensitivity of the analysis over conventional full scan MS with this method being the
first application of a SIM-stitch technique to the collection of LESA data.
Recommendations have also been made surrounding a number of key LESA pa-
rameters. Firstly it has been recommended that DBS should only be sampled once
applying a LESA technique due to the surface changes and relative intensity changes
that subsequently occur. Analysing a sample more than once therefore compromises
the ability to have confidence in the relative quantification required to perform non-
targeted metabolomics studies.
It has also been recommended that 5 µL of solvent is used for the sample extraction
to ensure good reproducibility in any extraction as well as ensuring the sample is well
mixed throughout the solvent plug in the conducive pipette tip before infusion into
the mass spectrometer as smaller volumes of solvent demonstrate a decrease in spray
current throughout analysis.
Whilst contact based LESA applications have been used in other ’omics’ sciences, it
has also been demonstrated within this chapter that a non-contact based LESA method
is more applicable for non-targeted methods to ensure many metabolites are extracted
from the surface of a DBS.
Through the application of LESA, high-throughput studies can be performed with
each sample taking less than four minutes to analyse. Furthermore, without the re-
quirement of sample extraction, preparation times are reduced and the potential areas
for mistakes are limited.
The LESA-MS method applied here is able to detect a similar number of significant
features between a single male and single female rat sample than what was detected
by applying DI-MS, demonstrating that sufficient biological information is being ex-
tracted from the sample during the five second extraction.
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Whilst the parameters presented here are recommendations, there is flexibility with
some parameters. Depending on the type of sample analysed it may be useful to
change the spray voltages or the height of dispensation, but with the nature of sur-
face sampling and the fundamental change occurring when a sample is analysed, some
recommendations are fixed such as only analysing a sample once.
However, there are limitations. With the loss of separation, the annotation of
metabolites is made much more difficult and therefore the technique should only really
be used as a rapid profiling technique rather than a confirmatory tool. Additionally,
with the requirement that each sample can only be analysed once, multiple replicates
are not possible thus there is no opportunity to check samples once again if the results
require.
Further work is required however with a key step being the validation of the
method in a biological application. Additionally it would also be useful to apply the
method to other sample types, whether or not these are based on collection cards, to
further understand the benefits and limitations of the method developed. It would
also be interesting to investigate the effect of tertiary solvent systems involving addi-
tional solvents such as IPA. The addition of IPA may also be useful for the extraction
of lipids at higher m/z ranges which was not investigates as part of this method devel-
opment chapter. Also, through the development of the LESA technology which has
occurred since the beginning of this project, it is now possible to apply separation to
a LESA extraction, therefore it would also be interesting to compare the performance
of LESA-LC-MS against UHPLC-MS in addition to the comparison of LESA-MS to DI-
MS as was shown in this chapter. Finally, in the area of proteomics, the coupling of
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high field asymmetric waveform ion mobility spectroscopy to LESA has been demon-
strated [154], therefore it would be interesting to further develop a method for non-
targeted metabolomics which uses this separation procedure whilst maintaining a high
throughput method.
In summary, the LESA-MS method shows similar performance to traditional man-
ual extraction followed by DI-MS. This could allow LESA-MS to be used in a metabolic
profiling scenario where resources are limited and information is required quickly.
However, it has been shown within this chapter, if the time and resources allow, then
applying a UHPLC-MS experimental design provides more data than applying a direct
infusion method (LESA-MS and DI-MS).
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Chapter 5
Application and comparison of dried
biofluid collection to whole biofluids in
a non-targeted metabolomics
investigation of Hypervitaminosis A
5.1 Introduction
Whilst the use of dried biofluid collection (DBC) is well documented for targeted
metabolomics research [199, 237, 238], their application towards discovery based stud-
ies is largely limited. As mentioned throughout this thesis, the advantages gained
from applying DBC allow for many applications where the cost of performing large
scale population based studies is a barrier to many research questions[239, 240]. One
area of research where population based studies are of huge importance are Vitamin
A supplementation programs that are being executed in many developing countries
around the world [241, 242].
Vitamin A deficiency in developing countries has been a major health concern since
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the early 1990’s and is on the list of the World Health Organisation (WHO) major nu-
trition topics to be investigated [243]. Due to the adverse health effects that being
deficient in Vitamin A can bring, since the late 1990’s the supplementation of Vitamin
A into the diets of populations within developing world countries has been a major
research focus. Supplementation programs are also delivered with large doses of Vi-
tamin A given to children every 6/12 months at health and immunisation checks. Vi-
tamin A is a key nutrient and has important functions in vision, immune competence
and reproduction [244]. Evidence has suggested that these supplementation programs
have been beneficial [245], however, whilst a person can be deficient in a specific group
of nutrients, they can also be in excess leading to another set of adverse health effects
on the other end of the scale.
Due to the method in which these supplementation programs are implemented, the
population receiving the additional dose of Vitamin A, usually young children, receive
infrequent, yet large doses of Vitamin A at a single point in time [244]. This supple-
mentation of large doses of Vitamin A at a single point of time is potentially leading
to Vitamin A levels increasing above the WHO recommended levels. Thus suscep-
tibility leading to hypervitaminosis is of much greater concern where the metabolic
consequences are not known.
Diet is a major contributing factor to the deficiency of Vitamin A [246]. With the
body unable to synthesise Vitamin A directly, we rely on taking in Vitamin A either
directly from our diet or through the intake of provitamins which are subsequently
transformed into Vitamin A within the body. Many forms of Vitamin A that are present
within food are present as retinol esters. These compounds need to be hydrolysed be-
fore absorption by the intestinal epithelial cells [247]. After absorption they are sub-
sequently re-esterified where they are incorporated with other neutral lipid esters into
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(A)
(B)
(C)
(D)
(E)
FIGURE 5.1: Structure of main forms of Vitamin A including the ma-
jor sources of Vitamin A from dietary forms of provitamin A. (A) -
Retinol, (B) - Retinyl Palmitate, (C) - α-Carotene, (D) - β-Carotene, (E) -
β-Cryptoxanthin. Figure modified from [244].
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chylomicra. The majority of the retinol esters are then transported and stored in the
liver. [248, 249]
With the liver being the main tissue where Vitamin A products are deposited, due
to its capacity to store and control the release of the lipid products, it is therefore of sig-
nificant interest into looking at the effects of Hypervitaminosis A within populations.
However, the collection of liver biopsies, for any analyses, not just metabolomics is
problematic. The invasive nature of the collection means the cost of collecting samples
is high and the number of people willing to go through with the procedure is very low,
limiting the ability to perform large scale population based studies.
Alternatively, serum and plasma can be used as alternatives for non-targeted
metabolomics analysis, however the cost of collecting, preparing and storing samples,
can once again be prohibitive, if large scale studies are required. This is where dried
biofluid spots can potentially aid in the research of large scale studies.
Whilst not identical to DBS, dried plasma and dried serum spots still represent
some of the advantages which collection of DBS affords. Samples would still be col-
lected in their native environment through venous blood draws, and then prepared
into either serum or plasma as was necessary. Subsequently, accurate volume aliquots
could then be deposited onto filter paper based collection cards and stored or trans-
ferred as needed. Providing facilities to prepare serum and plasma were available in
sample collection locations, then many more replicates of a single sample of plasma
or serum can be prepared and stored as dried biofluid spots in comparison to a single
aliquot of serum/plasma. With the additional temporary stability of compounds im-
parted on the sample through storage as a dried form, cold storage is not needed and-
sending samples to collaborators in other locations, whether that be within or outside
the country of collection is much cheaper, thus increasing the availability of analyses
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that may be performed on a single sample.
Within this chapter two populations of young children (Philippines & Guatemala)
which had undergone a Vitamin A supplementation program had serum or plasma
collected and then subsequent dried biofluid spots prepared from the same samples.
Non-targeted metabolomics applying a lipidomics UHPLC method was then under-
taken with a comparison made between the serum and dried serum spots and con-
versely the plasma and dried plasma spots to identify any similarities in biological
conclusion between collecting as a whole biofluid or as a dried spot. This study is a
part of a larger scale study named GioVitas led by Georg Lietz at Newcastle University
and funded by the Gates Foundation. Other studies falling under this larger ongoing
project have been aimed towards defining the importance of lipids compared to polar
metabolites and hence why lipids only were chosen for these dried samples. Finally,
a comparison is made between the two populations to demonstrate that the biological
outcomes of the two separate populations are demonstrating similar results indicating
that the result is valid.
5.2 Materials and Methods
5.2.1 Materials
HPLC grade acetonitrile, isopropanol and water along with formic acid (≥98%) was
purchased from VWR Chemicals (Lutterworth, UK). Ammonium formate was pur-
chased from Sigma Aldrich (Poole, UK).
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5.2.2 Sample Collection and Preparation
5.2.2.1 Preparation of serum (Guatemala)
Whole blood was collected from each subject into BD Royal Blue Trace Element va-
cutainers before allowing the blood to clot at room temperature. After clotting, each
vacutainer was centrifuged (1300g, 10 minutes, room temperature) and serum subse-
quently transferred into cryovials before being stored at -80◦C until shipping back to
the UK.
5.2.2.2 Preparation of plasma (Philippines)
Whole blood was collected from each subject into EDTA vacutainers before centrifug-
ing (1300g, 10 minutes, room temperature). The plasma layer was then transferred into
cryovials before storing at -80◦C and subsequent shipping to the UK.
5.2.2.3 Preparation of dried plasma and dried serum spots
Following the preparation of the plasma and serum, 40 µL of each biofluid was ac-
curately deposited onto Whatman 903 filter paper collection cards. Each of the dried
samples were allowed to dry horizontally for 3 hours at ambient temperature before
being placed into individual plastic zip-loc bags alongside desiccant packs.
All samples were shipped to the UK on dry ice before being stored at -80◦C until
extraction.
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5.2.3 Sample Extraction for Philippines and Guatemala Dried Serum
and Plasma Spots
Each sample was removed from storage at least 1 hour prior to extraction to defrost
and then subsequently kept on ice for the majority of the extraction process. After
defrosting, each spot was cut out of the collection card and into 8 smaller pieces to aid
in the extraction of metabolites from the spot. 460 µL of IPA and 40 µL of water was
then added to each sample followed by 20 minutes of gentle agitation using a vortex
mixer. After agitation, each sample was centrifuged (20 minutes, 21000 g, 4◦C) and
300 µL of supernatant subsequently transferred to a separate 2 mL Eppendorf tube.
Samples were then dried down under vacuum at 35◦C (Savant SPD111V SpeedVac
Concentrator connected to a RVT5105 Refridgerated Vapout Trap, Thermo Scientific,
UK) before being stored at -80◦C until analysis.
5.2.4 Sample extraction for Philippines and Guatemala serum and
plasma
As with DSS and DPS, samples were removed from storage 1 hour prior to extraction
to defrost and kept on ice throughout the extraction process. After defrosting, 40 µL
of each sample was transferred to an extraction Eppendorf where 460 µL of IPA was
then added. Each sample was then thoroughly mixed for 30 seconds at high speed
using a vortex mixer before being centrifuged (20 minutes, 21000 g, 4◦C) and 300 µL of
supernatant subsequently transferred to a separate 2 mL Eppendorf tube. Once more
samples were then dried under dried down under vacuum at 35◦C before being stored
at -80◦C until analysis. Alongside sample extraction, blank samples were extracted
using identical volumes and solvents.
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5.2.5 QC Sample Preparation
QC’s were prepared from either a pooled sample of DPS and plasma extracts or DSS
and serum extracts. From the QC pool, multiple QC samples were prepared by aliquot-
ing out 300 µL of each sample into individual Eppendorf tubes before drying down
along side extracted samples.
5.2.6 UHPLC-MS Analysis
When samples were ready to be analysed, all samples were removed from storage and
allowed to defrost on ice for 1 hour prior to reconstitution. Each sample was then
subsequently reconstituted in 96 µL of IPA/Water (75%/25%) before vortexing for 30
seconds at high speed using a vortex mixer. Samples were then transferred to low
volume LC vials ready for analysis.
Samples was analysed in both positive and negative ion mode applying a lipidomic
assay using a Vanquish UHPLC coupled to an electrospray Q Exactive Plus mass spec-
trometer (Thermo Scientific, San Jose, CA, US). Data was collected at mass resolution
of 70,000 (FWHM at m/z 200). A 2µL injection volume was applied using a Thermo
Hypersil GOLD column (2.1 x 100mm, 1.9µm), with a flow rate of 400µL/min flow
rate and with two mobile phases, mobile phase A (10mM ammonium formate in 60%
acetonitrile/water (v/v) + 0.1% formic acid) and mobile phase B (10mm ammonium
formate in 90% IPA/acetonitrile (v/v) + 0.1% formic acid). A 14 minute gradient elu-
tion was applied as follows: 0 min, 20% B; 0.5 min, 20%B; 8.5 min, 100% B; 9.5 min,
100% B; 11.5 min, 20% B. QC’s were injected every 5th sample, with 10 leading QC’s
prior to the collection of the first sample.
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5.2.7 Data processing
Data was pre-processed from .raw format using to the open source .mzML format us-
ing ProteoWizard (version 3.0.1921). XCMS (version 3.8.0) was then used to perform
peak picking and alignment (parameters are available in Appendix B). The resultant
peak matrix was then filtered to remove low quality peaks and sampled. Each dataset
was then inspected to identify if signal and batch correction was required. One dataset
(dried serum spots - negative ion mode) required signal and batch correction which
was performed using an in-house R package applying a QC-robust spline batch cor-
rection method as described by Kirwan et al. [233] Low quality samples were identified
through visual identification and comparison of the total number of features detected
and the sum of all intensities. For features to remain in the matrix, the following pa-
rameters had to be met; the mean of all QC samples had to be greater than the mean
of the blank by a factor of 10, the RSD of all QC’s had to be less than 30% and the
feature had to be present in at least 60% of all QC’s. Features were annotated using in
house pre-release software applying only MS1 accurate mass identification along with
adduct and isotope identification.
5.3 Results and Discussion
Due to the method in which samples were collected, a direct comparison can be made
between samples which were collected either as the biofluid (e.g. serum or plasma) and
those that were subsequently created as dried biofluids on filter paper collection cards
(e.g. dried serum spots or dried plasma spots). Samples collected in Guatemala were
either prepared as serum or dried serum spots, and those which were collected from
the Philippines were prepared as plasma or dried plasma spots. Due to this, analytical
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comparisons were only made between samples collected in the same country and same
subjects, however biological conclusions can be compared to validate either study from
the other.
5.3.1 Quality of UHPLC-MS data
The total number of features that were present in each dataset after the removal of low
quality features can be found in Table 5.1.
From this table it is clear to see that there are similar numbers of features being
extracted between both the dried plasma and serum spots, however there is a reduction
in the number of features than what was initially expected for the plasma, positive ion
mode dataset. This difference is difficult to explain and could be due to an issue with
that occured throughout the analysis that was not identified. Whilst the total number
of features present is slightly higher for the dried plasma spots when compared against
dried serum spots, it is clear that a similar amount of biological information is being
extracted, whether or not the spot was prepared with plasma or serum.
The extraction efficiency demonstrated through the total number of features present
within each dataset demonstrate that there is a large amount of biological information
that has been extracted, whether or not the sample was present in a dried form or not.
Initial inspection of the data after filtering demonstrates tight QC clustering in 7/8
datasets, with the Guatemala DSS Negative ion dataset showing lower than expected
QC clustering which is unrelated to batch effects. This reduction in QC quality could
TABLE 5.1: Total number of features present in each dataset after filtering.
Polarity DSS Serum DPS Plasma
Positive 4448 5643 4790 2328
Negative 2374 2724 2723 2525
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be related to the drop in performance of the LC column leading to broader peaks and
lower quality data overall. PCA plots demonstrating QC performance can be seen in
Figure 5.2 & 5.3.
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FIGURE 5.2: PCA scores plot demonstrating quality of UHPLC-MS data
for Guatemala study)
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FIGURE 5.3: PCA scores plot demonstrating quality of UHPLC-MS data
for the Philippines study)
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5.3.2 Base Peak Chromatograms
An initial visual comparison of the base peak chromatograms of both samples from
serum and dried serum spot samples can be found in Figure 5.4 & 5.5.
Clear visual similarities between both serum and DSS samples can be identified
with good correlation between major peaks present and retention times, as well as
intensities of many peaks. However there are clear differences at certain regions of the
chromatogram. When comparing DPS and plasma in Figure 5.4 there are additional
and more intense peaks present towards the start of the plasma chromatogram prior to
4 minutes. Additionally, these peaks are also not present in the serum or DSS base peak
chromatograms. The presence of these peaks in the chromatogram could be related
to additional features present within plasma which are not present in serum such as
clotting factors. Furthermore the peaks present could be related to compounds being
extracted directly from the filter paper rather than from the sample directly.
5.3.3 Comparison of extraction efficiency
To compare the extraction efficiency between extracting from whole biofluid and ex-
traction from collection cards, the total peak area of each sample was compared for
each dataset and ion mode. These values can be seen in the bar plot in Figure 5.6.
For the Philippines study, the total response shown in the sum of the peak areas,
shows that there is no clear statistical significant (t-test, p>0.05) difference in the total
analyte response between the two types of sample (whole or dried). However for the
Guatemala study, there is a significant difference (p < 0.005) between the total sum of
peak areas for dried and whole biofluid. Whilst this difference is significant, the extrac-
tion efficiency of the dried biofluid spots is still suitable for non-targeted metabolomics
applications.
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(A)
(B)
FIGURE 5.4: Base peak chromatograms of (A) dried plasma spots and (B)
plasma collected from the Philippines.
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(A)
(B)
FIGURE 5.5: Base peak chromatograms of (A) dried serum spots and (B)
serum.
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(A) Guatemala Study (B) Philippines Study
FIGURE 5.6: Total sum of peak areas for all datasets.
5.3.4 Common Features
Comparison between the number of common features present between both DSS and
serum and DPS and plasma was conducted. Features were determined as common if
they were within a 5ppm mass difference, as well eluting from the column within 15
seconds of the other to account for any retention time shift that may have occurred
between the two datasets. The common features are displayed in Figure 5.7
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(A) Guatemala - Posi-
tive
(B) Guatemala - Nega-
tive
(C) Philippines - Posi-
tive
(D) Philippines - Neg-
ative
FIGURE 5.7: Number of common and unique features present within each
dataset. Common features are match within a 5ppm mass difference and
elute within 15 seconds of the other.
From Figure 5.7, whilst there are many (≥1122) features that are common between
both the biofluid and the dried sample, there are still a large number of features which
are unique to each dataset.
The presence of features which are present in one form of the biofluid over the
other may be attributed to several factors. Firstly, where features are present within
the dried biofluid card over the whole biofluid, features may have leached from the
card and into the extraction solution when the sample has undergone extraction and
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preparation. Whilst this is attempted to be controlled for through the extraction of
blank cards, there potentially may be additional reactions and oxidation which may
happen on the surface of the card which cannot be accounted for through a blank ex-
traction of a collection card. Secondly, where features are present in the whole biofluid
compared to its dried counterpart, an increase in the ability for features to partition
into the extraction solution may be slightly easier than being extracted from the collec-
tion card. Another reason for unique features in each of the respective datasets could
be attributed to an individual metabolite being present as multiple features present in
separate datasets, therefore it would not have been detected as a common feature, but
would still be related to the same metabolite.
However, with the extraction of more than 1000 biologically related features which
are present within both datasets indicates that a large amount of biological information
is present whether or not it is whole or dried.
5.3.5 Multivariate Analysis
5.3.5.1 Principal Component Analysis
PCA plots were subsequently produced for each dataset and are shown in Figure 5.8
and 5.9. Samples from Guatemala were classified as either ’High’ or ’Normal’ intake of
Vitamin A based on a food questionnaire completed by the subject prior to the sample
being collected. For samples collected from the Philippines, a classification of ’High’
or ’Normal’ level of Vitamin A intake was determined from the calculated Vitamin A
levels from the liver. Any sample which had a Vitamin A level of less than 1000 µg/kg
of body weight were determined as ’Normal’ and those which were higher classified
as ’High’.
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(A) Serum - Positive (B) Serum - Negative
(C) DSS - Positive (D) DSS - Negative
FIGURE 5.8: PCA scores plot for samples in the Guatemala study with
each samples classified as either ’High’ intake of Vitamin A or ’Normal’
intake of Vitamin A.)
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(A) Plasma - Positive (B) Plasma - Negative
(C) DPS - Positive (D) DPS - Negative
FIGURE 5.9: PCA scores plot for samples in the Philippines study with
each samples classified as either ’High’ intake of Vitamin A or ’Normal’
intake of Vitamin A.)
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From the PCA plots it is clear to see that in most of the datasets, samples which
had been classified as having a ’High’ intake of Vitamin A are clustering together to a
higher degree than those which are not. However, although there is some separation
between the groups, there are samples present within the ’Normal’ class which appear
to be more biologically similar to the ”High’ group than the ’Normal’ group. This
observation indicates that there may be an additional factor which is grouping samples
together in addition to Vitamin A intake.
Additionally to observe the same pattern of grouping and separation between
whole biofluid and the corresponding dried sample, indicates the same biological in-
formation is being extracted from the collection card as well as from the whole biofluid.
As a point to note, unlike in the Guatemala study where each whole biofluid sam-
ple has a corresponding dried serum sample, with the Philippines study, not every
plasma sample has a corresponding dried plasma sample. Therefore there are fewer
samples present within the DPS dataset compared to the plasma dataset. This is due
to not enough plasma being present at the original time of preparation to prepare both
plasma and corresponding dried plasma spots. This was unable to be corrected for as
the samples had already been collected prior to the start of this research.
5.3.6 Univariate analysis
After multivariate analysis, a non-parametric Mann-Whitney U-Test was performed on
each data set with the total number of significant features then summarised in Table
5.2. Comparisons were made between the first and the third tertile of total Vitamin A
levels within the body.
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TABLE 5.2: Total number of significant changes for each data set including the total number of each major
lipid class defined as significantly changing by a Mann-Whitney U test (p<0.05, FDR corrected).
Lipid Class
Guatemala Study Philippines Study
Serum DSS Plasma DPS
Positive Negative Positive Negative Positive Negative Positive Negative
Total Number of Significant Features 157 53 327 19 81 87 283 215
Monoacylglycerols - 1 2 2 - - - -
Diacylglycerols 10 - 15 2 2 1 5 2
Tri(acyl|alkyl)glycerols 3 - 9 - - 1 7 3
Fatty acyl carnitines 10 4 8 - 7 6 11 5
Phosphatidic acids 5 - 14 - 3 2 36 7
Phosphatidylcholines 18 5 39 1 25 7 32 10
Phosphatidylethanolamines 3 - 13 - 3 2 7 4
Phosphatidylglycerols 3 3 13 - 7 4 11 4
Phosphatidylinositols - 13 16 - 4 5 5 10
Phosphatidylserines 52 10 67 5 10 12 19 18
Sphingomyelins 2 1 5 - 2 - 1 1
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Major classes of lipids were then grouped together to give an indication into which
classes of compounds were being up-regulated or down-regulated based on the Vi-
tamin A intake level of the subject. In the Guatemala data set, several groups of
lipids (phosphatidylserines (PS), phosphatidylcholines (PC) and diacylglycerols (DG))
are seen as to be significantly changing between the two intake groups of Vitamin
A. These same groups of lipids are also shown as significantly changing with both
datasets showing upregulation, not only in the dried serum spots prepared from the
whole serum, but also in the independently collected samples from the Philippines,
with both plasma and DPS also showing significant changes in the same groups.
The evidence that there are several lipid groups changing significantly in the serum
and plasma, and the corresponding dried biofluid cards, indicate that the accumulation
of vitamin A within the liver is having a biological effect on the patient which is then
found in the serum and plasma metabolome.
Further to the above observation is the identification of the same lipid classes iden-
tified as significantly different in the study based in the Philippines. In this study,
compared to other classes of lipids, it is the same groups in phosphatidylserines (PS)
and phosphatidylcholines which are showing more changes.
The presence of similar classes of lipids which are significantly changing in sepa-
rate populations demonstrates that a consistent metabolic change is occurring when
between recommended Vitamin A levels and higher Vitamin A levels. This obser-
vation agrees with an unpublished pig study which was conducted along side this
research. In this study, a controlled dose of retinyl proprionate was given to pigs
to induce hypervitaminosis A. Subsequent results showed significant changes in the
lipidome with many changes occuring in ceramides, glycerophospholipids, lysoglyc-
erophospholipids, sterol lipids and triacylglycerides. Identifying common classes of
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lipids such as glycerophospholipids that are changing between both the controlled pig
model and the human studies performed in the Philippines and Guatemala opens up
questions surrounding the potential for further targeted research.
With regard to the literature, there are many metabolic studies that look at the ef-
fects of Vitamin A deficiency, whereas the effects of being hypervitaminotic are limited.
Suzuki et al. [250] reported that recieving high doses of Vitamin A coincided with in-
creased concentrations of triglycerides in the serum. This agrees with the univariate
analysis performed which demonstrates that triglycerides are also being significantly
altered in the serum and plasma between subjects which have high and low levels of
vitamin A intake.
Furthermore, Grolier et al [251] also reported that hypervitaminotic concentrations
induced structural variations in the lipid membrane which were linked to enhance-
ments of both phosphitdylcholines and sphingomyelins, whilst Sharma et al also re-
ported that massive doeses of Vitamin A leads to phospholipid accumulation in rat
livers.
Both of the above conclusions from Grolier et al and Sharma et al [252] agree with
the statistical analysis in which there are large changes in phospholipids.
However as with any non-targeted study there are limitations, especially surround-
ing annotations. The annotations used to identify certain metabolites are only based
on accurate mass-to-charge ratios and therefore there is a high probability of misattri-
bution of a specific lipid being assigned to one class instead of another class, especially
in cases of isobaric compounds.
Therefore for future studies it would be imperative that when focusing on the
classes of lipids that could potentially be changing as described above, that further
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MS/MS data is collected to ensure accurate annotations, and that a more in-depth tar-
geted study towards particular classes is taken.
Due to the lack of literature that surrounds hypervitaminosis A and its effects on
biochemical pathways, it is difficult to draw any robust biological conclusions.
5.4 Conclusion
In this chapter, the use of dried serum and plasma spots were applied to a biological
non-targeted metabolomics application.
Although not identical, the use of dried plasma and serum spots compared to to
dried blood spots still has advantages within non-targeted metabolomic applications.
Particularly in cases where the cost of transporting samples under controlled temper-
ature conditions across multiple countries may be prohibitive. However, with the lack
of cellular components that are present within whole blood and therefore DBS, DPS
and DSS will contain less biological information.
The use of DPS and DSS in a non-targeted metabolomics study has demonstrated
similar analytical performance when compared to plasma and serum respectively.
With sufficient extraction efficiency and over 1100 common features between the dried
and whole form, there can be a high degree of confidence that there will be similar
biological information present in both sample types.
Current metabolomic research surrounding Vitamin A and the effects it has on the
liver when in excess is limited in the published literature. Therefore the work pre-
sented here represents the first investigation into the effect of high doses of Vitamin
A in human subjects and the effects that are occurring in both the serum and plasma
metabolome.
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A point to note as well is the non-toxic concentrations of Vitamin A which have
been supplied to the children taking part in both the Guatemala and Philippines study.
To demonstrate that there is a metabolic effect occurring at increased levels of Vita-
min A within the liver is an important conclusion with further analysis required to
determine what physical effects this may have, both shorter and longer term.
Further targeted analysis focusing on lipid classes and pathways would potentially
be a way in moving towards a more robust biological conclusion and determining any
biochemical pathway effects which are occurring due to any increase in Vitamin A lev-
els. Extra analysis could then be conducted using pathway analysis tools when more
specific annotations have been made allowing the extraction of any biochemical path-
ways which are being altered either due to the up or down regulation of the various
classes of lipids.
However, as just alluded to their are limitations to the study performed, primar-
ily regarding the annotation of data. Due to only annotating based on m/z, putative
class annotations are only possible and further work is required surrounding the more
confident annotation of many of the lipid classes being detected as significantly differ-
ent. Additionally, a more controlled study would increase the confidence in classifying
whether or not a subject has high Vitamin A intake rather than relying on food based
questionnaires which occurred for the Guatemala based study. Additional statistical
analysis using supervised multivariate analysis techniques would also be of use when
looking further into the data. Through the application of supervised methods such as
PLS-DA, more confidence could be gained in the ability to identify metabolites which
have significant effect on the models produced. Therefore allowing identification of
metabolites which are perturbed through the consumption of excess Vitamin A.
Furthermore with the use of a pig model to look at the effects of hypervitamosis A,
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additional samples could be taken from both adipose and liver tissues to build a more
complete effect of the metabolic changes (due to being rich in lipids) that are occurring
based on the high levels of Vitamin A.
In summary, DSS and DPS have been applied to a non-targeted metabolomics study
where similar biological conclusions have been reached compared to the analysis of
serum and plasma respectively. This shows that the use of collection cards is valid
for the study of metabolic health and with the improvement in techniques and anal-
ysis, collection cards represent a cheaper alternative to population based studies both
nationally and internationally.
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With the title of this thesis being ’The Investigation, Development and Application
of Non-Targeted Metabolomic Methods Applying Dried Blood Spot Collection’, I have
aimed to investigate three main areas of DBS collection which can be viewed as limiting
the wide scale use of collection cards in non-targeted research.
First, Chapters 2 and 3 are aimed at investigating two areas which are viewed as
critical to the application of DBS in large scale studies. With stability and normalisation
both key in ensuring the integrity of the data.
Chapter 2 - Stability of DBS & DUS
With Chapter 2, the stability of DBS in addition to DUS was investigated over a 12
month period at a variety of common temperatures applied in the storage of samples.
Recommendations were made surrounding the longer term storage of DBS and DUS
samples at reduced temperature, however it has been shown that samples were stable
up to a period of one month before these recommendations should ideally be imple-
mented. This provides plenty of time for samples to be collected remotely before being
sent back to either the clinic or laboratory for longer term storage. This time period
potentially allows patients to collect their own sample within their own homes or sam-
ples to be collected in remote locations where whole blood processing facilities may
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not be available.
Further work surrounding the assessment of stability on other collection devices
that are not filter paper based would be useful. With an increased number of com-
mercial dried biofluid sampling kits supplied by companies, it would be beneficial to
understand whether or not these can also be applied in non-targeted metabolomics
scenarios.
Chapter 3 - Normalisation
Chapter 3 describes a novel implementation of a well established assay used in
the determination of total protein content. Through the application of the Bradford
assay to the measurement of total protein content in a DBS, a measurement value is
obtained which can then be used to normalise the total blood volume which has been
deposited onto the DBS. This method also has the benefit of being applied after the ini-
tial metabolomics extraction, thus only be performed on the remaining sample that was
destined for waste. Applying normalisation both before the data was acquired as well
as after data acquisition was shown to improve data quality, however better analytical
performance was shown with normalisation prior to the acquisition of data through
reconstitution volumes. It was also shown that applying a computational based pa-
rameter such as TIC normalisation to the normalisation of data was unsuitable when
compared against the normalisation to total protein content.
Further work based on the results from this chapter could be expanding the range
of samples types and collection cards which this method could be applied to as well as
applying the assay to a biological question to further validate the implementation of
the assay to the normalisation of DBS.
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Chapter 4 - LESA Method Development
Chapter 4 was aimed at the development of a new method of analysis of DBS for
use within non-targeted studies. This was achieved through the use of LESA-MS tech-
nology. Whilst LESA-MS has been applied to the analysis of DBS, this has primarily
been in the area of proteomics. Additionally, LESA-MS has been used in non-targeted
metabolomics, but not applied to DBS. Therefore there was an opportunity to fill this
void in research and develop a new method of analysing DBS for non-targeted re-
search. Through careful optimisation of parameters and solvents, a LESA-MS method
was developed, with similar analytical performance to that of it’s closest direct infusion
technique. Multiple thousands of features were able to be extracted over five seconds
from the surface of a DBS through a stable LMJ formed of a mixture of acetonitrile
and water. The method was able to directly distinguish between two sample classes
presented through PCA with a similar number of statistically significant metabolites
being detected as by DI-MS. Whilst the performance of the method did not match tech-
niques applying separation, the use of the method has future applicability in the high
throughput screening of samples with out any sample preparation required. This re-
duces cost, increases throughput whilst still being able to extract a large amount of
biological information from the surface of a DBS. More critically however is that LESA
samples have to be left for a duration of time at ambient temperature to allow a clot
to form which subsequently aids the formation of the LMJ. Therefore, for areas which
require the immediate analysis of samples, the use of LESA could be limited for DBS
due to the inability to form a LMJ. Furthermore, LESA-MS on DBS initially appears to
be limited to a small variety of solvents, which could limit the groups of metabolites
which can be extracted from DBS, and thus removing areas of research which may
focus on specific areas of the metabolome such as lipidomics.
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Potential further work for this area of research could be applying LESA to a biolog-
ical study to allow for the high throughput screening of samples whilst requiring no
sample preparation. Furthermore, with recent developments in the LESA platform it
would also be beneficial to understand how well the method developed in this chapter
compares to UHPLC through the ability to couple LESA to an LC column to perform
separation on any extracted mixture.
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Chapter 5 - Application
Finally, the application of collection cards in a non-targeted metabolomics study
was demonstrated in Chapter 5. Through the use of DSS and DPS, and a direct com-
parison against serum and plasma respectively, two independent studies investigating
the effects of Hypervitaminosis A were conducted. Results show similar biological
changes accruing in both samples that were provided as whole or those which were
present on collection cards. This similarity demonstrates the validity in applying col-
lection cards in large population based studies. With large changes in glycerophospho-
lipids being detected across both studies in Guatemala and the Philippines, there are
biological effects from the high doses of Vitamin A that are given to children through
each countries supplementation programs. Further investigation into the effects that
high, but non-toxic concentrations of Vitamin A have on the subject is required. Es-
pecially seeing as the study performed only investigated serum and plasma, effects
on adipose and liver tissues directly would further strengthen conclusions whilst also
being able to build up a bigger picture of the metabolic health effects.
Through a combination of conclusions that have been reached across the vari-
ous chapters presented in this thesis, the use of DBS in large scale, non-targeted
metabolomics research in the future is possible. Providing recommendations sur-
rounding the storage of samples, integrity of the data can be ensured up to a certain
point. The normalisation of samples based on total protein content is a valid method
to correct for non-biological sources of variation, and the high throughput of samples
without prior extraction using LESA-MS, allows large amounts of biological data to be
collected from a simple five second extraction.
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6.1 Final Comments
Throughout this thesis I have demonstrated that the use of DBS and more broadly the
application of using collection cards for the storage and transportation of samples has
wide applicability in non-targeted metabolomics research areas.
With the advantages that collecting DBS has over samples collected via venipunc-
ture, there is potentially a much broader area of research open to non-targeted
metabolomics studies. Particularly in cases were the collection of samples is difficult
based either on local geography or the facilities available to prepare, store and trans-
port biofluids. With the use of collection cards, with relation to DBS and DUS, it has
been shown that providing samples are collected and stored within one month of col-
lection, then the integrity of the sample is not compromised and can still be applied to
non-targeted studies.
Further development surrounding the use of DBS in non-targeted scenarios is no
doubt required, especially surrounding whether or not there are alternative collection
methods which remove the need to apply any potential normalisation procedures. Al-
though applying a total protein content assay was shown in Chapter 3 to improve the
quality of data obtained and improve the non-biological effects that different volumes
have on the data. If commercial products which claim to collect accurate volumes of
blood such as Neoteryx’s Mitra kit are validated for non-targeted studies, then this
removes the need for an additional step in the laboratory when dealing with real sam-
ples. However, applying a Bradford assay to samples which have been kept in long
term storage in biobanks around the world, opens up a large volume of DBS samples
to be analysed where blood volume will not have been recorded.
The LESA method developed in Chapter 4 demonstrates the potential to perform
large scale screening of samples within non-targeted scenarios. With the lack of sample
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preparation required, the use of LESA opens up the opportunity for 100’s of samples
to be analysed in a single day. Whilst the method was developed to maximise the
number of features and ensure reproducibility of samples was within acceptable limits
for non-targeted studies, it also has the potential to be applied in a targeted manner
where only specific metabolites are of interest.
Finally, as mentioned earlier, the use of dried collection cards offer many opportuni-
ties for studies which may have previously been logistically impossible due to facility
or financial constraints, and Chapter 5 demonstrates the use of collection cards in sam-
ples which have been collected in developing world countries such as Guatemala and
the Philippines. With similar biological conclusions and similar biological classes of
compounds being detected as significantly changing, it therefore stands to reason that
the impact that using collection cards has on the overall study is minimal and should
therefore be considered when designing experiments.
In conclusion, the use of collection cards, especially DBS, have a large poten-
tial future as collection devices for samples which are obtained for non-targeted
metabolomics research. With improved logistical advantages, lower volumes and
with a wide variety of methods available to analyse samples, DBS should be consid-
ered to be an appropriate sample collection strategy when performing non-targeted
metabolomics experiments.
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Silva, E. A.; Pawliszyn, J. Trends in Analytical Chemistry 2014, 61, 168–180.
(68) Bligh, E. G.; Dyer, W. J. Canadian Journal of Biochemistry and Physiology 1959, 37,
911–917.
LIST OF REFERENCES 195
(69) Matyash, V.; Liebisch, G.; Kurzchalia, T. V.; Shevchenko, A.; Schwudke, D. Jour-
nal of Lipid Research 2008, 49, 1137–46.
(70) Sostare, J.; Di Guida, R.; Kirwan, J.; Chalal, K.; Palmer, E.; Dunn, W. B.; Viant,
M. R. Analytica Chimica Acta 2018, 1037, 301–315.
(71) Fernández-Peralbo, M. A.; De Castro, M. D. L. Trends in Analytical Chemistry
2012, 41, 75–85.
(72) Issaq, H. J.; Van, Q. N.; Waybright, T. J.; Muschik, G. M.; Veenstra, T. D. Journal
of Separation Science 2009, 32, 2183–2199.
(73) Guthrie, R.; Susi, A Pediatrics 1963, 32, 338–343.
(74) Blau, N.; van Spronsen, F. J.; Levy, H. L. The Lancet 2010, 376, 1417–1427.
(75) Jeanmonod, R.; Jeanmonod, D. In StatPearls [Internet]; StatPearls Publishing:
2018.
(76) Jager, N. G. L.; Rosing, H.; Linn, S. C.; Schellens, J. H. M.; Beijnen, J. H. Thera-
peutic Drug Monitoring 2015, 37, 833–836.
(77) Sakhi, A. K.; Bastani, N. E.; Ellingjord-Dale, M.; Gundersen, T. E.; Blomhoff, R.;
Ursin, G. BMC Cancer 2015, 15, 265.
(78) Dried Blood Spot Sampling - https://cleancompetition.org/2016/05/11/whats-
next-wednesday-dried-blood-spot-sampling/.
(79) Kadjo, A. F.; Stamos, B. N.; Shelor, C. P.; Berg, J. M.; Blount, B. C.; Dasgupta, P. K.
Analytical Chemistry 2016, 88, 6531–6537.
(80) Freeman, J. D.; Rosman, L. M.; Ratcliff, J. D.; Strickland, P. T.; Graham, D. R.;
Silbergeld, E. K. Clinical Chemistry 2018, 64, 656 LP –679.
196 LIST OF REFERENCES
(81) Solomon, S. S.; Solomon, S.; Rodriguez, I. I.; McGarvey, S. T.; Ganesh, A. K.;
Thyagarajan, S. P.; Mahajan, A. P.; Mayer, K. H. International Journal of STD &
AIDS 2002, 13, 25–28.
(82) Ngo-Giang-Huong, N.; Khamduang, W.; Leurent, B.; Collins, I.; Nantasen, I.;
Leechanachai, P.; Sirirungsi, W.; Limtrakul, A.; Leusaree, T.; Comeau, A. M. Jour-
nal of Acquired Immune Deficiency Syndromes 2008, 49, 465.
(83) Lofgren, S. M.; Morrissey, A. B.; Chevallier, C. C.; Malabeja, A. I.; Edmonds, S.;
Amos, B.; Sifuna, D. J.; Von Seidlein, L.; Schimana, W.; Stevens, W. S. AIDS 2009,
23, 2459.
(84) La Marca, G.; Malvagia, S.; Filippi, L.; Luceri, F.; Moneti, G.; Guerrini, R. Epilep-
sia 2009, 50, 2658–2662.
(85) Sadilkova, K.; Busby, B.; Dickerson, J. A.; Rutledge, J. C.; Jack, R. M. Clinica
Chimica Acta 2013, 421, 152–156.
(86) Arai, N.; Narisawa, K.; Hayakawa, H.; Tada, K. Pediatrics 1982, 70, 426–430.
(87) O’Mara, M.; Hudson-Curtis, B.; Olson, K.; Yueh, Y.; Dunn, J.; Spooner, N. Bio-
analysis 2011, 3, 2335–2347.
(88) Ren, X.; Paehler, T.; Zimmer, M.; Guo, Z.; Zane, P.; Emmons, G. T. Bioanalysis
2010, 2, 1469–1475.
(89) Holub, M.; Tuschl, K.; Ratschmann, R.; Strnadová, K. A.; Mühl, A.; Heinze, G.;
Sperl, W.; Bodamer, O. A. Clinica Chimica Acta 2006, 373, 27–31.
(90) Denniff, P.; Spooner, N. Bioanalysis 2010, 2, 1385–1395.
(91) Mei, J. V.; Alexander, J. R.; Adam, B. W.; Hannon, W. H. The Journal of Nutrition
2001, 131, 1631S–1636S.
LIST OF REFERENCES 197
(92) Billett, H. H., Hemoglobin and Hematocrit, 1990.
(93) Thirup, P. Sports Medicine 2003, 33, 231–243.
(94) Capiau, S.; Stove, V. V.; Lambert, W. E.; Stove, C. P. Analytical Chemistry 2013, 85,
404–410.
(95) Meesters, R. J. W.; Hooff, G. P. Bioanalysis 2013, 5, 2187–2208.
(96) Holub, M.; Tuschl, K.; Ratschmann, R.; Strnadová, K. A.; Mühl, A.; Heinze, G.;
Sperl, W.; Bodamer, O. A. Clinica Chimica Acta 2006, 373, 27–31.
(97) Oglesbee, D.; Sanders, K. A.; Lacey, J. M.; Magera, M. J.; Casetta, B.; Strauss,
K. A.; Tortorelli, S.; Rinaldo, P.; Matern, D. Clinical Chemistry 2008, 54, 542–549.
(98) Otero-Fernández, M.; Cocho, J.; Tabernero, M. J.; Bermejo, A. M.; Bermejo-
Barrera, P.; Moreda-Piñeiro, A. Analytica Chimica Acta 2013, 784, 25–32.
(99) Redondo, A. H.; Körber, C.; König, S.; Längin, A.; Al-Ahmad, A.; Weinmann, W.
Analytical and Bioanalytical Chemistry 2012, 402, 2417–2424.
(100) Zheng, N.; Zeng, J.; Ji, Q. C.; Angeles, A.; Aubry, A.-F.; Basdeo, S.; Buzescu, A.;
Landry, I. S.; Jariwala, N.; Turley, W. Analytica Chimica Acta 2016, 934, 170–179.
(101) Numako, M.; Takayama, T.; Noge, I.; Kitagawa, Y.; Todoroki, K.; Mizuno, H.;
Min, J. Z.; Toyo’oka, T. Analytical chemistry 2015, 88, 635–639.
(102) Abdel-Rehim, A.; Abdel-Rehim, M. Biomedical Chromatography 2014, 28, 875–
877.
(103) Rago, B.; Liu, J.; Tan, B.; Holliman, C. Journal of Pharmaceutical and Biomedical
Analysis 2011, 55, 1201–1207.
(104) Sen, A.; Wang, Y.; Chiu, K.; Whiley, L.; Cowan, D.; Chang, R. C.-C.; Legido-
Quigley, C. Analytical Chemistry 2013, 85, 7257–7263.
198 LIST OF REFERENCES
(105) Ulaszewska, M. M.; Weinert, C. H.; Trimigno, A.; Portmann, R.; Andres
Lacueva, C.; Badertscher, R.; Brennan, L.; Brunius, C.; Bub, A.; Capozzi, F.;
Cialiè Rosso, M.; Cordero, C. E.; Daniel, H.; Durand, S.; Egert, B.; Ferrario, P. G.;
Feskens, E. J. M.; Franceschi, P.; Garcia-Aloy, M.; Giacomoni, F.; Giesbertz, P.;
González-Domínguez, R.; Hanhineva, K.; Hemeryck, L. Y.; Kopka, J.; Kulling,
S. E.; Llorach, R.; Manach, C.; Mattivi, F.; Migné, C.; Münger, L. H.; Ott, B.; Pi-
cone, G.; Pimentel, G.; Pujos-Guillot, E.; Riccadonna, S.; Rist, M. J.; Rombouts,
C.; Rubert, J.; Skurk, T.; Sri Harsha, P. S. C.; Van Meulebroek, L.; Vanhaecke,
L.; Vázquez-Fresno, R.; Wishart, D.; Vergères, G. Molecular Nutrition & Food Re-
search 2019, 63, 1800384.
(106) Steuer, A. E.; Brockbals, L.; Kraemer, T. Frontiers in Chemistry 2019, 7, DOI: 10.
3389/fchem.2019.00319.
(107) Mei, J. V.; Zobel, S. D.; Hall, E. M.; De Jesús, V. R.; Adam, B. W.; Hannon, W. H.
Bioanalysis 2010, 2, 1397–1403.
(108) Luckwell, J.; Denniff, P.; Capper, S.; Michael, P.; Spooner, N.; Mallender, P.; John-
son, B.; Clegg, S.; Green, M.; Ahmad, S. Bioanalysis 2013, 5, 2613–2630.
(109) Smit, P. W.; Elliott, I.; Peeling, R. W.; Mabey, D.; Newton, P. N. American Journal
of Tropical Medicine and Hygiene 2014, 90, 195–210.
(110) Kip, A. E.; Kiers, K. C.; Rosing, H; Schellens, J. H. M.; Beijnen, J. H.; Dorlo, T. P. C.
Journal of Pharmaceutical and Biomedical Analysis 2017, 135, 160–166.
(111) HemaSpot-HF Blood Collection Device - Spot On Sciences -
https://www.spotonsciences.com/products/hemaspot-hf/.
LIST OF REFERENCES 199
(112) Blood collection kit Mitra R© Cartridge Neoteryx, LLC -
https://www.medicalexpo.com/prod/neoteryx-llc/product-119251-
847730.html.
(113) Brooks, K; DeLong, A; Balamane, M; Schreier, L; Orido, M; Chepkenja, M; Kem-
boi, E; D’Antuono, M; Chan, P. A.; Emonyi, W Journal of Clinical Microbiology
2016, 54, 223–225.
(114) Saracino, M. A.; Marcheselli, C.; Somaini, L.; Pieri, M. C.; Gerra, G.; Ferranti, A.;
Raggi, M. A. Analytical and Bioanalytical Chemistry 2012, 404, 503–511.
(115) Kong, S. T.; Lin, H. S.; Ching, J.; Ho, P. C. Analytical Chemistry 2011, 83, 4314–
4318.
(116) Barcenas, M.; Suhr, T. R.; Scott, C. R.; Turecek, F.; Gelb, M. H. Clinica Chimica
Acta 2014, 433, 39–43.
(117) Markley, J. L.; Brüschweiler, R.; Edison, A. S.; Eghbalnia, H. R.; Powers, R.;
Raftery, D.; Wishart, D. S. Current Opinion in Biotechnology 2017, 43, 34–40.
(118) Schrimpe-Rutledge, A. C.; Codreanu, S. G.; Sherrod, S. D.; McLean, J. A. Journal
of The American Society for Mass Spectrometry 2016, 27, 1897–1905.
(119) González-Domínguez, R.; Sayago, A.; Fernández-Recamales, Bioanalysis 2017,
9, 131–148.
(120) Koulman, A.; Tapper, B. A.; Fraser, K.; Cao, M.; Lane, G. A.; Rasmussen, S. Rapid
Communications in Mass Spectrometry 2007, 21, 421–428.
(121) Southam, A. D.; Payne, T. G.; Cooper, H. J.; Arvanitis, T. N.; Viant, M. R. Analyt-
ical Chemistry 2007, 79, 4595–4602.
200 LIST OF REFERENCES
(122) Gika, H. G.; Wilson, I. D.; Theodoridis, G. A. Journal of Chromatography B 2014,
966, 1–6.
(123) Boelaert, J.; t’Kindt, R.; Schepers, E.; Jorge, L.; Glorieux, G.; Neirynck, N.; Lynen,
F.; Sandra, P.; Vanholder, R.; Sandra, K. Metabolomics 2014, 10, 425–442.
(124) Broeckling, C. D.; Heuberger, A. L.; Prenni, J. E. Journal of Visualized Experiments
2013, e50242.
(125) Tang, D.; Zou, L.; Yin, X.; Ong, C. N. Mass Spectrometry Reviews 2016, 35, 574–
600.
(126) Cubbon, S.; Antonio, C.; Wilson, J.; Thomas-Oates, J. Mass Spectrometry Reviews
2010, 29, 671–684.
(127) Fei, F.; Bowdish, D. M. E.; McCarry, B. E. Analytical and Bioanalytical Chemistry
2014, 406, 3723–3733.
(128) Bakalyar, S. R.; Phipps, C.; Spruce, B.; Olsen, K. Journal of Chromatography A 1997,
762, 167–185.
(129) Swartz, M. E. Journal of Liquid Chromatography & Related Technologies 2005, 28,
1253–1263.
(130) Mazzeo, J. R.; D.Neue, U.; Kele, M.; Plumb, R. S. Analytical Chemistry 2005, 77,
460 A–467 A.
(131) Broeckhoven, K; Desmet, G Trends in Analytical Chemistry 2014, 63, 65–75.
(132) Gray, N.; Adesina-Georgiadis, K.; Chekmeneva, E.; Plumb, R. S.; Wilson, I. D.;
Nicholson, J. K. Analytical Chemistry 2016, 88, 5742–5751.
(133) Zotou, A. Central European Journal of Chemistry 2012, 10, 554–569.
(134) Wilson, S. R.; Vehus, T.; Berg, H. S.; Lundanes, E. Bioanalysis 2015, 7, 1799–815.
LIST OF REFERENCES 201
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FIGURE A.1: Compound Discoverer 3.1 Workflow
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FIGURE A.2: Parameters applied for ’Select Spectra’ module.
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FIGURE A.3: Parameters applied for ’Align Rention Times’ module.
FIGURE A.4: Parameters applied for ’Detect Compounds’ module.
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FIGURE A.5: Parameters applied for ’Group Compounds’ module.
FIGURE A.6: Parameters applied for ’Fill Gaps’ module.
FIGURE A.7: Parameters applied for ’Normalise Areas’ module.
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FIGURE A.8: Parameters applied for ’Assign Compound Annotations’
module.
FIGURE A.9: Parameters applied for ’Search ChemSpider’ module.
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FIGURE A.10: Parameters applied for ’Search mzCloud’ module.
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FIGURE A.11: Parameters applied for ’Predict Compositions’ module.
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FIGURE A.12: Parameters applied for ’Mark Background Compounds’
module.
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Appendix B
XCMS Processing Parameters
1 #####HILIC XCMS PARAMETERS#####
2 xcmsParams <- list(
3 ’ppm’ = 12,
4 ’peakwidth_low’ = 4,
5 ’peakwidth_high’ = 30,
6 ’snthresh’ = 5,
7 ’prefilter_low’ = 5,
8 ’prefilter_high’ = 1000,
9 ’mzCenterFun’ = "wMean",
10 ’integrate’ = 1L,
11 ’mzdiff’ = 0.001,
12 ’fitguass’ = FALSE,
13 ’noise’ = 1000,
14 ’gapinit’ = 0.5,
15 ’gapExtend’ = 2.4,
16 ’minfrac’ = 0.5,
17 ’bw’ = 0.25,
18 ’binsize’ = 0.01,
19 ’verboseColumns’ = TRUE
20 )
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21 #####LIPIDS XCMS PARAMETERS#####
22 xcmsParams <- list(
23 ’ppm’ = 14,
24 ’peakwidth_low’ = 6,
25 ’peakwidth_high’ = 30,
26 ’snthresh’ = 5,
27 ’prefilter_low’ = 5,
28 ’prefilter_high’ = 1000,
29 ’mzCenterFun’ = "wMean",
30 ’integrate’ = 1L,
31 ’mzdiff’ = 0.001,
32 ’fitguass’ = FALSE,
33 ’noise’ = 1000,
34 ’gapinit’ = 0.4,
35 ’gapExtend’ = 2.4,
36 ’minfrac’ = 0.5,
37 ’bw’ = 0.25,
38 ’binsize’ = 0.01,
39 ’verboseColumns’ = TRUE
40 )
41 #####REVERSED PHASE XCMS PARAMETERS#####
42 xcmsParams <- list(
43 ’ppm’ = 11,
44 ’peakwidth_low’ = 3,
45 ’peakwidth_high’ = 30,
46 ’snthresh’ = 5,
47 ’prefilter_low’ = 5,
48 ’prefilter_high’ = 1000,
49 ’mzCenterFun’ = "wMean",
50 ’integrate’ = 1L,
Appendix B. XCMS Processing Parameters 225
51 ’mzdiff’ = 0.001,
52 ’fitguass’ = FALSE,
53 ’noise’ = 1000,
54 ’gapinit’ = 0.4,
55 ’gapExtend’ = 2.4,
56 ’minfrac’ = 0.5,
57 ’bw’ = 0.5,
58 ’binsize’ = 0.01,
59 ’verboseColumns’ = TRUE
60 )
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228 Appendix C. Stability Study - PCA Plots
FIGURE C.1: PCA scores plot for DBS and plasma samples collected over
180 days at three different storage temperatures and analysed applying
a lipidomic positive ion mode UHPLC-MS assay. DBS samples are dark
blue in colour, plasma samples are orange in colour and QC samples are
light blue in colour. Sample quantities may not be equal due to low quality
samples which were removed in the filtering process due to high numbers
of missing values.
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FIGURE C.2: PCA scores plot for DBS and plasma samples collected over
180 days at three different storage temperatures and analysed applying
a lipidomic negative ion mode UHPLC-MS assay. DBS samples are dark
blue in colour, plasma samples are light blue in colour and QC samples are
orange in colour. Sample quantities may not be equal due to low quality
samples which were removed in the filtering process due to high numbers
of missing values.
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FIGURE C.3: PCA scores plot for DBS and plasma samples collected over
365 days at three different storage temperatures and analysed applying a
HILIC positive ion mode UHPLC-MS assay. DBS samples are dark blue
in colour, plasma samples are orange in colour and QC samples are light
blue in colour. Sample quantities may not be equal due to low quality
samples which were removed in the filtering process due to high numbers
of missing values.
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FIGURE C.4: PCA scores plot for DBS and plasma samples collected over
365 days at three different storage temperatures and analysed applying a
HILIC negative ion mode UHPLC-MS assay. DBS samples are dark blue
in colour, plasma samples are orange in colour and QC samples are light
blue in colour. Sample quantities may not be equal due to low quality
samples which were removed in the filtering process due to high numbers
of missing values.
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FIGURE C.5: PCA scores plot for DUS and urine samples collected over
365 days at three different storage temperatures and analysed applying a
HILIC positive ion mode UHPLC-MS assay. DUS samples are dark blue
in colour, urine samples are orange in colour and QC samples are light
blue in colour. Sample quantities may not be equal due to low quality
samples which were removed in the filtering process due to high numbers
of missing values.
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FIGURE C.6: PCA scores plot for DUS and urine samples collected over
365 days at three different storage temperatures and analysed applying a
HILIC negative ion mode UHPLC-MS assay. DUS samples are dark blue
in colour, urine samples are orange in colour and QC samples are light
blue in colour. Sample quantities may not be equal due to low quality
samples which were removed in the filtering process due to high numbers
of missing values.
234 Appendix C. Stability Study - PCA Plots
FIGURE C.7: PCA scores plot for DUS and urine samples collected over
365 days at three different storage temperatures and analysed applying
a reversed phase positive ion mode UHPLC-MS assay. DUS samples are
dark blue in colour, urine samples are light blue in colour and QC sam-
ples are orange in colour. Sample quantities may not be equal due to low
quality samples which were removed in the filtering process due to high
numbers of missing values.
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FIGURE C.8: PCA scores plot for DUS and urine samples collected over
365 days at three different storage temperatures and analysed applying a
reversed phase negative ion mode UHPLC-MS assay. DUS samples are
dark blue in colour, urine samples are light blue in colour and QC sam-
ples are orange in colour. Sample quantities may not be equal due to low
quality samples which were removed in the filtering process due to high
numbers of missing values.
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FIGURE E.1: Plot demonstrating the number of statistically significant
metabolites at each time point and temperature. Plot represents the HILIC
positive results for the DBS and plasma comparison.
FIGURE E.2: Plot demonstrating the number of statistically significant
metabolites at each time point and temperature. Plot represents the HILIC
negative results for the DBS and plasma comparison.
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FIGURE E.3: Plot demonstrating the number of statistically significant
metabolites at each time point and temperature. Plot represents the
lipidomics positive results for the DBS and plasma comparison.
FIGURE E.4: Plot demonstrating the number of statistically significant
metabolites at each time point and temperature. Plot represents the HILIC
positive results for the DBS and plasma comparison.
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FIGURE E.5: Plot demonstrating the number of statistically significant
metabolites at each time point and temperature. Plot represents the HILIC
positive results for the DUS and urine comparison.
FIGURE E.6: Plot demonstrating the number of statistically significant
metabolites at each time point and temperature. Plot represents the HILIC
negative results for the DUS and urine comparison.
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FIGURE E.7: Plot demonstrating the number of statistically significant
metabolites at each time point and temperature. Plot represents the
reversed-phase positive results for the DUS and urine comparison.
FIGURE E.8: Plot demonstrating the number of statistically significant
metabolites at each time point and temperature. Plot represents the
reversed-phase negative results for the DUS and urine comparison.
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Appendix F
Stability Study - Significant
Metabolites at Room Temperature
TABLE F.1: List of annotated metabolites which are statistically significant
between day 28 and day 1 in DBS at room temperature.
P-value (follow-
ing correction
for multiple
testing using
Benjamin-
Hochberg
method)
Ratio be-
tween
d28/d1
Metabolite name(s) MW (g/-
mol)
RT (min) Assay
0.04088908 2.792 Carboxymethylproline 173.0689 1.325 HILIC negative
0.013562818 0.195 Nonenoylglycine 213.13623 1.553 HILIC positive
0.028649307 1.51 Adenine 135.05443 2.025 HILIC positive
0.028649307 8.716 N1,N8-
Diacetylspermidine
229.17871 7.567 HILIC positive
0.030135996 0.279 Tryptophan 204.08963 2.51 HILIC positive
0.030135996 0.382 5-
Hydroxyindoleacetylglycine
248.0794 4.15 HILIC positive
0.030135996 1.762 Dehydrocholesterol 384.3389 0.468 HILIC positive
0.030135996 3.278 LysoCPA(18:0) 420.26327 1.297 HILIC positive
0.034093704 0.121 (d18:1) sphingosine 299.28195 2.59 HILIC positive
0.034093704 0.268 Acetyl-N-formyl-5-
methoxykynurenamine
264.11054 0.613 HILIC positive
0.034093704 0.342 N5-Phenyl-L-
glutamine
222.10012 2.445 HILIC positive
0.034093704 0.354 Isoleucyl-Valine 230.16268 0.738 HILIC positive
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0.034093704 1.325 1,2-Diamino-4-
nitrobenzene
153.05361 2.842 HILIC positive
0.034093704 1.53 Dihydroxyoxo-
octadecenoic acid
328.22432 0.549 HILIC positive
0.034093704 1.756 Diamino-
nitrotoluene
167.06926 1.01 HILIC positive
0.034093704 1.83 4-(beta-
Acetylaminoethyl)imidazole
153.08974 0.592 HILIC positive
0.034093704 1.936 Streptamine phos-
phate
258.06111 5.363 HILIC positive
0.034093704 2.579 Delta-
Guanidinovaleric
acid
159.10057 2.846 HILIC positive
0.034093704 2.616 Methylpyrrole 81.0577 3.422 HILIC positive
0.034093704 2.631 xi-4,5-Dihydro-
2,4(5)-dimethyl-1H-
imidazole
98.08426 3.427 HILIC positive
0.034093704 2.78 Alanyl-Asparagine 203.09037 2.98 HILIC positive
0.034093704 3.557 4-O-(beta-L-
Arabinofuranosyl)-
(2S,4S)-4-
hydroxyproline
263.10008 0.589 HILIC positive
0.034093704 3.715 N-Acetyl-L-2-amino-
6-oxopimelate
231.0739 0.617 HILIC positive
0.034093704 4.027 4-Hydroxy-5-
phosphooxypentane-
2,3-dione
212.00823 6.637 HILIC positive
0.034093704 4.213 LysoPE(P-16:0) 437.28994 1.308 HILIC positive
0.034093704 4.59 N-(1-Deoxy-1-
fructosyl)threonine
281.11203 1.488 HILIC positive
0.034093704 4.651 Vinylacetylglycine 143.05809 1.636 HILIC positive
0.034093704 4.892 6-Imino-5-
oxocyclohexa-1,3-
dienecarboxylate
151.02672 0.698 HILIC positive
0.034093704 5.313 Valyl-Valine 216.1471 7.377 HILIC positive
0.035400865 1.239 3,3’-
Dimethoxybenzidine
244.12083 3.397 HILIC positive
0.038185897 0.741 Salsolinol 179.09435 1.6 HILIC positive
0.038185897 1.307 4-
(Trimethylammonio)but-
2-enoate
143.09434 6.992 HILIC positive
0.038185897 2.681 Betahistine 136.09992 2.796 HILIC positive
0.038185897 4.531 2,3-Diaminosalicylic
acid
168.05333 0.694 HILIC positive
0.038821505 0.349 1,4-Dideoxy-1,4-
imino-D-ribitol
133.07369 3.988 HILIC positive
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0.042035837 4.454 Decatrienoylcarnitine 309.19346 3.715 HILIC positive
0.042082564 1.908 (+/-)11,12-Ep-15S-
HETrE
336.22936 0.502 HILIC positive
0.042106997 0.766 Oxo-
Tetradecadienoic
acid
238.15654 0.631 HILIC positive
0.04228911 4.293 Glutamylthreonine 248.10046 0.621 HILIC positive
0.042738221 1.595 Pyrroline-5-
carboxylate
113.04753 0.752 HILIC positive
0.043323605 0.405 Aminocyclopropanecarboxylic
acid
101.04754 2.351 HILIC positive
0.043323605 1.683 Piperazine-2-
carboxamide
129.09003 3.802 HILIC positive
0.044956722 1.563 17-
Methyltestosterone
302.22398 0.495 HILIC positive
0.044956722 2.146 2,3-Butanediol gluco-
side
252.12186 3.031 HILIC positive
0.047585791 1.836 N-Nitrosoproline 144.05332 0.683 HILIC positive
0.049339137 0.093 Hydroxy-
methylbutenoic
acid
116.04706 0.939 HILIC positive
0.051478333 0.698 Epinephrine sulfate 263.04602 0.753 HILIC positive
0.051478333 1.668 N-
Methylhexanamide
129.11524 2.559 HILIC positive
0.051478333 2.136 Mandelonitrile 133.05258 0.579 HILIC positive
0.051800892 1.693 Methyltryptophan 218.10522 0.623 HILIC positive
0.051800892 2.079 5-
Aminopentanamide
116.0948 5.91 HILIC positive
0.051800892 2.098 2-Hydroxy-2-
methylbutanenitrile
99.06826 5.914 HILIC positive
0.051800892 3.112 N-Methyl-N,4-
dinitrosoaniline
165.0536 5.446 HILIC positive
0.051800892 5.105 Tyrosyl-Tyrosine 344.13664 0.94 HILIC positive
0.051975492 1.662 Hydroxytridecanoyl
carnitine
373.2821 0.497 HILIC positive
0.053017773 0.728 Amino-
methylpentanoic
acid
131.09441 5.384 HILIC positive
0.054835237 1.457 Methylhistidine 169.08527 1.062 HILIC positive
0.054835237 2.072 3-(Pyrazol-1-yl)-L-
alanine
155.06926 3.227 HILIC positive
0.056623851 1.765 PG(O-16:0/18:1) 734.54651 0.47 HILIC positive
0.057928423 1.882 4-
Hydroxyphenylacetaldehyde
oxime
151.06312 0.651 HILIC positive
0.057928423 2.511 Methylcytosine 125.05866 4.592 HILIC positive
0.058511189 1.455 beta-Tyrosine 181.07365 0.766 HILIC positive
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0.063028496 1.64 Glycerophosphocholine257.10254 7.622 HILIC positive
0.063076878 0.762 Cytidine 243.08516 5.084 HILIC positive
0.06384563 0.427 2-amino-6-
oxohexanoate
145.07367 0.61 HILIC positive
0.064486446 1.556 N1-
Acetylspermidine
187.16821 7.617 HILIC positive
0.065833234 1.375 3-[4-methoxy-3-
(sulfooxy)phenyl]propanoic
acid
276.03073 6.897 HILIC positive
0.065833234 1.807 2-Oxoarginine 173.07979 3.327 HILIC positive
0.065895836 1.434 Nicotinate D-
ribonucleotide
336.04786 5.768 HILIC positive
0.067346392 0.514 Hydroxyhexadienoate 128.04711 0.606 HILIC positive
0.067346392 1.336 1H-Indole-3-
acetamide
174.07907 0.716 HILIC positive
0.067346392 1.537 N-palmitoyl threo-
nine
357.28753 0.505 HILIC positive
0.068750415 0.768 N1-Methyl-2-
pyridone-5-
carboxamide
152.05838 0.997 HILIC positive
0.068949175 9.707 3-Carboxy-2,3,4,9-
tetrahydro-1H-
pyrido[3,4-b]indole-
1-propanoic acid
288.11062 1.306 HILIC positive
0.06933875 0.777 4-Oxo-4-(3-pyridyl)-
butanamide
178.07396 4.888 HILIC positive
0.06933875 1.429 Naphthylamine 143.07332 2.706 HILIC positive
0.06933875 1.792 4-Hydroxy-1H-
indole-3-acetonitrile
172.06342 0.64 HILIC positive
0.06933875 1.801 3,4,5,6-
Tetrahydrohippuric
acid
183.08932 4.86 HILIC positive
0.06933875 2.065 Hexadecadienoylcarnitine395.30288 3.194 HILIC positive
0.06933875 2.168 Methyl5-(but-3-
en-1-yl)amino-
1,3,4-oxadiazole-2-
carboxylate
197.07974 5.439 HILIC positive
0.06933875 2.27 Pyridosine 254.12609 0.603 HILIC positive
0.06933875 2.775 Pyroglutamylglycine 186.06384 2.99 HILIC positive
0.071207367 0.407 Hydroxylinoleoylcarnitine439.32939 3.484 HILIC positive
0.071207367 2.609 2-Hydroxyestrone
sulfate
366.11201 7.078 HILIC positive
0.074178895 2.348 2,7-Anhydro-alpha-
N-acetylneuraminic
acid
291.09501 6.704 HILIC positive
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0.074205423 1.356 L-Histidine
trimethylbetaine
197.11618 7.651 HILIC positive
0.074270377 1.965 Dihydro-4-mercapto-
3(2H)-furanone
118.00875 2.042 HILIC positive
0.076115942 0.523 13’-Hydroxy-alpha-
tocopherol
446.37554 0.465 HILIC positive
0.076393965 0.614 Pyridoxamine 168.08961 1.39 HILIC positive
0.081529605 1.729 7,8-
Diaminononanoate
188.1522 8.469 HILIC positive
0.081529605 4.01 4-(beta-
Acetylaminoethyl)imidazole
153.09038 0.932 HILIC positive
0.08638167 0.637 15-methyl-15R-
PGF2alpha
368.25567 0.536 HILIC positive
0.08638167 1.558 LysoPC(16:1) 493.31652 4.157 HILIC positive
0.08638167 2.086 Lysyl-Valine 245.17366 8.239 HILIC positive
0.086930116 1.465 Nonenoic acid 156.1147 0.509 HILIC positive
0.086930116 3.465 Alanyl-Proline 186.09999 5.877 HILIC positive
0.087014995 1.347 Alpha-linolenyl car-
nitine
421.3183 3.164 HILIC positive
0.087014995 1.371 (+/-)11,12-EpETrE 320.23451 0.489 HILIC positive
0.09055682 1.536 2-[(4-
methoxyphenyl)formamido]acetic
acid
209.06847 0.707 HILIC positive
0.09055682 2.236 Ethyl-methyloxazole 111.06822 0.72 HILIC positive
0.091455023 1.413 11,18-di-HEPE 334.21357 0.518 HILIC positive
0.097910096 1.31 Palmitoylcarnitine 399.33614 3.172 HILIC positive
0.099201128 1.296 11-Hydroxy-9,15,16-
trioxooctadecanoic
acid
342.20349 0.523 HILIC positive
0.099201128 1.436 Dimethylnonanoyl
carnitine
329.256 0.513 HILIC positive
0.099738242 2.111 11,12-DiHETrE-EA 381.28709 0.502 HILIC positive
0.019799282 0.758 PS(O-18:0/22:6) 821.55527 8.07 Lipids negative
0.078082155 1.382 Hydroxy-
Octadecanoic acid
300.26653 4.842 Lipids negative
0.078082155 1.949 Dihydroxy-
dioxohexanoate
176.0319 0.603 Lipids negative
0.078005797 0.235 Docosahexaenoic
acid
328.23928 8.035 Lipids positive
0.078005797 0.319 DG(34:2) 592.5067 8.023 Lipids positive
0.078005797 0.79 PE(18:2/P-18:1) 725.53592 7.73 Lipids positive
0.078005797 1.55 Succinylproline 215.07941 0.628 Lipids positive
0.078005797 1.962 24,25-
didehydrovitamin
D3
382.32325 6.756 Lipids positive
0.078005797 2.956 N-acetyl-
aminoadipate
203.07933 0.6 Lipids positive
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0.078005797 4.692 PA(27:0) 578.39479 6.897 Lipids positive
0.078005797 15.074 Arginyl-Isoleucine 287.19656 0.539 Lipids positive
0.085263958 0.723 PE(22:4/P-18:1) 777.56743 7.988 Lipids positive
TABLE F.2: List of annotated metabolites which are statistically significant
between day 28 and day 1 in DBS at room temperature.
P-value (follow-
ing correction
for multiple
testing using
Benjamin-
Hochberg
method)
Ratio
between
d365/d1
Metabolite name(s) MW (g/-
mol)
RT (min) Assay
0.0167 0.05 (9R,10S,12Z)-9,10-
Dihydroxy-8-oxo-12-
octadecenoic acid
328.2253 0.49 HILIC neg
0.0172 0.05 Ascorbate 2-sulfate 255.9891 0.64 HILIC neg
0.0377 0.06 hydroxy-
heptadecatrienoic
acid
280.2037 0.50 HILIC neg
0.0108 0.07 4-Carboxy-2-hydroxy-
6-methoxy-6-oxohexa-
2,4-dienoate
216.0272 0.64 HILIC neg
0.0240 0.07 Trihydroxybenzoic acid 170.0218 0.64 HILIC neg
0.0351 0.09 Choline phosphate 184.0736 0.55 HILIC neg
0.0293 0.10 D-Arabinonate 166.0478 1.15 HILIC neg
0.0195 0.11 Vanillyl alcohol 154.0631 0.65 HILIC neg
0.0135 0.11 5-Hydroxyisourate 184.0232 1.49 HILIC neg
0.0503 0.11 Heptadiynediol 124.0526 0.53 HILIC neg
0.0518 0.13 Epoxy-hexadecenoic
acid
268.2041 0.49 HILIC neg
0.0179 0.17 2-Hydroxyglutarate 148.0372 1.12 HILIC neg
0.0119 0.18 Dihydroxybutyric acid 120.0423 1.16 HILIC neg
0.0252 0.21 Undecanedioic acid 216.1363 0.50 HILIC neg
0.0187 0.23 2-Aminobut-2-enoate 101.0477 5.59 HILIC neg
0.0090 0.23 N4-Acetylcytidine 285.0963 2.48 HILIC neg
0.0197 0.23 Propylglutaric acid 174.0892 1.33 HILIC neg
0.0179 0.25 Methyl-pentenoic acid 114.0681 1.33 HILIC neg
0.0235 0.26 5,6-Dihydroxy-3-
methyl-2-oxo-1,2-
dihydroquinoline
191.0584 0.84 HILIC neg
0.0254 0.28 S-(N-Hydroxy-N-
methylcarbamoyl)glutathione
380.0989 1.51 HILIC neg
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0.0183 0.28 N-Acetyl-D-
galactosamine
221.0901 5.47 HILIC neg
0.0400 0.29 Propionic acid 74.0367 1.34 HILIC neg
0.0186 0.30 Methyl-hexenoate 128.0837 1.34 HILIC neg
0.0834 0.31 Monomethyl sulfate 111.9831 0.86 HILIC neg
0.0115 0.31 Trihydroxybenzene 126.0318 0.78 HILIC neg
0.0267 0.32 Trihydroxybenzene 126.0318 0.58 HILIC neg
0.0584 0.32 26-Glucosyl-1,3,11,22-
tetrahydroxyergosta-
5,24-dien-26-oate
638.3648 0.52 HILIC neg
0.0231 0.32 3-Ureidoisobutyrate 146.0692 6.82 HILIC neg
0.0100 0.38 Deoxyuridine 228.0748 1.31 HILIC neg
0.0254 0.40 2-Hydroxy-2,4-
pentadienoate
114.0319 1.33 HILIC neg
0.0179 0.40 Acrylic acid 72.0212 1.34 HILIC neg
0.0132 0.41 PC(31:1) 717.5319 3.01 HILIC neg
0.0293 0.41 Sulfolithocholylglycine 513.2763 2.85 HILIC neg
0.0275 0.47 (5Z,9E,12S,14Z)-8,11,12-
Trihydroxyicosa-5,9,14-
trienoate
354.2409 0.49 HILIC neg
0.0351 0.47 N-
Acetylaspartylglutamic
acid
304.0910 1.86 HILIC neg
0.0135 0.48 Hydroxydodecanoic
acid
216.1726 0.54 HILIC neg
0.0318 0.48 4-Carboxypyrazole 112.0274 1.14 HILIC neg
0.0184 0.48 (22R)-22,25-
dihydroxyvitamin
D3 / (22R)-22,25-
dihydroxycholecalciferol
408.2882 0.78 HILIC neg
0.0254 0.50 Butenoate 86.0367 1.02 HILIC neg
0.0092 0.51 Octadienol 126.1045 0.58 HILIC neg
0.0281 0.52 N-(1-Deoxy-1-
fructosyl)histidine
317.1225 3.75 HILIC neg
0.0716 0.52 Taurallocholic acid 515.2920 3.72 HILIC neg
0.0252 0.53 hydroxybutyric acid 104.0474 1.08 HILIC neg
0.0395 0.54 hydroxybutyric acid 104.0474 0.96 HILIC neg
0.0186 0.54 N’-
Phosphoguanidinoethyl
methyl phosphate
277.0237 5.30 HILIC neg
0.0184 0.55 3-Nitrotyrosine 226.0592 1.14 HILIC neg
0.0365 0.56 3-Pyridinebutanoic acid 165.0790 4.93 HILIC neg
0.0219 0.56 Adenosine 267.0971 2.22 HILIC neg
0.0235 0.58 N-Ribosylhistidine 287.1120 3.50 HILIC neg
0.0651 0.59 2-Methylserine 119.0583 6.59 HILIC neg
0.0595 0.60 Octenol 128.1202 0.57 HILIC neg
0.0448 0.60 p-Cresol sulfate 188.0144 0.46 HILIC neg
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0.0429 0.60 Pyrogallol-1-O-sulphate 205.9886 0.87 HILIC neg
0.0440 0.60 Octenediol 144.1151 0.65 HILIC neg
0.0398 0.60 (1-Ribosylimidazole)-4-
acetate
258.0855 1.86 HILIC neg
0.0248 0.61 Parabanic Acid 114.0067 0.63 HILIC neg
0.0395 0.61 4-Carboxypyrazole 112.0274 1.03 HILIC neg
0.0599 0.61 Acetolactate 132.0423 2.54 HILIC neg
0.0379 0.61 3’-Amino-3’-
deoxythimidine
241.1065 3.50 HILIC neg
0.0535 0.61 Vanillin 4-sulfate 232.0042 1.40 HILIC neg
0.0423 0.62 5,6-Dihydrouridine 246.0854 2.72 HILIC neg
0.0599 0.62 2-Deoxypentonic acid 150.0529 2.61 HILIC neg
0.0286 0.62 Taurochenodeoxycholic
acid
499.2974 2.93 HILIC neg
0.0377 0.63 hydroxyicosanoic acid 328.2981 0.58 HILIC neg
0.0651 0.63 5-Carboxy-2’-
deoxyuridine
272.0649 1.13 HILIC neg
0.0518 0.65 hydroxy-tetradecenoic
acid
242.1884 0.53 HILIC neg
0.0503 0.65 Imidazoleacetic acid 126.0430 0.87 HILIC neg
0.0340 0.65 Mandelonitrile 133.0528 1.50 HILIC neg
0.0286 0.66 Taurochenodeoxycholic
acid
499.2974 3.10 HILIC neg
0.0212 0.69 Oxoheptanoic acid 144.0787 0.63 HILIC neg
0.0557 0.69 Dihydroferulic acid 4-
sulfate
276.0307 1.07 HILIC neg
0.0866 0.70 Phenylacetic acid 136.0526 2.09 HILIC neg
0.0941 0.70 (R)-3-(4-
Hydroxyphenyl)lactate
182.0580 2.09 HILIC neg
0.0354 0.70 4-Amino-5-
oxopentanoate
131.0583 2.04 HILIC neg
0.0254 0.75 3-Hydroxy-4-
methylanthranilate
167.0583 0.85 HILIC neg
0.0357 0.78 PS(39:1) 831.6004 3.56 HILIC neg
0.0863 1.21 Heptenol 114.1045 0.60 HILIC neg
0.0725 1.26 Creatinine 113.0591 2.96 HILIC neg
0.0724 1.39 3,5-Dihydroxy-
phenylglycine
183.0532 1.35 HILIC neg
0.0673 1.40 1H-Indole-3-
carboxaldehyde
145.0528 0.49 HILIC neg
0.0630 1.51 3,4-
Methylenedioxybenzoic
acid
166.0266 2.75 HILIC neg
0.0426 1.55 Lactate 90.0315 3.99 HILIC neg
0.0149 1.56 N-Acetyl-L-2-amino-6-
oxopimelate
231.0744 0.66 HILIC neg
0.0405 1.67 PG(O-16:0/18:0) 736.5651 0.47 HILIC neg
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0.0354 1.94 2-[(4-
methoxyphenyl)formamido]acetic
acid
209.0689 0.64 HILIC neg
0.0328 2.01 3-hydroxybenzoic acid-
3-O-sulphate
217.9883 0.82 HILIC neg
0.0254 2.08 1H-Indole-3-
carboxaldehyde
145.0528 0.74 HILIC neg
0.0183 2.13 2-Indolecarboxylic acid 161.0477 0.55 HILIC neg
0.0826 2.16 4-Hydroxy-2-butenoic
acid gamma-lactone
84.0213 0.73 HILIC neg
0.0395 2.16 Caffeic acid 3-sulfate 259.9992 0.71 HILIC neg
0.0977 2.27 (2-
Methoxyethoxy)propanoic
acid
148.0736 1.72 HILIC neg
0.0475 2.28 Tyrosol 4-sulfate 218.0249 0.42 HILIC neg
0.0377 2.44 Hydroxyhippuric acid 195.0532 1.35 HILIC neg
0.0184 2.58 Formyl-5-
hydroxykynurenamine
208.0849 2.50 HILIC neg
0.0092 2.67 Pentenoic acid 100.0525 0.58 HILIC neg
0.0184 2.67 Methyl-hexenoate 128.0838 0.84 HILIC neg
0.0158 2.77 Trihydroxytoluene 140.0474 0.50 HILIC neg
0.0503 2.78 Benzeneacetonitrile 117.0580 2.73 HILIC neg
0.0159 2.81 Hydroxybenzaldehyde 122.0369 0.50 HILIC neg
0.0464 2.90 2-Oxosuccinamate 131.0220 0.64 HILIC neg
0.0236 3.02 3-hydroxy-3-(3-
hydroxyphenyl)propanoic
acid-O-sulphate
262.0148 0.68 HILIC neg
0.0286 3.04 Adenine 135.0546 1.89 HILIC neg
0.0187 3.30 2-Isopropyl-3-
oxosuccinate
174.0528 1.36 HILIC neg
0.0167 3.37 2-Amino-2-
deoxyisochorismate
225.0639 3.28 HILIC neg
0.0250 3.43 Phenol 94.0418 2.75 HILIC neg
0.0138 4.06 11-deoxy-16,16-
dimethyl-PGE2
364.2618 0.48 HILIC neg
0.0145 4.18 Methylhexanoic acid 130.0995 0.81 HILIC neg
0.0135 4.66 3,4-
Dihydroxybenzylamine
139.0634 0.68 HILIC neg
0.0139 5.48 3,5-Dihydroxy-
phenylglycine
183.0532 0.68 HILIC neg
0.0539 5.80 trihydroxy palmitic acid 304.2253 0.70 HILIC neg
0.0128 6.00 2-Aminomuconate
semialdehyde
141.0427 0.54 HILIC neg
0.0599 7.25 Isonicotinic acid 123.0322 0.58 HILIC neg
0.0135 8.20 2-Aminomuconate
semialdehyde
141.0427 0.74 HILIC neg
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0.0138 9.43 N,N-Dihydroxy-L-
tyrosine
213.0638 1.36 HILIC neg
0.0090 10.29 3,4-
Dihydroxymandelonitrile
165.0427 1.55 HILIC neg
0.0092 10.39 2,6-
Dihydroxynicotinate
155.0220 0.99 HILIC neg
0.0090 10.60 2-Furoylglycine 169.0377 0.98 HILIC neg
0.0156 12.43 10,11-DiHDPE 362.2462 0.49 HILIC neg
0.0090 12.58 2-Aminobenzoic acid 137.0477 1.57 HILIC neg
0.0090 12.96 1-Pyrroline-5-
carboxylate
113.0478 1.33 HILIC neg
0.0090 13.61 3-Hydroxykynurenine 224.0798 1.32 HILIC neg
0.0090 14.61 N-Acetyl-L-glutamate
5-semialdehyde
173.0689 1.33 HILIC neg
0.0090 16.30 2-Methylbutyrylglycine 159.0896 1.35 HILIC neg
0.0090 17.49 (S)-2-amino-6-
oxohexanoate
145.0740 2.05 HILIC neg
0.0135 21.29 N-Formylmethionine 177.0460 2.29 HILIC neg
0.0090 22.94 2,5,6-Trihydroxy-5,6-
dihydroquinoline
179.0583 0.75 HILIC neg
0.0090 43.92 Indoleacrylic acid 187.0634 0.54 HILIC neg
0.0090 44.37 2,6-
Dihydroxynicotinate
155.0219 2.17 HILIC neg
0.0090 58.32 alhpa-
tocopheronolactone
278.1510 0.68 HILIC neg
0.0090 88.96 2-Aminophenol 109.0529 0.52 HILIC neg
0.0130 0.00 1,4-Dideoxy-1,4-imino-
D-ribitol
133.0737 3.99 HILIC pos
0.0187 0.02 2-Aminobut-2-enoate 101.0475 2.35 HILIC pos
0.0310 0.04 (S)-2-amino-6-
oxohexanoate
145.0737 0.61 HILIC pos
0.0267 0.08 5-
Hydroxyindoleacetylglycine
248.0794 4.15 HILIC pos
0.0173 0.09 amino-octadecanoic
acid
299.2820 2.59 HILIC pos
0.0647 0.14 (-)-11-Hydroxy-9,15,16-
trioxooctadecanoic
acid
342.2035 0.52 HILIC pos
0.0947 0.14 1-pyrroline-3-hydroxy-
5-carboxylic Acid
129.0424 5.93 HILIC pos
0.0562 0.15 Eicosanoyl-EA 355.3445 1.60 HILIC pos
0.0770 0.16 Vinylacetylglycine 143.0581 5.32 HILIC pos
0.0130 0.17 Oxohexenoic acid 128.0471 0.61 HILIC pos
0.0102 0.19 Formyl-N-acetyl-5-
methoxykynurenamine
264.1105 0.61 HILIC pos
0.0667 0.21 Methylphenylalanine 179.0944 1.60 HILIC pos
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0.0800 0.22 Trimethylamine N-
oxide
75.0683 5.13 HILIC pos
0.0407 0.23 3’-CMP 323.0515 2.62 HILIC pos
0.0308 0.23 2-Aminoacrylic acid 87.0319 5.49 HILIC pos
0.0864 0.23 12-oxo-14,18-
dihydroxy-9Z,13E,15Z-
octadecatrienoic acid
324.1930 0.51 HILIC pos
0.0511 0.24 1H-Indole-2,3-dione 147.0318 0.43 HILIC pos
0.0287 0.28 Farnesyl diphosphate 382.1306 5.24 HILIC pos
0.0725 0.29 (3S,3’R,4xi)-beta,beta-
Carotene-3,3’,4-triol
584.4222 0.46 HILIC pos
0.0130 0.30 Streptamine phosphate 258.0611 5.36 HILIC pos
0.0469 0.31 Formiminoglutamic
acid
174.0638 5.49 HILIC pos
0.0551 0.35 3-hydroxyundecanoyl
carnitine
345.2509 0.58 HILIC pos
0.0287 0.44 4-Aminopyridine 94.0530 7.13 HILIC pos
0.0358 0.45 dodecenoic acid 198.1629 0.46 HILIC pos
0.0148 0.47 nonenoylglycine 213.1362 1.55 HILIC pos
0.0370 0.48 Oleoyl glycine 339.2768 0.50 HILIC pos
0.0287 0.49 6-Hydroxy-1H-indole-
3-acetamide
190.0739 4.58 HILIC pos
0.0316 0.49 3,4-
Dihydroxymandelonitrile
165.0424 0.55 HILIC pos
0.0615 0.50 PE(P-20:0/22:6) 803.5809 2.79 HILIC pos
0.0526 0.51 Hydroxyhexanoycarnitine275.1729 5.43 HILIC pos
0.0797 0.51 (alpha-keto-
dimethyl-delta-N,N-
Dimethylguanidynol)
valeric acid
201.1110 5.83 HILIC pos
0.0968 0.52 3-hydroxytridecanoyl
carnitine
373.2821 0.50 HILIC pos
0.0756 0.55 LysoPE(20:1) 507.3322 4.13 HILIC pos
0.0589 0.57 Digallate 322.0311 5.28 HILIC pos
0.0358 0.61 2-Amino-4-
methylpentanoic acid
131.0944 5.38 HILIC pos
0.0779 0.61 Norepinephrine sulfate 249.0304 1.40 HILIC pos
0.0860 0.62 3-Acetamidopropanal 115.0632 0.76 HILIC pos
0.0947 0.62 N-Decanoylglycine 229.1674 0.49 HILIC pos
0.0899 0.63 3-hydroxydecanoyl car-
nitine
331.2353 4.34 HILIC pos
0.0965 0.64 3-hydroxy-5-
octenoylcarnitine
301.1885 5.53 HILIC pos
0.0858 0.66 Cytidine 243.0852 5.08 HILIC pos
0.0973 0.73 Isovalerylcarnitine 245.1623 4.54 HILIC pos
0.0968 0.75 (2E)-4-hydroxy-3-
methylbut-2-enoic acid
116.0472 1.13 HILIC pos
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0.0800 1.33 N-Nitrosodiethylamine 102.0792 6.03 HILIC pos
0.0894 1.34 Butenoate 86.0366 0.99 HILIC pos
0.0245 1.47 2,3-Diaminopropanoate 104.0585 1.82 HILIC pos
0.0993 1.50 N-(2-
Methylpropyl)acetamide
115.0995 3.19 HILIC pos
0.0622 1.62 PE(20:0) 523.3268 4.11 HILIC pos
0.0666 1.79 midazole-4-
acetaldehyde
110.0479 0.77 HILIC pos
0.0488 1.84 amino-octanoic acid 159.1257 0.59 HILIC pos
0.0929 1.85 Penicillenic acid 244.0514 1.74 HILIC pos
0.0271 1.89 3-Methylglutamyl-
5-semialdehyde-N6-
lysine
273.1684 2.12 HILIC pos
0.0404 1.90 11,12-DiHETrE-EA 381.2871 0.50 HILIC pos
0.0492 1.96 2-Amino-4-hydroxy-
3-methylpentanoic
acid
147.0893 6.50 HILIC pos
0.0889 1.97 Hydroxynicotine 178.1101 0.58 HILIC pos
0.0848 2.05 DG(42:8) 692.5369 0.46 HILIC pos
0.0534 2.11 3-Pyridinebutanoic acid 165.0788 0.52 HILIC pos
0.0662 2.16 N1-Acetylspermidine 187.1682 7.62 HILIC pos
0.0770 2.23 1,4-cholestadie24,25-
didehydrovitamin
D3 / 24,25-
didehydrocholecalciferol
382.3231 0.47 HILIC pos
0.0666 2.26 LysoPC(18:1) 521.3475 4.11 HILIC pos
0.0204 2.37 6-
Hydroxypseudooxynicotine
194.1053 0.72 HILIC pos
0.0308 2.59 2-Oxoarginine 173.0798 3.33 HILIC pos
0.0405 3.01 Methylphenylalanine 179.0943 3.50 HILIC pos
0.0316 3.07 2,3-Butanediol gluco-
side
252.1219 3.03 HILIC pos
0.0249 3.16 4-Guanidinobutanoate 145.0849 6.07 HILIC pos
0.0287 3.19 Pyrazinoic acid 124.0272 1.93 HILIC pos
0.0358 3.19 (E)-4-
(Trimethylammonio)but-
2-enoate
143.0943 6.99 HILIC pos
0.0332 4.01 N-Nitrosoproline 144.0533 0.68 HILIC pos
0.0331 4.18 Imidazoleacetic acid 126.0427 0.68 HILIC pos
0.0130 4.40 4-Guanidinobutanal 129.0900 3.80 HILIC pos
0.0287 4.69 4-(beta-
Acetylaminoethyl)imidazole
153.0897 0.59 HILIC pos
0.0386 4.72 2-Aminoquinoline 144.0686 0.56 HILIC pos
0.0287 4.85 Isoleucyl-Valine 230.1628 7.40 HILIC pos
0.0666 5.18 2,3,4,5-tetranor-
thromboxane B1
316.1882 3.38 HILIC pos
0.0132 5.61 1-Methylhistidine 169.0853 1.06 HILIC pos
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0.0800 5.83 PA(O-18:0/19:1) 702.5574 0.47 HILIC pos
0.0285 5.95 Benzeneacetonitrile 117.0577 3.37 HILIC pos
0.0256 6.10 2-[(4-
methoxyphenyl)formamido]acetic
acid
209.0685 0.71 HILIC pos
0.0213 6.60 Histidine 155.0693 3.23 HILIC pos
0.0130 6.62 Alanyl-Proline 186.1000 5.88 HILIC pos
0.0308 6.92 Dopamine 151.0631 0.65 HILIC pos
0.0249 7.46 decatrienoylcarnitine 309.1935 3.72 HILIC pos
0.0506 7.66 N-Formyl-4-amino-
5-aminomethyl-2-
methylpyrimidine
166.0852 3.39 HILIC pos
0.0132 7.99 1-Methylhistidine 169.0852 1.42 HILIC pos
0.0102 8.20 1,1,3,3-tetramethylurea 116.0948 5.91 HILIC pos
0.0297 8.28 6-Methylquinoline 143.0733 2.71 HILIC pos
0.0287 8.92 Isonicotinylglycine 180.0532 1.13 HILIC pos
0.0177 9.00 PGH2-EA 393.2872 3.18 HILIC pos
0.0189 9.24 4,5-Dihydro-2,4(5)-
dimethyl-1H-imidazole
98.0843 3.43 HILIC pos
0.0309 9.51 2,3-Diaminosalicylic
acid
168.0533 0.69 HILIC pos
0.0356 9.96 6-Imino-5-
oxocyclohexa-1,3-
dienecarboxylate
151.0267 0.70 HILIC pos
0.0342 11.40 Glc-Cholesterol(22:0) 870.7290 0.45 HILIC pos
0.0189 11.52 beta-Tyrosine 181.0737 0.77 HILIC pos
0.0135 12.07 3-Methylene-indolenine 129.0577 2.93 HILIC pos
0.0190 12.23 Alanyl-Asparagine 203.0904 2.98 HILIC pos
0.0287 12.35 Mandelonitrile 133.0526 0.58 HILIC pos
0.0102 12.56 N-Methyl-N,4-
dinitrosoaniline
165.0536 5.45 HILIC pos
0.0190 12.82 1H-Indole-3-acetamide 174.0791 0.58 HILIC pos
0.0130 14.25 2-O-Methylcytosine 125.0587 4.59 HILIC pos
0.0225 14.48 Pyroglutamylglycine 186.0638 2.99 HILIC pos
0.0532 18.00 Cyclo(L-tyrosyl-L-
tyrosyl)
326.1260 0.50 HILIC pos
0.0187 18.84 Cyclo(L-Phe-L-Pro) 244.1209 4.22 HILIC pos
0.0509 19.16 CE(20:5) 670.5683 0.46 HILIC pos
0.0249 23.96 Tyrosyl-Tyrosine 344.1366 0.94 HILIC pos
0.0387 35.40 N-Stearoyl tyrosine 447.3342 3.00 HILIC pos
0.0130 38.67 Cervonyl carnitine 471.3343 2.98 HILIC pos
0.0130 39.37 Vinylacetylglycine 143.0581 1.64 HILIC pos
0.0130 39.39 Methyltryptophan 218.1052 0.62 HILIC pos
0.0130 45.88 Valyl-Valine 216.1471 7.38 HILIC pos
0.0130 65.13 3-
hydroxyarachidonoylcarnitine
463.3291 3.42 HILIC pos
0.0130 78.78 N1,N8-
Diacetylspermidine
229.1787 7.57 HILIC pos
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0.0130 91.38 N-Acetylhistidine 197.0797 5.44 HILIC pos
0.0130 114.46 Phenylethylmalonamide 206.1053 3.39 HILIC pos
0.0925 153.00 3-Methyloxindole 147.0682 3.53 HILIC pos
0.0130 200.69 4-(beta-
Acetylaminoethyl)imidazole
153.0900 1.07 HILIC pos
0.0022 0.00 PC(33:4) 739.5156 7.49 Lipids neg
0.0022 0.00 PC(35:3) 769.5627 8.02 Lipids neg
0.0020 0.00 PC(35:5) 765.5309 7.51 Lipids neg
0.0021 0.00 PE(18:3/P-18:1) 723.5207 7.69 Lipids neg
0.0022 0.00 PE(20:3/P-18:1) 751.5519 8.03 Lipids neg
0.0020 0.00 PS(39:3) 827.5679 7.42 Lipids neg
0.0022 0.00 GalNAcbeta1-
4Galbeta1-4Glcbeta-
Cer(d18:1/18:0)
1092.7322 4.44 Lipids neg
0.0022 0.00 LysoPC(15:0) 481.3168 3.24 Lipids neg
0.0020 0.00 LysoPC(17:0) 509.3480 4.44 Lipids neg
0.0059 0.00 LysoPE(20:2) 505.3168 2.56 Lipids neg
0.0041 0.00 LysoPS(21:0) 567.3539 3.41 Lipids neg
0.0484 0.00 PC(18:4/P-18:1) 763.5502 7.85 Lipids neg
0.0035 0.00 PC(33:1) 745.5620 7.82 Lipids neg
0.0020 0.00 PC(35:4) 767.5467 7.42 Lipids neg
0.0039 0.00 PC(37:5) 793.5619 7.42 Lipids neg
0.0022 0.00 PC(37:6) 791.5464 7.24 Lipids neg
0.0020 0.00 PC(39:6) 819.5781 7.65 Lipids neg
0.0022 0.00 PE(18:2/P-18:1) 725.5368 7.74 Lipids neg
0.0037 0.00 PE(20:4/P-18:1) 749.5362 7.70 Lipids neg
0.0032 0.00 PE(22:4/P-18:1) 777.5679 8.01 Lipids neg
0.0096 0.00 PE(40:9) 785.5002 6.70 Lipids neg
0.0022 0.00 PI(36:4) 858.5264 7.13 Lipids neg
0.0036 0.00 PS(37:0) 805.5833 7.82 Lipids neg
0.0022 0.00 PS(38:4) 811.5361 7.55 Lipids neg
0.0079 0.00 PS(39:2) 829.5831 7.53 Lipids neg
0.0021 0.00 PS(40:6) 835.5350 7.42 Lipids neg
0.0022 0.00 PS(P-18:0/22:6) 819.5398 8.03 Lipids neg
0.0020 0.00 LysoPC(P-15:0) 465.3222 4.96 Lipids neg
0.0034 0.00 LysoPE(20:4) 501.2861 2.35 Lipids neg
0.0022 0.00 PC(33:3) 741.5316 7.60 Lipids neg
0.0034 0.00 PC(37:4) 795.5781 8.01 Lipids neg
0.0020 0.00 PC(O-15:0/20:4) 753.5680 8.07 Lipids neg
0.0040 0.00 PE(20:5/P-18:1) 747.5209 7.54 Lipids neg
0.0022 0.00 PE(22:4/P-18:0) 779.5839 8.24 Lipids neg
0.0028 0.00 PE(22:5/P-18:1) 775.5518 7.89 Lipids neg
0.0020 0.00 PS(35:0) 777.5525 7.47 Lipids neg
0.0020 0.00 PS(38:1) 817.5837 7.70 Lipids neg
0.0039 0.00 PS(41:4) 853.5831 7.41 Lipids neg
0.0033 0.00 PS(43:4) 881.6144 7.77 Lipids neg
0.0033 0.00 LysoPE(18:1) 479.3016 3.58 Lipids neg
0.0022 0.00 PC(33:2) 715.5158 7.58 Lipids neg
0.0018 0.00 PC(P-16:0/15:1) 701.5369 8.07 Lipids neg
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0.0022 0.00 PE(P-16:0) 437.2910 3.82 Lipids neg
0.0041 0.00 PI(36:2) 862.5572 7.58 Lipids neg
0.0030 0.00 PI(38:5) 884.5420 7.16 Lipids neg
0.0020 0.00 PS(36:2) 787.5369 7.63 Lipids neg
0.0102 0.00 PS(39:0) 833.6156 8.14 Lipids neg
0.0022 0.00 PS(40:3) 841.5836 7.61 Lipids neg
0.0020 0.00 PS(O-18:0/19:1) 789.5888 7.76 Lipids neg
0.0045 0.00 (8E,10S,12Z,15Z)-10-
Hydroperoxyoctadeca-
8,12,15-trienoate
310.2147 1.45 Lipids neg
0.0048 0.00 LysoPE(20:2) 505.3168 2.35 Lipids neg
0.0020 0.00 PE(16:1/P-18:1) 699.5205 7.79 Lipids neg
0.0064 0.00 PE(38:7) 761.5005 6.82 Lipids neg
0.0020 0.00 PS(38:6) 807.5028 7.48 Lipids neg
0.0075 0.00 PS(41:3) 855.5988 7.56 Lipids neg
0.0073 0.01 (8E,10S,12Z,15Z)-10-
Hydroperoxyoctadeca-
8,12,15-trienoate
310.2147 1.52 Lipids neg
0.0020 0.01 12-Oxo-c-LTB3 641.2997 4.44 Lipids neg
0.0051 0.01 9,10-epoxy-3E,12Z-
Octadecadienoic acid
294.2198 2.12 Lipids neg
0.0019 0.01 LysoPC(16:0) 495.3328 3.87 Lipids neg
0.0020 0.01 N-palmitoyl-
phosphoethanolamine
379.2491 2.29 Lipids neg
0.0022 0.01 PS(40:7) 833.5180 7.55 Lipids neg
0.0025 0.01 PS(O-16:0/20:5) 767.5110 7.35 Lipids neg
0.0085 0.01 9,10-epoxy-3E,12Z-
Octadecadienoic acid
294.2198 2.25 Lipids neg
0.0020 0.01 PC(35:2) 771.5786 8.20 Lipids neg
0.0029 0.01 PS(O-18:0/20:5) 795.5419 7.72 Lipids neg
0.0076 0.01 9-oxo-12Z-
Octadecenoic acid
296.2352 1.72 Lipids neg
0.0129 0.01 Eicosatetraenoic acid 304.2402 4.40 Lipids neg
0.0022 0.01 PC(P-16:0/17:2) 727.5528 8.10 Lipids neg
0.0020 0.01 PI(40:5) 912.5729 7.49 Lipids neg
0.0025 0.01 PI(40:6) 910.5583 7.37 Lipids neg
0.0027 0.01 PC(16:0/5:0(CHO)) 593.3700 3.69 Lipids neg
0.0034 0.01 PC(35:6) 763.5158 7.35 Lipids neg
0.0023 0.01 PI(38:3) 888.5728 7.66 Lipids neg
0.0025 0.01 PS(35:1) 775.5371 7.11 Lipids neg
0.0020 0.01 PS(36:0) 791.5698 7.65 Lipids neg
0.0024 0.01 PS(36:3) 785.5212 7.29 Lipids neg
0.0207 0.01 PS(42:10) 855.5058 6.54 Lipids neg
0.0062 0.01 (9Z,11E)-12-((3S,5R)-5-
((R)-1-hydroxypropyl)-
1,2-dioxolan-3-
yl)dodeca-9,11-dienoic
acid
326.2097 1.03 Lipids neg
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0.0057 0.01 Hydroperoxyoctadecadienoic
acid
312.2304 2.12 Lipids neg
0.0020 0.01 LysoPC(15:0) 481.3172 4.56 Lipids neg
0.0035 0.01 PE(18:0/20:4(Ke)) 781.5259 7.35 Lipids neg
0.0024 0.01 PI(37:4) 872.5421 7.32 Lipids neg
0.0024 0.01 PS(O-18:0/22:6) 821.5553 8.07 Lipids neg
0.0078 0.01 (+/-)-11-HEPE 318.2196 2.13 Lipids neg
0.0020 0.01 LysoPC(O-15:0) 467.3380 3.74 Lipids neg
0.0035 0.01 PC(32:4) 725.5003 7.28 Lipids neg
0.0024 0.01 (13E)-(15S)-15-
Hydroxy-9-oxoprosta-
10,13-dienoate
336.2304 1.50 Lipids neg
0.0123 0.01 PE(40:8) 787.5160 7.04 Lipids neg
0.0028 0.01 PI(O-16:0/22:4) 872.5795 7.71 Lipids neg
0.0020 0.01 PS(36:4) 783.5032 7.58 Lipids neg
0.0022 0.01 PS(41:0) 859.6311 8.18 Lipids neg
0.0070 0.01 LysoPE(16:0) 453.2861 3.12 Lipids neg
0.0066 0.01 PC(18:4/P-16:0) 737.5362 7.86 Lipids neg
0.0036 0.01 PI(40:4) 914.5908 7.74 Lipids neg
0.0015 0.01 PS(36:1) 789.5527 7.90 Lipids neg
0.0022 0.01 PS(P-18:0/17:2) 757.5264 6.24 Lipids neg
0.0055 0.01 10-Hydroperoxy-H4-
neuroprostane
392.2207 0.81 Lipids neg
0.0035 0.01 LysoPE(18:1) 479.3015 3.36 Lipids neg
0.0389 0.01 LysoPE(24:6) 553.3171 2.25 Lipids neg
0.0023 0.01 PS(25:0) 637.3961 4.37 Lipids neg
0.0089 0.01 PS(39:4) 825.5531 6.85 Lipids neg
0.0020 0.01 Trypanothione 723.3034 3.25 Lipids neg
0.0031 0.02 LysoPS(18:1) 523.2914 2.93 Lipids neg
0.0054 0.02 PE(18:4/P-18:1) 721.5051 7.40 Lipids neg
0.0058 0.02 PI(O-18:0/20:5) 870.5631 7.37 Lipids neg
0.0024 0.02 PS(40:4) 839.5681 7.79 Lipids neg
0.0076 0.02 PS(43:6) 877.5835 7.27 Lipids neg
0.0020 0.02 PS(O-20:0/19:1) 817.6206 8.09 Lipids neg
0.0015 0.02 LysoPC(P-15:0) 465.3222 4.06 Lipids neg
0.0074 0.02 UDP-GlcNAc 607.0826 0.53 Lipids neg
0.0079 0.02 Ascorbyl palmitate 414.2623 1.62 Lipids neg
0.0020 0.02 N-palmitoyl threonine 357.2884 5.14 Lipids neg
0.0022 0.02 PC(31:1) 717.5309 7.87 Lipids neg
0.0067 0.02 (+/-)-11-HEPE 318.2196 2.83 Lipids neg
0.0022 0.02 LysoPE(16:0) 453.2860 3.36 Lipids neg
0.0020 0.02 Sphinganine 1-
phosphate
381.2648 2.64 Lipids neg
0.0076 0.02 (13E)-(15S)-15-
Hydroxy-9-oxoprosta-
10,13-dienoate
336.2303 2.03 Lipids neg
0.0020 0.02 CDP-DG(38:6) 1025.5127 7.42 Lipids neg
0.0032 0.02 PC(16:0/5:0(COOH)) 609.3630 3.27 Lipids neg
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0.0044 0.02 PC(34:4) 753.5325 7.67 Lipids neg
0.0020 0.02 PI(36:1) 864.5770 7.85 Lipids neg
0.0041 0.02 (13E)-(15S)-15-
Hydroxy-9-oxoprosta-
10,13-dienoate
336.2304 1.72 Lipids neg
0.0034 0.02 12-oxo-14,18-
dihydroxy-9Z,13E,15Z-
octadecatrienoic acid
324.1940 0.84 Lipids neg
0.0034 0.02 LysoPE(18:2) 477.2858 2.45 Lipids neg
0.0025 0.02 Octadecadienoic acid 280.2401 4.61 Lipids neg
0.0111 0.02 PE(O-16:0) 439.3066 3.88 Lipids neg
0.0110 0.02 PG(36:1) 776.5553 7.69 Lipids neg
0.0048 0.02 9-oxo-12Z-
Octadecenoic acid
296.2352 1.86 Lipids neg
0.0039 0.02 PI(38:6) 882.5268 6.98 Lipids neg
0.0026 0.02 PS(34:2) 759.5055 7.26 Lipids neg
0.0031 0.02 (+/-)11,12-EpETrE 320.2352 2.11 Lipids neg
0.0122 0.02 11,18-di-HEPE 334.2148 2.25 Lipids neg
0.0026 0.02 12-Oxo-c-LTB3 641.3001 4.21 Lipids neg
0.0039 0.02 LysoPS(18:2) 521.2757 2.07 Lipids neg
0.0020 0.02 PS(40:1) 845.6149 8.04 Lipids neg
0.0028 0.03 (+/-)11,12-DiHETrE 338.2458 2.11 Lipids neg
0.0022 0.03 1,25-Dihydroxyvitamin
D3 3-glycoside
578.3825 5.75 Lipids neg
0.0088 0.03 15-methyl-15R-
PGF2alpha
368.2569 1.62 Lipids neg
0.0048 0.03 Hydroxy-
oxooctadecatrienoic
acid
308.1991 1.18 Lipids neg
0.0103 0.03 (13E)-11a-Hydroxy-
9,15-dioxoprost-13-
enoic acid
352.2255 1.57 Lipids neg
0.0027 0.03 PC(16:0/9:0(COOH)) 665.4277 3.90 Lipids neg
0.0047 0.03 Propane-1,2-diol 1-
phosphate
156.0190 0.58 Lipids neg
0.0022 0.03 PS(44:7) 889.5811 7.77 Lipids neg
0.0129 0.03 (8E,10S,12Z,15Z)-10-
Hydroperoxyoctadeca-
8,12,15-trienoate
310.2147 1.92 Lipids neg
0.0392 0.03 D-erythro-L-galacto-
Nonulose
270.0951 0.59 Lipids neg
0.0199 0.03 1-(8-[5]-ladderane-
octanoyl)-2-(8-[3]-
ladderane-octanyl)-sn-
glycerophosphoethanolamine
771.5209 7.23 Lipids neg
0.0095 0.03 hydroxy-dodecenoic
acid
214.1570 1.22 Lipids neg
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0.0068 0.04 Cholesterol sulfate 466.3119 5.50 Lipids neg
0.0368 0.04 12,15-Epoxy-13,14-
dimethyleicosa-
10,12,14-trienoic acid
348.2665 3.03 Lipids neg
0.0060 0.04 PS(37:3) 799.5375 7.00 Lipids neg
0.0335 0.04 PS(42:8) 859.5371 7.04 Lipids neg
0.0020 0.04 PS(24:0) 623.3804 4.37 Lipids neg
0.0221 0.04 Octadecenoic acid 282.2559 5.36 Lipids neg
0.0020 0.04 LysoPI(18:0) 600.3281 3.93 Lipids neg
0.0123 0.04 Hydroxyprogesterone 332.1991 1.47 Lipids neg
0.0038 0.04 (Z)-15-Oxo-11-
eicosenoic acid
324.2666 2.93 Lipids neg
0.0317 0.04 11-Dehydro-
thromboxane B2
368.2203 0.82 Lipids neg
0.0059 0.05 Arginine 174.1115 0.55 Lipids neg
0.0165 0.05 (13E)-(15S)-15-
Hydroxy-9-oxoprosta-
10,13-dienoate
336.2304 2.18 Lipids neg
0.0025 0.05 (20S)-1alpha,20,25-
trihydroxyvitamin D3
/ (20S)-1alpha,20,25-
trihydroxycholecalciferol
432.3243 1.84 Lipids neg
0.0062 0.05 10,13-epoxy-11,12-
dimethyl-10,12-
octadecadienoic acid
322.2509 2.63 Lipids neg
0.0156 0.05 S-Carboxymethyl-L-
cysteine
179.0251 0.57 Lipids neg
0.0030 0.05 Glycerol 3-phosphate 172.0137 0.62 Lipids neg
0.0049 0.05 PI(42:11) 928.5140 8.24 Lipids neg
0.0020 0.05 Epoxy-hexadecenoic
acid
268.2040 2.21 Lipids neg
0.0022 0.05 LysoPS(22:0) 581.3700 4.01 Lipids neg
0.0035 0.05 PS(29:0) 693.4589 4.83 Lipids neg
0.0059 0.05 2-C-Methyl-D-
erythritol 4-phosphate
216.0401 0.58 Lipids neg
0.0034 0.05 PC(19:0) 551.3591 2.98 Lipids neg
0.0042 0.05 9-oxo-12Z-
Octadecenoic acid
296.2352 3.17 Lipids neg
0.0210 0.05 11,18-di-HEPE 334.2148 1.44 Lipids neg
0.0021 0.05 LysoPS(18:0) 525.3070 3.96 Lipids neg
0.0022 0.06 9-oxo-12Z-
Octadecenoic acid
296.2352 2.74 Lipids neg
0.0063 0.06 D-erythro-D-galacto-
octitol
242.0991 0.55 Lipids neg
0.0020 0.06 hydroxy-oxo-
hexadecanoic acid
286.2147 2.37 Lipids neg
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0.0037 0.06 (22E)-(24R)-
1alpha,24,25-
trihydroxy-22,23-
didehydrovitamin
D3 / (22E)-(24R)-
1alpha,24,25-
trihydroxy-22,23-
didehydrocholecalciferol
430.3086 1.97 Lipids neg
0.0495 0.06 PC(37:7) 789.5303 7.25 Lipids neg
0.0042 0.06 N-Adenylyl-L-
phenylalanine
494.1318 4.61 Lipids neg
0.0028 0.07 1D-chiro-Inositol 180.0633 0.57 Lipids neg
0.0020 0.07 MG(16:0) 330.2772 5.14 Lipids neg
0.0300 0.07 Docosapentaenoic acid 330.2562 4.79 Lipids neg
0.0195 0.07 Phenylacetylglycine
dimethylamide
220.1213 0.92 Lipids neg
0.0036 0.08 PC(15:0/P-18:1) 729.5689 8.35 Lipids neg
0.0155 0.08 Hydroperoxydocosahexaenoic
acid
360.2305 1.40 Lipids neg
0.0036 0.08 Hydroxytetracosanoic
acid
384.3606 7.17 Lipids neg
0.0140 0.08 PE(18:0/20:4(OH)) 783.5421 6.73 Lipids neg
0.0339 0.08 PS(O-16:0/19:0) 763.5736 8.02 Lipids neg
0.0673 0.09 20-Trihydroxy-
leukotriene-B4
384.2152 0.76 Lipids neg
0.0020 0.09 LysoPC(P-17:0) 493.3538 5.85 Lipids neg
0.0066 0.09 LysoPI(16:0) 572.2966 2.66 Lipids neg
0.0216 0.10 Octadecatrienoic acid 278.2246 3.89 Lipids neg
0.0203 0.10 1,5-Anhydro-D-glucitol 164.0684 0.57 Lipids neg
0.0029 0.10 hydroxy-pentacosanoic
acid
398.3763 6.24 Lipids neg
0.0310 0.10 methoxy-hydroxy-
octadecadienoic acid
326.2460 4.43 Lipids neg
0.0600 0.10 11-dehydro-TXB3 366.2046 0.82 Lipids neg
0.0217 0.11 (20R)-17alpha,20-
dihydroxycholesterol
418.3450 7.23 Lipids neg
0.0285 0.11 7-Methyl-1,4,5-
naphthalenetriol
4-[xylosyl-(1->6)-
glucoside]
484.1597 0.78 Lipids neg
0.0400 0.11 LysoPS(22:6) 569.2759 1.83 Lipids neg
0.0030 0.11 9-oxo-12Z-
Octadecenoic acid
296.2352 2.24 Lipids neg
0.0311 0.12 3-(2,4-dihydroxy-3,5-
dimethoxyphenyl)propanoic
acid
242.0799 0.78 Lipids neg
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0.0022 0.13 2-O-(alpha-D-
Glucopyranosyl)-D-
glycerate
268.0793 0.57 Lipids neg
0.0254 0.13 (+/-)-11-HEPE 318.2196 1.82 Lipids neg
0.0028 0.13 LPA(16:0) 410.2436 3.20 Lipids neg
0.0020 0.13 (6R,7S)-6,7-
Epoxyoctadecanoic
acid
298.2509 4.00 Lipids neg
0.0605 0.14 LysoPI(20:4) 620.2967 1.96 Lipids neg
0.0022 0.14 LysoPC(O-17:0) 495.3694 5.92 Lipids neg
0.0022 0.15 hydroxy-hexadecenoic
acid
270.2196 2.84 Lipids neg
0.0041 0.15 Glycerophosphoglycerol 246.0505 0.57 Lipids neg
0.0076 0.15 hydroxy-decanoic acid 188.1413 1.03 Lipids neg
0.0039 0.15 LPA(18:2) 434.2435 2.53 Lipids neg
0.0031 0.15 Manno-2-heptulose 210.0738 0.57 Lipids neg
0.0285 0.18 Hexacosanedioic acid 426.3715 6.29 Lipids neg
0.0033 0.19 1alpha,25-dihydroxy-
23-azavitamin D3 /
1alpha,25-dihydroxy-
23-azacholecalciferol
417.3244 4.42 Lipids neg
0.0088 0.19 Tetranorbiotin 188.0264 0.58 Lipids neg
0.0386 0.20 11-dehydro-2,3-dinor-
TXB2
340.1890 0.74 Lipids neg
0.0051 0.21 MG(18:4) 350.2462 0.89 Lipids neg
0.0074 0.21 Tocopheronic acid 294.1472 0.78 Lipids neg
0.0867 0.21 methyl-heptadecanoic
acid
284.2715 6.08 Lipids neg
0.0032 0.21 Dityrosine 360.1324 0.64 Lipids neg
0.0511 0.21 dimethyl-tetradecanoic
acid
256.2403 5.25 Lipids neg
0.0512 0.22 LysoPA(20:4) 458.2438 2.27 Lipids neg
0.0284 0.23 (25S)-5alpha-cholestan-
3beta,6beta,15alpha,16beta,26-
pentol
452.3482 5.91 Lipids neg
0.0040 0.24 10-keto myristic acid 242.1883 2.06 Lipids neg
0.0099 0.25 3-(Pyrazol-1-yl)-L-
alanine
155.0694 0.56 Lipids neg
0.0271 0.27 SQMG(16:1) 554.2734 5.91 Lipids neg
0.0066 0.29 Glycyl-Phenylalanine 222.1004 0.61 Lipids neg
0.0222 0.29 MG(22:1) 412.3557 5.97 Lipids neg
0.0335 0.32 11,18-di-HEPE 334.2148 1.58 Lipids neg
0.0419 0.33 10,13-diepi-10-F4c-
NeuroP
378.2411 1.22 Lipids neg
0.0140 0.34 Thymidine 242.0902 0.59 Lipids neg
0.0264 0.34 2-hydroxy-tricosanoic
acid
370.3450 6.90 Lipids neg
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0.0421 0.35 5a-Dihydrotestosterone
sulfate
370.1815 5.68 Lipids neg
0.0390 0.37 hydroxy-hexadecanoic
acid
272.2354 2.00 Lipids neg
0.0097 0.40 11beta,12beta-
Dihydroxy-5beta-
cholan-24-oic Acid
392.2931 1.63 Lipids neg
0.0020 0.40 (5Z,9E,12S,14Z)-8,11,12-
Trihydroxyicosa-5,9,14-
trienoate
354.2409 1.33 Lipids neg
0.0031 0.44 eicosapentaenoic acid 302.2247 2.52 Lipids neg
0.0020 0.45 LysoPA(22:6) 482.2438 2.22 Lipids neg
0.0066 0.46 LysoPA(18:1) 436.2592 3.41 Lipids neg
0.0573 0.46 N-palmitoyl tyrosine 419.3040 3.84 Lipids neg
0.0021 0.51 N-linoleoyl valine 379.3090 4.17 Lipids neg
0.0331 0.51 hydroxyoctadecanoic
acid
300.2665 3.17 Lipids neg
0.0285 0.51 N-palmitoyl valine 355.3090 4.77 Lipids neg
0.0015 0.51 N-oleoyl phenylalanine 429.3246 5.00 Lipids neg
0.0022 0.52 Coenzyme Q10 862.6804 5.69 Lipids neg
0.0321 0.55 Deoxycytidine 227.0906 0.57 Lipids neg
0.0528 0.57 methyl-tridecanedioic
acid
258.1834 1.11 Lipids neg
0.0084 0.61 Tryptophan 204.0898 0.61 Lipids neg
0.0699 0.65 Ethyl glucuronide 222.0739 0.57 Lipids neg
0.0339 1.51 hydroxy-heneicosanoic
acid
342.3136 6.29 Lipids neg
0.0089 1.52 N-lactoyl-
Phenylalanine
237.1001 0.64 Lipids neg
0.0329 1.99 Dihydroxydocosanoic
acid
372.3243 3.78 Lipids neg
0.0696 2.03 D-Altritol 182.0787 0.57 Lipids neg
0.0531 2.76 Vanillyl alcohol 154.0629 0.64 Lipids neg
0.0164 2.79 D-Apiitol 152.0683 0.57 Lipids neg
0.0170 2.93 (10R,13R,16R)-delta14-
9-PhytoF[9R,12R]
344.2201 0.67 Lipids neg
0.0197 3.23 N-Acetyl-leucyl-leucine 286.1897 0.72 Lipids neg
0.0226 3.31 1D-5-O-methyl-chiro-
inositol
194.0789 0.57 Lipids neg
0.0388 3.37 3-carboxy-4-
methyl-5-pentyl-2-
furanpropanoic acid
268.1311 0.66 Lipids neg
0.0183 3.50 hydroxy-decenoic acid 186.1257 0.83 Lipids neg
0.0088 3.59 11beta,12beta-
Dihydroxy-5beta-
cholan-24-oic Acid
392.2937 1.05 Lipids neg
0.0080 3.59 N-D-Glucosylarylamine 255.1106 0.64 Lipids neg
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0.0135 3.76 Quinic acid 192.0631 0.59 Lipids neg
0.0060 4.17 5,6-Dihydroxy-3-
methyl-2-oxo-1,2-
dihydroquinoline
191.0580 0.65 Lipids neg
0.0247 4.51 (10R,13R,16R)-delta11-
14-NeuroF[14R,17R]
394.2365 0.91 Lipids neg
0.0099 4.59 Hexanoylcarnitine 259.1784 0.68 Lipids neg
0.0125 4.73 Homoveratric acid 196.0733 0.66 Lipids neg
0.0082 5.11 Pseudouridine 244.0694 0.58 Lipids neg
0.0573 5.74 S-
Acetyldihydrolipoamide
249.0848 0.57 Lipids neg
0.0045 5.81 Dihydroxyheptenedioate 190.0476 0.59 Lipids neg
0.0041 5.95 oxo-decynoic acid 182.0944 0.65 Lipids neg
0.0167 6.07 7-Methylinosine 283.1055 0.65 Lipids neg
0.0064 6.50 (2S)-2-amino-3-
(4-hydroxy-3-
methoxyphenyl)-2-
methylpropanoic acid
225.1000 0.65 Lipids neg
0.0296 6.68 2, 3, 4-
Trimethoxycinnamate
238.0842 0.64 Lipids neg
0.0032 6.96 3-Methyldioxyindole 163.0632 0.65 Lipids neg
0.0049 7.25 3-
Phenylpropionylglycine
207.0894 0.65 Lipids neg
0.0184 7.28 1-Methylseleno-N-
acetyl-D-galactosamine
299.0287 0.65 Lipids neg
0.0026 7.74 Mandelate 152.0473 0.66 Lipids neg
0.0022 7.94 11-Deoxycortisol 346.2150 1.04 Lipids neg
0.0099 7.99 Glycocholic Acid 465.3096 0.79 Lipids neg
0.0044 8.03 Dodecenedioic acid 228.1362 0.79 Lipids neg
0.0133 8.13 Dihydrolipoate 208.0582 0.58 Lipids neg
0.0055 8.29 Isopropylmaleate 158.0577 0.64 Lipids neg
0.0040 8.62 Dimethyl-
decadiendioic acid
226.1207 0.74 Lipids neg
0.0071 9.22 (22R)-22,25-
dihydroxyvitamin
D3 / (22R)-22,25-
dihydroxycholecalciferol
408.2881 1.07 Lipids neg
0.0028 9.63 4-O-(beta-L-
Arabinofuranosyl)-
(2S,4S)-4-
hydroxyproline
263.1005 0.59 Lipids neg
0.0022 9.85 Dodecenedioic acid 228.1361 0.66 Lipids neg
0.0039 9.88 Aldehydo-N-acetyl-D-
glucosamine
221.0899 0.57 Lipids neg
0.0441 9.92 decenoic acid 170.1306 0.76 Lipids neg
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0.0050 10.15 11beta,12beta-
Dihydroxy-5beta-
cholan-24-oic Acid
392.2932 1.78 Lipids neg
0.0028 10.52 3-
Hydroxydodecanedioic
acid
246.1466 0.65 Lipids neg
0.0061 10.70 2-Phenylethanol glu-
curonide
298.1051 0.64 Lipids neg
0.0024 10.83 TG(9:0) 260.1258 0.63 Lipids neg
0.0036 10.95 Phaseolic acid 262.1415 0.64 Lipids neg
0.0062 11.39 2-Carboxy-D-arabinitol 196.0581 0.57 Lipids neg
0.0120 11.49 N-(1-Deoxy-1-
fructosyl)serine
267.0956 0.57 Lipids neg
0.0022 11.84 3-Indolehydracrylic
acid
205.0736 0.66 Lipids neg
0.0022 12.16 4’-
phosphonatopantothenate
299.0772 0.59 Lipids neg
0.0075 12.19 Vanilloloside 316.1159 0.64 Lipids neg
0.0698 12.21 15-methyl-15R-PGD2 366.2410 0.76 Lipids neg
0.0021 12.29 2-Methylquinolin-4-ol 159.0685 0.69 Lipids neg
0.0021 12.65 3-ethylphenyl Sulfate 202.0299 0.66 Lipids neg
0.0220 13.81 3-Imidazole-2-
oxopropanoate
154.0385 0.58 Lipids neg
0.0036 14.19 Dimethylglutaric acid 160.0734 0.65 Lipids neg
0.0034 14.73 hydroxy-decenoic acid 186.1256 0.64 Lipids neg
0.0040 16.69 oxo-decenoic acid 184.1099 0.66 Lipids neg
0.0126 17.44 Glutamylproline 244.1059 0.58 Lipids neg
0.0025 17.78 2,3-Dihydroxybenzoate 154.0265 0.63 Lipids neg
0.0015 18.16 Indolylacryloylglycine 244.0846 0.65 Lipids neg
0.0015 20.56 cis-
Cyclo(aspartylphenylalanyl)
262.0952 0.62 Lipids neg
0.0020 21.61 N-Acetyl-D-
galactosamine 6-sulfate
301.0467 0.56 Lipids neg
0.0028 21.62 hydroxy-Octadienoic
acid
156.0785 0.64 Lipids neg
0.0026 22.60 Glycylproline 172.0847 0.58 Lipids neg
0.0208 22.93 LysoPC(10:0) 412.2467 0.77 Lipids neg
0.0037 23.06 Dimethyl-
octadienedioic acid
198.0891 0.66 Lipids neg
0.0037 24.43 hydroxy-dodecadienoic
acid
212.1414 0.77 Lipids neg
0.0022 24.50 3-Phospho-D-
erythronate
216.0027 0.58 Lipids neg
0.0061 26.07 2,2’-Iminobispropanoic
acid
161.0687 0.59 Lipids neg
0.0027 28.69 hydroxyoctenoylglycine 215.1157 0.61 Lipids neg
0.0034 29.21 1-Octen-3-yl glucoside 290.1728 0.65 Lipids neg
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0.0025 29.28 1-Keto-D-chiro-inositol 178.0475 0.58 Lipids neg
0.0030 29.34 2,6-Dimethyl-1,8-
octanedioic acid
202.1204 0.66 Lipids neg
0.0028 29.97 Aspartyl-Threonine 234.0851 0.57 Lipids neg
0.0020 33.63 Oxooctanoic acid 158.0941 0.65 Lipids neg
0.0043 33.67 N-butanoyl-
lhomoserine lactone
171.0895 0.66 Lipids neg
0.0022 33.77 2,5,6-Trihydroxy-5,6-
dihydroquinoline
179.0581 0.64 Lipids neg
0.0045 34.31 2-Dehydro-D-
galactonate
194.0425 0.60 Lipids neg
0.0028 36.97 Ferulic acid 4-sulfate 274.0148 0.59 Lipids neg
0.0022 37.02 N-(1-Deoxy-1-
fructosyl)threonine
281.1123 0.56 Lipids neg
0.0022 37.78 3,4-Dihydroxy-L-
phenylalanine
197.0688 0.64 Lipids neg
0.0026 37.88 (22R)-22,25-
dihydroxyvitamin
D3 / (22R)-22,25-
dihydroxycholecalciferol
408.2883 0.82 Lipids neg
0.0044 38.46 dihydroxydecanoic acid 204.1358 0.65 Lipids neg
0.0026 40.95 Dihydroxy-
dioxohexanoate
176.0319 0.60 Lipids neg
0.0047 41.95 3-Methoxy-4-
Hydroxyphenylglycol
sulfate
264.0302 0.60 Lipids neg
0.0027 43.58 (22E)-
3alpha,6beta,7beta-
Trihydroxy-5beta-chol-
22-en-24-oic Acid
406.2726 0.84 Lipids neg
0.0022 43.99 Indole-3-carboxilic acid-
O-sulphate
241.0045 0.59 Lipids neg
0.0022 44.73 3-Isopropylmalate 176.0683 0.62 Lipids neg
0.0025 51.59 4-(Glutamylamino) bu-
tanoate
232.1059 0.57 Lipids neg
0.0056 52.05 1-Deoxy-D-xylulose
5-phosphate
214.0244 0.58 Lipids neg
0.0039 52.13 4-Sulfobenzoate 201.9935 0.60 Lipids neg
0.0022 53.51 Hydroxydecanedioic
acid
218.1152 0.64 Lipids neg
0.0023 55.59 Serylserine 192.0746 0.57 Lipids neg
0.0066 56.62 Isocitric acid 192.0269 0.60 Lipids neg
0.0065 58.89 3-hydroxy-3-(3-
hydroxyphenyl)propanoic
acid-O-sulphate
262.0146 0.59 Lipids neg
0.0022 59.36 Hydroxypropionylcarnitine233.1263 0.62 Lipids neg
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0.0020 59.55 Methylcrotonylglycine 157.0737 0.64 Lipids neg
0.0025 59.79 Nonenoic acid 156.1149 0.65 Lipids neg
0.0024 61.85 5-Hydroxydopamine 169.0739 0.62 Lipids neg
0.0020 65.20 Dehydroepiandrosterone
sulfate
368.1657 0.68 Lipids neg
0.0040 84.87 nonynoic acid 154.0993 0.67 Lipids neg
0.0020 88.85 2-Methylbutyrylglycine 159.0894 0.65 Lipids neg
0.0020 92.76 (22E)-
3alpha,6beta,7beta-
Trihydroxy-5beta-chol-
22-en-24-oic Acid
406.2726 0.98 Lipids neg
0.0024 94.27 2-O-Benzoyl-D-glucose 284.0895 0.62 Lipids neg
0.0020 105.43 3,4,5,6-
Tetrahydrohippuric
acid
183.0895 0.64 Lipids neg
0.0022 111.56 Methylhippuric acid 193.0737 0.65 Lipids neg
0.0029 113.99 hexadecatetraenoic acid 248.1777 1.74 Lipids neg
0.0078 132.15 Indoxyl sulfate 213.0095 0.61 Lipids neg
0.0022 137.47 4-Sulfobenzyl alcohol 188.0142 0.64 Lipids neg
0.0022 151.37 3-Hydroxy-5-methyl-L-
tyrosine
211.0843 0.65 Lipids neg
0.0022 248.28 O-methoxycatechol-O-
sulphate
204.0091 0.64 Lipids neg
0.0022 581.73 Glutamyl-taurine 254.0579 0.68 Lipids neg
0.0035 0.00 NeuAcalpha2-
3Galbeta-
Cer(d18:1/20:0)
1046.7262 4.45 Lipids pos
0.0053 0.00 PC(34:3) 755.5464 7.19 Lipids pos
0.0086 0.00 PC(36:2) 785.5957 7.40 Lipids pos
0.0072 0.00 PC(40:9) 827.5435 7.26 Lipids pos
0.0060 0.00 LysoPA(19:0) 452.2903 2.33 Lipids pos
0.0049 0.00 PC(32:0) 733.5644 7.19 Lipids pos
0.0057 0.00 PC(36:4) 809.5926 7.77 Lipids pos
0.0035 0.00 PC(36:4) 781.5613 7.41 Lipids pos
0.0073 0.00 PC(38:5) 807.5758 7.40 Lipids pos
0.0035 0.00 PC(38:6) 805.5615 7.26 Lipids pos
0.0049 0.00 (3-sulfo)Galbeta-
Cer(d18:1/18:0(2OH))
823.5484 7.88 Lipids pos
0.0144 0.00 LysoPS(20:0) 553.3384 1.03 Lipids pos
0.0057 0.00 PA(39:3) 740.5349 7.19 Lipids pos
0.0103 0.00 PC(20:2/P-18:1) 795.6139 8.00 Lipids pos
0.0063 0.00 PC(34:2) 757.5610 7.50 Lipids pos
0.0046 0.00 PC(36:3) 783.5787 7.52 Lipids pos
0.0043 0.00 PC(40:6) 833.5926 7.63 Lipids pos
0.0096 0.00 1,3,7-Trioxo-5beta-
cholan-24-oic Acid
402.2409 1.07 Lipids pos
0.0049 0.00 DG(44:8) 720.5664 7.52 Lipids pos
0.0063 0.00 Hexadecadienylcarnitine 423.3343 2.57 Lipids pos
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0.0058 0.00 LysoPC(16:0) 495.3316 3.26 Lipids pos
0.0035 0.00 LysoPC(18:0) 523.3630 4.45 Lipids pos
0.0044 0.00 LysoPC(22:4) 571.3610 4.59 Lipids pos
0.0046 0.00 PC(40:5) 835.6073 7.76 Lipids pos
0.0049 0.00 PC(40:8) 829.5581 7.41 Lipids pos
0.0057 0.00 PS(O-16:0/18:0) 749.5594 6.09 Lipids pos
0.0046 0.00 PS(O-16:0/20:3) 771.5411 6.09 Lipids pos
0.0075 0.01 PA(O-16:0/21:0) 704.5734 7.66 Lipids pos
0.0103 0.01 PC(20:3/P-18:1) 793.5977 7.67 Lipids pos
0.0039 0.01 PC(20:4/P-18:1) 791.5801 7.51 Lipids pos
0.0046 0.01 PC(36:6) 777.5282 7.19 Lipids pos
0.0053 0.01 PS(O-16:0/20:2) 773.5563 6.10 Lipids pos
0.0050 0.01 PS(O-16:0/20:3) 771.5411 6.24 Lipids pos
0.0049 0.01 1-(6-[3]-ladderane-
hexanoyl)-2-(8-[3]-
ladderane-octanyl)-sn-
glycerophosphoethanolamine
745.5024 7.68 Lipids pos
0.0044 0.01 15-HETE-DA 455.3015 2.71 Lipids pos
0.0250 0.01 3-Deoxyvitamin D3 368.3438 7.19 Lipids pos
0.0261 0.01 Cholesterol 386.3546 7.19 Lipids pos
0.0067 0.01 LysoPC(16:0) 495.3316 3.01 Lipids pos
0.0047 0.01 LysoPC(17:0) 509.3480 3.88 Lipids pos
0.0085 0.01 LysoPS(20:1) 551.3223 1.02 Lipids pos
0.0106 0.01 PC(16:1/2:0) 535.3275 1.03 Lipids pos
0.0043 0.01 PC(37:5) 793.5593 7.69 Lipids pos
0.0049 0.01 PI(34:2) 834.5276 7.40 Lipids pos
0.0062 0.01 PS(O-18:0/17:2) 759.5425 7.59 Lipids pos
0.0065 0.01 (3-sulfo)Galbeta-
Cer(d18:1/16:0(2OH))
795.5158 8.01 Lipids pos
0.0132 0.01 (3beta,17alpha,23S)-
17,23-Epoxy-3,29-
dihydroxy-27-
norlanosta-7,9(11)-
diene-15,24-dione
470.3036 1.09 Lipids pos
0.0052 0.01 LysoPE(22:0) 537.3795 4.96 Lipids pos
0.0076 0.01 MG(18:0) 358.3078 3.19 Lipids pos
0.0218 0.01 N-Stearoyl tyrosine 447.3345 2.46 Lipids pos
0.0062 0.01 PC(32:2) 729.5308 7.10 Lipids pos
0.0035 0.01 PC(34:1) 787.6087 7.76 Lipids pos
0.0133 0.01 PI(36:5) 856.5067 7.20 Lipids pos
0.0046 0.01 PS(O-16:0/22:2) 801.5883 6.60 Lipids pos
0.0049 0.01 LysoPA(18:0) 424.2951 4.97 Lipids pos
0.0055 0.01 LysoPC(16:1) 493.3167 2.26 Lipids pos
0.0267 0.01 LysoPC(20:4) 543.3319 2.45 Lipids pos
0.0100 0.01 LysoPC(22:5) 569.3474 2.60 Lipids pos
0.0124 0.01 PI(38:4) 886.5557 7.49 Lipids pos
0.0201 0.01 CL(78:6) 1537.1032 7.51 Lipids pos
0.0077 0.01 LysoPC(16:1) 493.3167 2.34 Lipids pos
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0.0046 0.01 LysoPE(20:3) 503.2987 2.62 Lipids pos
0.0057 0.01 MG(18:2) 354.2765 3.68 Lipids pos
0.0064 0.01 Palmitoylcarnitine 399.3345 3.19 Lipids pos
0.0059 0.01 PE(22:6/P-18:1) 773.5337 8.01 Lipids pos
0.0052 0.01 LysoPC(14:0) 467.3013 2.05 Lipids pos
0.0043 0.01 PS(38:7) 805.4868 7.15 Lipids pos
0.0049 0.01 PS(O-18:0/20:5) 795.5389 7.18 Lipids pos
0.0211 0.01 LysoPS(20:2) 549.3065 0.95 Lipids pos
0.0065 0.01 PC(40:7) 831.5739 7.56 Lipids pos
0.0054 0.01 PS(40:8) 831.5023 7.18 Lipids pos
0.0226 0.01 PS(42:11) 853.4869 6.69 Lipids pos
0.0043 0.01 PS(O-20:0/20:5) 823.5719 7.11 Lipids pos
0.0168 0.01 nitrooctadecenoic Acid 327.2408 1.91 Lipids pos
0.0074 0.01 PC(18:2/P-18:1) 767.5829 7.44 Lipids pos
0.0049 0.01 PI(36:3) 860.5411 7.21 Lipids pos
0.0044 0.01 PI(38:7) 880.5078 7.11 Lipids pos
0.0070 0.01 PS(O-16:0/22:2) 801.5880 6.69 Lipids pos
0.0057 0.01 CPA(16:0) 392.2328 3.83 Lipids pos
0.0388 0.01 PI(40:7) 908.5374 7.48 Lipids pos
0.0060 0.01 PS(31:2) 717.4576 4.61 Lipids pos
0.0120 0.01 PS(O-18:0/20:3) 799.5727 6.72 Lipids pos
0.0043 0.01 TG(57:9) 914.7344 6.54 Lipids pos
0.0043 0.02 LysoPC(16:0) 495.3321 2.56 Lipids pos
0.0049 0.02 LysoPC(20:2) 547.3638 3.71 Lipids pos
0.0049 0.02 LysoPC(P-18:0) 507.3688 3.94 Lipids pos
0.0076 0.02 CerP(d18:1/8:0) 505.3525 3.00 Lipids pos
0.0158 0.02 LysoPC(20:3) 545.3482 2.95 Lipids pos
0.0130 0.02 15-methyl-15R-
PGF2alpha
368.2563 1.78 Lipids pos
0.0240 0.02 1alpha,25-dihydroxy-
24-oxo-23-azavitamin
D2 / 1alpha,25-
dihydroxy-24-oxo-
23-azaergocalciferol
445.3193 1.85 Lipids pos
0.0065 0.02 LysoPC(20:0) 551.3949 5.41 Lipids pos
0.0059 0.02 LysoPE(22:5) 527.3012 2.53 Lipids pos
0.0159 0.02 PC(36:5) 779.5465 6.84 Lipids pos
0.0049 0.02 PS(38:2) 815.5672 6.18 Lipids pos
0.0128 0.02 LysoPA(16:1) 408.2280 1.58 Lipids pos
0.0174 0.02 LysoPA(24:0) 522.3682 7.19 Lipids pos
0.0043 0.02 LysoPC(14:0) 467.3013 1.86 Lipids pos
0.0104 0.02 LysoPC(P-16:0) 479.3376 3.68 Lipids pos
0.0051 0.02 PC(33:5) 737.4997 7.19 Lipids pos
0.0142 0.02 PS(40:9) 829.4868 6.81 Lipids pos
0.0137 0.02 eicosadienoylcarnitine 451.3661 3.59 Lipids pos
0.0063 0.02 LysoPS(22:1) 579.3534 3.37 Lipids pos
0.0291 0.02 PE-Cer(d14:2/23:0) 700.5518 7.11 Lipids pos
0.0128 0.02 11’-Carboxy-gamma-
chromanol
404.2923 1.85 Lipids pos
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0.0049 0.02 PI(34:1) 836.5391 7.39 Lipids pos
0.0305 0.02 (8E,10S,12Z,15Z)-10-
Hydroperoxyoctadeca-
8,12,15-trienoate
310.2142 1.92 Lipids pos
0.0055 0.02 7,8-Diaminononanoate 188.1524 0.55 Lipids pos
0.0115 0.02 Hexadecenoylcarnitine 397.3191 2.28 Lipids pos
0.0112 0.02 15-methyl-15R-PGD2 366.2406 1.16 Lipids pos
0.0180 0.02 MG(20:4) 378.2769 3.77 Lipids pos
0.0127 0.02 PA(16:0) 424.2226 1.06 Lipids pos
0.0093 0.02 PS(29:2) 689.4246 4.48 Lipids pos
0.0064 0.02 PS(42:9) 857.5172 7.39 Lipids pos
0.0043 0.02 LysoPE(22:1) 535.3638 4.02 Lipids pos
0.0061 0.02 N-stearoyl serine 371.3035 3.96 Lipids pos
0.0137 0.03 (22,23-dinor)-24-vinyl-
cholest-5-en-3beta,24-
diol
400.3338 5.29 Lipids pos
0.0251 0.03 3-
hydroxylinoleoylcarnitine
439.3298 0.99 Lipids pos
0.0080 0.03 LysoPC(18:2) 519.3318 2.37 Lipids pos
0.0526 0.03 LysoPC(20:1) 549.3795 4.34 Lipids pos
0.0068 0.03 LysoPE(22:6) 525.2858 2.20 Lipids pos
0.0161 0.03 PG(29:2) 676.4312 4.61 Lipids pos
0.0069 0.03 LysoPC(18:3) 517.3171 1.89 Lipids pos
0.0191 0.03 9,10-epoxy-3E,12Z-
Octadecadienoic acid
294.2193 2.25 Lipids pos
0.0105 0.03 LysoPC(O-18:0) 509.3846 4.91 Lipids pos
0.0039 0.03 PC(42:8) 857.5892 7.90 Lipids pos
0.0055 0.03 PS(34:0) 763.5392 7.26 Lipids pos
0.0069 0.03 PS(41:7) 847.5397 7.77 Lipids pos
0.0043 0.03 SM(d18:2/18:1) 726.5671 7.20 Lipids pos
0.0055 0.03 1-(14-methyl-
pentadecanoyl)-2-(8-
[3]-ladderane-octanyl)-
sn-glycerol
602.5272 7.57 Lipids pos
0.0507 0.03 PC(42:11) 851.5443 6.94 Lipids pos
0.0076 0.03 PS(42:1) 873.6427 4.22 Lipids pos
0.0104 0.03 LysoPC(22:0) 579.4263 6.18 Lipids pos
0.0043 0.03 PS(O-18:0/22:6) 821.5564 6.07 Lipids pos
0.0086 0.03 LysoPC(18:4) 515.2988 2.35 Lipids pos
0.0080 0.03 LysoPC(O-20:0) 537.4160 5.81 Lipids pos
0.0081 0.03 LysoPC(P-18:0) 507.3690 4.82 Lipids pos
0.0049 0.04 LysoPE(20:5) 499.2676 2.67 Lipids pos
0.0043 0.04 PS(39:7) 819.5026 7.35 Lipids pos
0.0129 0.04 (+/-)-10-HDoHE 344.2353 5.25 Lipids pos
0.0143 0.04 octadecadiynoic acid 276.2086 2.48 Lipids pos
0.0062 0.04 PI(40:8) 906.5235 7.14 Lipids pos
0.0320 0.04 CDP-DG(28:0) 897.4506 6.69 Lipids pos
0.0059 0.04 docosadienoylcarnitine 479.3973 6.31 Lipids pos
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0.0062 0.04 LysoPC(O-16:0) 481.3531 3.76 Lipids pos
0.0052 0.04 Isolimonic acid 506.2170 3.96 Lipids pos
0.0195 0.04 O-(13-
carboxytridecanoyl)carnitine
401.2775 1.23 Lipids pos
0.0137 0.04 PC(42:7) 859.6112 7.67 Lipids pos
0.0044 0.04 (10R)-1alpha,19,25-
trihydroxy-10,19-
dihydrovitamin D3
/ (10R)-1alpha,19,25-
trihydroxy-10,19-
dihydrocholecalciferol
434.3393 5.82 Lipids pos
0.0152 0.04 DG(40:8) 664.5047 7.94 Lipids pos
0.0218 0.04 LysoPC(24:0) 607.4578 6.81 Lipids pos
0.0057 0.04 PC(31:0) 719.5489 7.21 Lipids pos
0.0221 0.04 PE(42:10) 811.5148 7.24 Lipids pos
0.0058 0.04 (23Z)-25-hydroxy-
16,17,23,24-
tetradehydrovitamin
D3 / (23Z)-25-
hydroxy-16,17,23,24-
tetradehydrocholecalciferol
396.3031 1.85 Lipids pos
0.0187 0.04 hydroxyoctadecatrienoylcarnitine437.3141 1.13 Lipids pos
0.0060 0.04 PC(16:0/9:0(CHO)) 649.4319 4.79 Lipids pos
0.0359 0.04 6alpha-
Glucuronosylhyodeoxycholate
567.3176 0.65 Lipids pos
0.0074 0.04 LysoPC(22:1) 577.4107 5.47 Lipids pos
0.0128 0.04 (22,23-dinor)-24-vinyl-
cholest-5-en-3beta,24-
diol
400.3337 5.47 Lipids pos
0.0057 0.04 Heptadecanoyl carni-
tine
413.3504 3.74 Lipids pos
0.0395 0.04 LysoPC(22:6) 567.3321 2.11 Lipids pos
0.0055 0.04 LysoPE(O-16:0) 439.3061 3.89 Lipids pos
0.0064 0.05 1-Palmitoyl-2-(5-
hydroxy-8-oxo-
6-octenedioyl)-
sn-glycero-3-
phosphocholine
665.3902 3.18 Lipids pos
0.0049 0.05 3-
hydroxyeicosanoylcarnitine
471.3921 4.38 Lipids pos
0.0079 0.05 LysoPA(P-16:0) 394.2485 4.74 Lipids pos
0.0085 0.05 PS(33:5) 739.4397 4.62 Lipids pos
0.0375 0.05 carboxyheptadecenoylcarnitine455.3244 0.79 Lipids pos
0.0411 0.05 hydroxy-
octadecadienynoic
acid
292.2037 1.53 Lipids pos
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0.0196 0.05 13’-Hydroxy-alpha-
tocopherol
446.3759 6.54 Lipids pos
0.0059 0.05 MG(18:1) 356.2925 4.74 Lipids pos
0.0057 0.05 PA(P-16:0/13:0) 590.4312 7.30 Lipids pos
0.0221 0.05 PC(41:7) 845.5896 7.93 Lipids pos
0.0199 0.05 (25S)-24S,26-cyclo-
5alpha-cholestan-3beta-
ol
384.3392 5.47 Lipids pos
0.0096 0.05 PC(22:4/P-18:0) 821.6286 7.91 Lipids pos
0.0503 0.05 hydroxy-
octadecadienynoic
acid
292.2036 1.91 Lipids pos
0.0052 0.05 PS(28:1) 677.4266 4.75 Lipids pos
0.0352 0.06 (8E,10S,12Z,15Z)-10-
Hydroperoxyoctadeca-
8,12,15-trienoate
310.2142 1.52 Lipids pos
0.0097 0.06 PG(O-16:0/12:0) 652.4679 6.44 Lipids pos
0.0165 0.06 PS(O-18:0/20:5) 795.5389 6.10 Lipids pos
0.0057 0.06 (17S,20R)-1alpha,25-
dihydroxy-17,20-
methano-21-norvitamin
D3 / (17S,20R)-
1alpha,25-dihydroxy-
17,20-methano-21-
norcholecalciferol
414.3136 1.85 Lipids pos
0.0097 0.06 (22R)-1alpha,22,25-
trihydroxy-26,27-
dimethyl-23,23,24,24-
tetradehydro-24a,24b-
dihomovitamin D3
/ (22R)-1alpha,22,25-
trihydroxy-26,27-
dimethyl-23,23,24,24-
tetradehydro-24a,24b-
dihomocholecalciferol
484.3529 6.21 Lipids pos
0.0261 0.06 LysoPA(17:0) 424.2587 3.50 Lipids pos
0.0050 0.06 PC(20:1) 563.3598 1.32 Lipids pos
0.0068 0.06 11-
Dehydrocorticosterone
344.1983 4.62 Lipids pos
0.0053 0.06 LysoPS(20:4) 545.2743 2.94 Lipids pos
0.0103 0.06 PC(38:8) 801.5296 7.01 Lipids pos
0.0090 0.06 PS(30:1) 705.4578 4.60 Lipids pos
0.0053 0.07 Hydroxyhexadecanoylcarnitine415.3300 3.38 Lipids pos
0.0097 0.07 PS(27:1) 663.4112 4.77 Lipids pos
0.0087 0.07 PS(42:7) 861.5483 6.07 Lipids pos
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0.0166 0.07 Tetradecenoylcarnitine 369.2878 1.54 Lipids pos
0.0218 0.07 4,8 Dimethylnonanoyl
carnitine
329.2565 1.32 Lipids pos
0.0117 0.07 PA(40:8) 744.4710 7.34 Lipids pos
0.0049 0.07 PI-Cer(d20:1/16:0) 807.5625 4.62 Lipids pos
0.0053 0.07 28-Glucosyl-3b-
hydroxy-12-oleanene-
30-methoxy-28-oic acid
3-[arabinosyl-(1->3)-
glucuronide]
970.4777 7.11 Lipids pos
0.0046 0.07 LysoPS(22:4) 573.3047 1.24 Lipids pos
0.0049 0.07 PA(27:0) 578.3948 6.90 Lipids pos
0.0057 0.07 PA(O-16:0/13:0) 592.4473 7.89 Lipids pos
0.0517 0.07 DG(38:6) 640.5063 7.62 Lipids pos
0.0162 0.07 hydroxytetradecanoylcarnitine387.2987 1.55 Lipids pos
0.0901 0.07 PC(42:10) 853.5622 6.78 Lipids pos
0.0509 0.07 DG(40:7) 666.5201 8.23 Lipids pos
0.0035 0.07 LysoPC(22:2) 575.3952 4.74 Lipids pos
0.0083 0.07 PC(22:1) 591.3878 5.24 Lipids pos
0.0091 0.08 PA(36:2) 700.5048 7.21 Lipids pos
0.0183 0.08 1alpha,25-
dihydroxy-2beta-(6-
hydroxyhexyl)vitamin
D3 / 1alpha,25-
dihydroxy-2beta-(6-
hydroxyhexyl)cholecalciferol
516.4179 6.18 Lipids pos
0.0059 0.08 PI(42:9) 932.5392 7.36 Lipids pos
0.0497 0.08 MG(22:6) 402.2769 3.54 Lipids pos
0.0683 0.08 PA(O-16:0/21:0) 704.5740 8.38 Lipids pos
0.0127 0.08 6a-hydroxy DHEA 3-
sulfate
384.1589 3.90 Lipids pos
0.0248 0.08 N-oleoyl alanine 353.2927 2.36 Lipids pos
0.0094 0.08 (E)-2-Butenyl-4-methyl-
threonine
187.1215 3.21 Lipids pos
0.0057 0.08 Kinetensin 4-7 571.2869 2.63 Lipids pos
0.0397 0.08 PE(42:11) 809.4964 7.02 Lipids pos
0.0046 0.08 LysoPE(16:1) 451.2695 2.35 Lipids pos
0.0236 0.08 PC(32:1) 731.5452 7.76 Lipids pos
0.0128 0.08 Pentadecanoylcarnitine 385.3188 2.61 Lipids pos
0.0875 0.08 DG(44:10) 716.5394 7.18 Lipids pos
0.0207 0.09 5’-Methylthioadenosine 297.0895 0.62 Lipids pos
0.0207 0.09 hydroxyoctadecenoylcarnitine441.3445 2.45 Lipids pos
0.0077 0.09 PA(39:2) 742.5514 6.83 Lipids pos
0.0311 0.09 PE(6:0/6:0) 411.2019 0.61 Lipids pos
0.0053 0.09 LysoPS(O-18:0) 511.3274 1.21 Lipids pos
0.0088 0.09 MG(18:3) 352.2612 3.21 Lipids pos
0.0480 0.09 N-palmitoyl tyrosine 419.3032 3.54 Lipids pos
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0.0583 0.09 N-stearoyl serine 371.3035 2.08 Lipids pos
0.0084 0.09 PE(P-16:0/13:0) 633.4734 6.80 Lipids pos
0.0063 0.09 DG(36:8) 608.4418 7.30 Lipids pos
0.0095 0.09 DG(40:6) 668.5355 8.32 Lipids pos
0.0334 0.09 4,8 Dimethylnonanoyl
carnitine
329.2565 1.38 Lipids pos
0.0151 0.09 O-(17-
carboxyheptadecanoyl)carnitine
457.3404 0.85 Lipids pos
0.0188 0.10 (20R)-17alpha,20-
dihydroxycholesterol
418.3443 6.45 Lipids pos
0.0049 0.10 LysoPE(22:2) 533.3482 3.14 Lipids pos
0.0115 0.10 Cer(d14:2/20:1(2OH)) 549.4760 6.31 Lipids pos
0.0294 0.10 2alpha-
(Hydroxymethyl)-
17-methyl-5alpha-
androstane-
3beta,17beta-diol
336.2662 2.25 Lipids pos
0.0719 0.10 LysoPC(20:5) 541.3171 1.12 Lipids pos
0.0157 0.10 PS(35:4) 769.4885 5.25 Lipids pos
0.0059 0.10 1-
Naphthylacetylspermine
370.2719 2.42 Lipids pos
0.0163 0.10 1,4-cholestadie24,25-
didehydrovitamin
D3 / 24,25-
didehydrocholecalciferol
382.3237 7.22 Lipids pos
0.0656 0.10 (23R)-1alpha,23,25-
trihydroxy-24-
oxovitamin D3 /
(23R)-1alpha,23,25-
trihydroxy-24-
oxocholecalciferol
446.3034 1.15 Lipids pos
0.0268 0.10 (8E,10S,12Z,15Z)-10-
Hydroperoxyoctadeca-
8,12,15-trienoate
310.2142 1.65 Lipids pos
0.0077 0.10 DG(42:7) 694.5533 7.18 Lipids pos
0.0151 0.11 Hepteneoylglycine 185.1045 4.62 Lipids pos
0.0079 0.11 PA(30:1) 618.4262 7.18 Lipids pos
0.0060 0.11 Arachidyl carnitine 455.3973 5.19 Lipids pos
0.0283 0.11 (25S)-24S,26-cyclo-
5alpha-cholestan-3beta-
ol
384.3392 6.11 Lipids pos
0.0055 0.11 PI(39:7) 894.5232 7.31 Lipids pos
0.0219 0.11 DG(38:4) 644.5381 8.22 Lipids pos
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0.0200 0.11 1-Palmitoyl-2-(5-
keto-6-octenedioyl)-
sn-glycero-3-
phosphocholine
663.3750 2.85 Lipids pos
0.0053 0.11 1alpha,25-dihydroxy-
24-oxo-23-azavitamin
D2 / 1alpha,25-
dihydroxy-24-oxo-
23-azaergocalciferol
445.3188 4.04 Lipids pos
0.0079 0.11 LysoPC(24:1) 605.4420 6.06 Lipids pos
0.0150 0.12 Amino acid(Arg-) 174.1116 0.54 Lipids pos
0.0288 0.12 (20R)-17alpha,20-
dihydroxycholesterol
418.3444 4.88 Lipids pos
0.0076 0.12 PG(34:2) 746.5096 6.54 Lipids pos
0.0089 0.12 PS(O-16:0/20:3) 771.5411 6.53 Lipids pos
0.0642 0.12 11-deoxy-PGF1a 340.2610 3.10 Lipids pos
0.0050 0.12 Alpha-linolenyl carni-
tine
421.3173 3.85 Lipids pos
0.0069 0.12 Docosahexaenoic acid 328.2393 8.04 Lipids pos
0.0256 0.13 DG(38:5) 642.5224 7.93 Lipids pos
0.0228 0.13 2-
Methylbutyroylcarnitine
245.1634 0.94 Lipids pos
0.0212 0.13 Oleoylethanolamide 325.2978 4.27 Lipids pos
0.0124 0.13 PS(30:2) 703.4421 4.61 Lipids pos
0.0076 0.13 LysoPI(20:3) 622.3099 3.94 Lipids pos
0.0081 0.13 PC(16:0) 509.3121 1.38 Lipids pos
0.0057 0.13 PI(44:12) 954.5214 7.35 Lipids pos
0.0120 0.14 LysoPS(18:3) 519.2574 2.70 Lipids pos
0.0059 0.14 PC(28:0) 677.4992 7.00 Lipids pos
0.0125 0.14 LysoPS(20:3) 547.2888 3.95 Lipids pos
0.0077 0.14 PI(42:6) 934.5535 7.46 Lipids pos
0.0051 0.14 Stearoylcarnitine 427.3659 4.14 Lipids pos
0.0284 0.14 N-propyl-
16,16-dimethyl-
5Z,8Z,11Z,14Z-
docosatetraenoyl amine
401.3654 6.11 Lipids pos
0.0044 0.14 PS(26:1) 649.3953 3.62 Lipids pos
0.0072 0.14 Butyrylcarnitine 231.1469 0.60 Lipids pos
0.0079 0.14 CerP(d18:1/14:0) 589.4472 5.96 Lipids pos
0.0537 0.15 (22,23-dinor)-24-vinyl-
cholest-5-en-3beta,24-
diol
400.3337 5.80 Lipids pos
0.0086 0.15 4-(3-Methylbut-2-enyl)-
L-tryptophan
272.1525 0.86 Lipids pos
0.0535 0.15 Anandamide (18:4, n-3) 319.2508 2.37 Lipids pos
0.0043 0.15 27-Nor-5b-cholestane-
3a,7a,12a,24,25-pentol
438.3341 5.49 Lipids pos
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0.0128 0.15 LysoPS(16:0) 497.2756 2.71 Lipids pos
0.0331 0.15 PA(37:1) 716.5358 7.18 Lipids pos
0.0077 0.16 17alpha-(N-Acetyl-D-
glucosaminyl)-estradiol
3-D-glucuronide
651.2886 3.88 Lipids pos
0.0789 0.16 LysoPS(22:2) 577.3384 1.25 Lipids pos
0.0080 0.16 PC(18:0) 537.3434 2.94 Lipids pos
0.0106 0.16 PS(30:3) 729.4577 4.85 Lipids pos
0.0119 0.16 Histidine trimethylbe-
taine
197.1163 0.55 Lipids pos
0.0321 0.16 2alpha-
(Hydroxymethyl)-
17-methyl-5alpha-
androstane-
3beta,17beta-diol
336.2661 3.95 Lipids pos
0.0072 0.16 LysoPC(P-20:0) 535.4003 5.73 Lipids pos
0.0076 0.16 (20S)-20-cyclopropyl-
1alpha,25-dihydroxy-
16,17-didehydro-21-
norvitamin D3 /
(20S)-20-cyclopropyl-
1alpha,25-dihydroxy-
16,17-didehydro-21-
norcholecalciferol
440.3290 5.25 Lipids pos
0.0508 0.16 Dodecenoylcarnitine 341.2565 1.91 Lipids pos
0.0141 0.16 PC(41:6) 847.6049 6.08 Lipids pos
0.0394 0.16 Alanyl-gamma-D-
glutamyl-meso-2,6-
diaminoheptanedioate
390.1756 3.90 Lipids pos
0.0228 0.16 PS(31:4) 713.4266 3.66 Lipids pos
0.0662 0.16 (22E)-1alpha-
hydroxy-22,23-
didehydrovitamin
D3 / (22E)-1alpha-
hydroxy-22,23-
didehydrocholecalciferol
398.3183 3.94 Lipids pos
0.0351 0.16 hydroxyoctadecanoylcarnitine443.3606 3.44 Lipids pos
0.0159 0.16 Icosadienoic acid 308.2714 4.30 Lipids pos
0.0060 0.17 DG(34:2) 592.5067 8.02 Lipids pos
0.0147 0.17 Decaprenol phosphate 778.6001 7.42 Lipids pos
0.0082 0.17 Propanoylcarnitine 217.1312 0.59 Lipids pos
0.0059 0.18 DG(36:3) 618.5223 8.04 Lipids pos
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0.0564 0.18 (9Z,11E)-12-((3S,5R)-5-
((R)-1-hydroxypropyl)-
1,2-dioxolan-3-
yl)dodeca-9,11-dienoic
acid
326.2094 0.96 Lipids pos
0.0602 0.19 (4E,8E,10E-
d18:3)sphingosine
295.2508 2.06 Lipids pos
0.0241 0.19 1alpha,25-dihydroxy-
19-nor-22-oxavitamin
D3 / 1alpha,25-
dihydroxy-19-nor-
22-oxacholecalciferol
406.3081 4.55 Lipids pos
0.0250 0.19 9,10-epoxy-3E,12Z-
Octadecadienoic acid
294.2194 2.35 Lipids pos
0.0577 0.20 11’-Carboxy-gamma-
chromanol
404.2925 3.90 Lipids pos
0.0320 0.20 octadecapentaenoic
acid
274.1935 1.13 Lipids pos
0.0076 0.20 PE(42:9) 813.5298 7.08 Lipids pos
0.0059 0.20 Dodecanoylcarnitine 343.2722 1.29 Lipids pos
0.0057 0.20 CerP(d18:1/12:0) 561.4158 5.16 Lipids pos
0.0874 0.21 16:0 Sitosteryl ester 652.6186 3.01 Lipids pos
0.0389 0.21 DG(28:0) 372.2877 1.86 Lipids pos
0.0108 0.21 hydroxy cholesterol 402.3497 5.71 Lipids pos
0.0691 0.21 LysoPS(20:5) 543.2601 0.97 Lipids pos
0.0204 0.21 PC(22:0) 593.4054 5.35 Lipids pos
0.0062 0.21 LysoPS(O-20:0) 539.3591 1.63 Lipids pos
0.0184 0.21 decadienoic acid 168.1150 1.91 Lipids pos
0.0162 0.21 LysoPC(O-17:0) 495.3689 4.36 Lipids pos
0.0470 0.21 (3R)-11-cis-3-
Hydroxyretinal
300.2088 1.52 Lipids pos
0.0148 0.21 2-(8-[3]-ladderane-
octanyl)-sn-glycero-3-
phosphocholine
529.3516 4.83 Lipids pos
0.0620 0.21 DG(38:7) 638.4912 7.34 Lipids pos
0.0079 0.22 1-Aminopropan-2-ol O-
phosphate
155.0348 0.56 Lipids pos
0.0265 0.22 14-methyl-20,14-retro-
retinoic acid
314.2244 1.52 Lipids pos
0.0328 0.23 2-Hexaprenyl-3-
methyl-6-methoxy-
1,4-benzoquinol
562.4362 7.93 Lipids pos
0.0090 0.23 N-Nonanoylglycine 215.1530 5.16 Lipids pos
0.0322 0.23 Tetradecadiencarnitine 367.2724 1.16 Lipids pos
0.0043 0.23 Docosanoylcarnitine 483.4284 5.95 Lipids pos
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0.0104 0.23 (22E)-1alpha-
hydroxy-22,23-
didehydrovitamin
D3 / (22E)-1alpha-
hydroxy-22,23-
didehydrocholecalciferol
398.3186 5.09 Lipids pos
0.0432 0.24 Carnitine 161.1051 0.57 Lipids pos
0.0201 0.24 LysoPC(O-16:0) 481.3531 3.61 Lipids pos
0.0125 0.24 LysoPE(24:0) 565.4110 5.82 Lipids pos
0.0101 0.24 PS(31:3) 715.4402 4.83 Lipids pos
0.0107 0.24 PS(32:4) 727.4402 4.61 Lipids pos
0.0199 0.24 5-Aminoimidazole
ribonucleotide
295.0584 0.55 Lipids pos
0.0321 0.25 PG(O-16:0/18:1) 734.5464 7.19 Lipids pos
0.0322 0.25 hydroxy cholesterol 402.3497 6.11 Lipids pos
0.0288 0.25 PS(26:0) 651.4112 3.70 Lipids pos
0.0282 0.26 (22,23-dinor)-24-vinyl-
cholest-5-en-3beta,24-
diol
400.3342 2.18 Lipids pos
0.0197 0.26 LysoPI(13:0) 530.2499 2.36 Lipids pos
0.0203 0.26 PC(39:7) 817.5595 8.05 Lipids pos
0.0563 0.26 2-methylcitric acid 206.0433 0.55 Lipids pos
0.0225 0.26 PC(20:0) 565.3745 3.85 Lipids pos
0.0136 0.27 Glycerophosphocholine 257.1026 0.55 Lipids pos
0.0490 0.27 PS(O-16:0/20:3) 771.5410 7.04 Lipids pos
0.0360 0.27 PS(35:2) 773.5199 5.23 Lipids pos
0.0464 0.28 LysoPE(20:1) 507.3327 4.67 Lipids pos
0.0306 0.29 Cer(d14:2/18:1(2OH)) 521.4425 5.82 Lipids pos
0.0255 0.29 3-Hexaprenyl-4,5-
Dihydroxybenzoic
acid
562.4001 7.19 Lipids pos
0.0318 0.29 13’-Hydroxy-alpha-
tocopherol
446.3760 6.90 Lipids pos
0.0064 0.29 1,4-cholestadie24,25-
didehydrovitamin
D3 / 24,25-
didehydrocholecalciferol
382.3235 6.99 Lipids pos
0.0183 0.30 PG(O-16:0/20:5) 754.5128 6.69 Lipids pos
0.0201 0.30 1-(O-alpha-D-
glucopyranosyl)-
25-keto-(1,3R,27R)-
octacosanetriol
618.4735 5.88 Lipids pos
0.0351 0.31 1,4-cholestadie24,25-
didehydrovitamin
D3 / 24,25-
didehydrocholecalciferol
382.3233 7.18 Lipids pos
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0.0428 0.32 PI(O-20:0/21:0) 922.6870 7.47 Lipids pos
0.0214 0.32 PS(28:0) 679.4424 4.68 Lipids pos
0.0152 0.33 hydroxy-heneicosanoic
acid
342.3130 5.32 Lipids pos
0.0476 0.33 Phorbol 12-tiglate 13-
decanoate
600.3638 5.75 Lipids pos
0.0148 0.36 3-Hexaprenyl-4,5-
Dihydroxybenzoic
acid
562.3997 7.23 Lipids pos
0.0357 0.37 DG(34:4) 616.5066 7.73 Lipids pos
0.0096 0.37 PC(36:8) 773.4975 7.34 Lipids pos
0.0697 0.37 PC(O-16:0/21:0) 789.6636 8.00 Lipids pos
0.0072 0.37 13’-Hydroxy-alpha-
tocopherol
446.3757 7.45 Lipids pos
0.0077 0.38 (20R)-17alpha,20-
dihydroxycholesterol
418.3443 5.66 Lipids pos
0.0796 0.38 PS(37:2) 801.5500 6.34 Lipids pos
0.0778 0.39 DG(36:5) 614.4907 7.46 Lipids pos
0.0051 0.39 1-(8-[3]-ladderane-
octanoyl-2-(8-[3]-
ladderane-octanyl)-
sn-glycerol
650.5277 7.36 Lipids pos
0.0294 0.40 LysoPA(17:1) 422.2429 6.08 Lipids pos
0.0586 0.40 LysoPA(14:0) 382.2118 1.40 Lipids pos
0.0913 0.41 LysoPE(22:1) 535.3638 3.79 Lipids pos
0.0741 0.41 Type III cyanolipid 22:0
ester
419.3762 6.11 Lipids pos
0.0960 0.44 Plastoquinone-1 204.1144 0.93 Lipids pos
0.0493 0.45 (25S)-24S,26-cyclo-
5alpha-cholestan-3beta-
ol
384.3391 7.10 Lipids pos
0.0567 0.46 CPA(18:2) 416.2319 2.54 Lipids pos
0.0047 0.46 Eicosatrienoic acid 306.2553 2.94 Lipids pos
0.0574 0.47 Protoporphyrin 562.2579 3.92 Lipids pos
0.0295 0.48 Hydroxyquinine 340.1779 4.62 Lipids pos
0.0560 0.48 PS(O-16:0/17:2) 731.5103 7.19 Lipids pos
0.0316 0.53 DG(34:3) 590.4914 6.79 Lipids pos
0.0358 0.54 trimethoxybenzoic acid 212.0674 0.56 Lipids pos
0.0260 0.54 PS(33:3) 743.4730 4.35 Lipids pos
0.0428 0.55 (22,23-dinor)-24-vinyl-
cholest-5-en-3beta,24-
diol
400.3343 4.86 Lipids pos
0.0234 0.57 N-Octanoyl-L-
homoserine lactone
227.1528 4.62 Lipids pos
0.0531 0.58 LysoPC(O-14:1) 451.3082 4.21 Lipids pos
0.0662 0.65 PA(O-16:0/14:1) 604.4443 4.62 Lipids pos
0.0078 0.68 12-HETE-Gly 377.2565 1.41 Lipids pos
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0.0874 1.27 Sphinganine 301.2978 2.96 Lipids pos
0.0680 1.39 12-Oxo-20-carboxy-
leukotriene B4
364.1884 0.83 Lipids pos
0.0983 1.45 N-Docosahexaenoyl
phenylalanine
475.3107 4.01 Lipids pos
0.0832 1.47 Ketosphingosine 297.2667 4.62 Lipids pos
0.0874 1.48 (22E)-(24R)-1alpha,24-
dihydroxy-26,27-cyclo-
22,23-didehydro-
20-epivitamin D3 /
(22E)-(24R)-1alpha,24-
dihydroxy-26,27-cyclo-
22,23-didehydro-20-
epicholecalciferol
412.2973 4.06 Lipids pos
0.0817 1.49 N-(3E-hexadecenoyl)-
deoxysphing-4-enine-1-
sulfonate
599.4605 4.63 Lipids pos
0.0810 1.61 anhydroretinol 268.2191 4.12 Lipids pos
0.0508 1.67 LysoPC(O-14:1) 451.3058 5.01 Lipids pos
0.0670 1.68 3-hydroxyoctanoyl car-
nitine
303.2045 0.60 Lipids pos
0.0396 1.69 Cer(d18:0/22:0) 623.6217 8.32 Lipids pos
0.0125 1.75 Anandamide (18:2, n-6) 323.2821 3.45 Lipids pos
0.0577 1.83 Prenylated FMNH2 526.1807 6.07 Lipids pos
0.0314 1.86 LysoPA(20:5) 456.2277 1.11 Lipids pos
0.0422 1.90 11-cis retro-gamma-
retinal
284.2132 3.43 Lipids pos
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FIGURE G.1: RSD of all high quality features in the lipidomics, negative
ion mode assay before and after normalisation either pre or post data ac-
quisition or normalising applying total ion current alone. Vertical line in-
dicates a 30% RSD cut off.
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FIGURE G.2: RSD of all high quality features in the HILIC, positive ion
mode assay before and after normalisation either pre or post data acquisi-
tion or normalising applying total ion current alone. Vertical line indicates
a 30% RSD cut off.
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FIGURE G.3: RSD of all high quality features in the HILIC, negative ion
mode assay before and after normalisation either pre or post data acquisi-
tion or normalising applying total ion current alone. Vertical line indicates
a 30% RSD cut off.
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FIGURE G.4: Sum of all intensities from features that are present in at least
75% of all replicates within every group for the Lipidomics negative ion
mode assay. (A) Post-data acquisition normalisation. (B) Pre-data acquisi-
tion normalisation.
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FIGURE G.5: Sum of all intensities from features that are present in at least
75% of all replicates within every group for the HILIC positive ion mode
assay. (A) Post-data acquisition normalisation. (B) Pre-data acquisition
normalisation.
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FIGURE G.6: Sum of all intensities from features that are present in at least
75% of all replicates within every group for the HILIC negative ion mode
assay. (A) Post-data acquisition normalisation. (B) Pre-data acquisition
normalisation.
